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Introduction and aims 
 
 The detection of toxic substances, in particular of illicit drugs, plays an important 
role in the forensic inquiry.  It is important to point out whether or not a person was 
under the influence at the very moment of an accident or criminal offence.  
Whereas the blood or plasma level of a substance often correlates with recent 
cerebral effects in a living person, this is not necessarily applicable to the dead due to 
interfering thanato-chemical processes.  Problems include post-mortem degradation, 
redistribution and sometimes even post-mortem production of a substance.  When drug 
instability is important, falsely decreased levels may be measured or the drug can 
become undetectable.  On the other hand, post-mortem redistribution and/or neo-
formation may result in falsely elevated concentrations.  The competition between drug 
instability and redistribution should be taken into account when considering a specific 
concentration as being therapeutic, toxic or lethal.  These post-mortem phenomena have 
been investigated for several compounds such as ethanol, cocaine, benzodiazepines, 
barbiturates and antidepressant medication.  For ethanol, bacterial post-mortem 
production has been proven (1), whereas for cocaine, instability is prominent (2).  In 
addition, the interpretation of cocaine levels may be difficult due to competing post-
mortem processes, namely tissue release on the one hand, and chemical and enzymatic 
degradation of the substance on the other (3,4).  Some benzodiazepines - and 
nitrobenzodiazepines in particular - are chemically and metabolically very unstable (5).  
Post-mortem decrease of anticonvulsant serum concentrations, especially for 
phenobarbital and phenytoin, has been described and therefore interpretation with 
respect to “subtherapeutic” serum levels or noncompliance should be interpreted with 
caution (6).  Post-mortem redistribution into cardiac blood has also been substantiated, 
for example for barbiturates (7), amitriptyline (8-12) and procainamide (13).   To a 
certain extent, the interference of post-mortem phenomena can be avoided by sampling 
blood as soon as possible after death from an isolated peripheral vein such as the femoral 
vein (14).  In addition, since the vitreous humour is to a minor extent influenced by 
autolytic processes - due to its well-isolated position –, this specimen can be interesting 
for toxicological investigation.  Moreover, the vitreous fluid is convenient (e.g. simple to 
sample and not affected by hemolysis).  Vitreous humour levels have been studied for 
various substances such as alcohol (15), morphine (16), and cocaine (17).  In humans, 
quantification of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) in the 
vitreous humour has only been performed in a few cases (18,19).   
 Abuse of amphetamine derivatives such as MDMA and 3,4-methylenedioxy-
amphetamine (MDA) is an important public issue and fatalities are not infrequent in 
current forensic practice.  For the amphetamine derivatives and MDMA in particular, 
very little data from fatalities are available in the literature.  Since amphetamine-related 
fatalities, including those of MDMA users, are on the increase in medico-legal practice 
(e.g. 20-22), fundamental research on these post-mortem phenomena is required. Though 
MDMA appears to be stable in vitro (23,24), the post-mortem (re)distribution of MDMA 
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in the body has barely been explored, with the exception of a few case reports (25-28): 
apart from blood and urine concentrations, only a few tissue levels have been reported. 
These data show that high MDMA concentrations can be found in organs such as the 
brain (25-28) and the liver (25-27). For amphetamine (AMP), methamphetamine 
(METH) and MDA, more literature data are available, for example (14,29-38).  These 
case reports indicate that concentrations in cardiac blood are obviously higher than those 
in peripheral blood.  In addition, significant levels of AMP, METH and MDA have been 
found in several tissues such as liver and brain, but also in blood-rich organs such as the 
lungs, which means that these substances are liable to post-mortem redistribution. 
Animal experiments dealing with this issue for amphetamine or its analogues are scarce 
(39,40).  Hilberg and colleagues described an experiment in which post-mortem 
redistribution of amphetamine in the rat was studied (39), with further extrapolation to a 
few medico-legal cases (41). Moriya et al. demonstrated redistribution of 
methamphetamine into cardiac blood via pulmonary blood vessels in the early post-
mortem period (40).  
 
The question remains open as to whether an MDMA blood level can be toxic or 
even potentially lethal.  Moreover, referring to possible thanatological changes, it is not 
clear whether the observed post-mortem MDMA blood level actually represents the 
concentration at the time of death.   In this thesis research, the post-mortem distribution 
and redistribution of MDMA was studied in order to evaluate which fluid and/or tissue 
sample after death most closely represents the ante-mortem concentration.  Furthermore, 
the question was posed as to whether the post-mortem phenomena relating to MDMA 
are in line with those for the other amphetamine derivatives.    In addition, the 
significance of post-mortem MDMA levels in vitreous humour was evaluated. 
 
In Part One of this work, a summary of the relevant literature and a survey of the 
amphetamine-related fatalities examined at the Department of Forensic Medicine of 
Ghent University was discussed.   
In Chapter 1, a literature review focusing on the (ab)use of amphetamines with 
particular emphasis on MDMA is presented.  The clinico-pharmacological effects, the 
epidemiological importance, the medico-legal implications and thanato-toxicological 
literature data for MDMA are discussed.  
In Chapter 2, the amphetamine-related fatalities encountered at the Department 
of Forensic Medicine of Ghent University between January 1976 and April 2002 are 
reviewed.  Apart from the toxicological findings, possible mechanisms of death are 
examined and discussed in the light of the available literature data.  
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In the experimental work featured in Part Two, the post-mortem problems for 
MDMA were examined using an experimental rabbit model.  In the first study presented, 
the value of post-mortem vitreous humour MDMA levels was examined (Chapter 3).  
The pharmacokinetics of MDMA in the rabbit after intravenous (iv) administration and 
the correlation between MDMA blood and vitreous humour levels were investigated.  In 
addition, a fully validated high pressure liquid chromatographic (HPLC) method with 
fluorescence detection for quantification of MDMA and its metabolite MDA was 
designed (42). 
  Chapters 4 and 5 report further studies of the post-mortem stability and 
redistribution of MDMA in the rabbit model in order to determine which body fluid(s) 
and/or tissue(s) after death most closely represent the actual ante-mortem concentration.   
Chapter 4 deals with the distribution of MDMA and its metabolite MDA in 
different body fluids and tissues of rabbits that were killed 2 hours after iv 
administration of MDMA.  Three groups of rabbits were studied.  In the first group 
(control group), the study was performed immediately after sacrifying and in the second 
group, the animals were preserved at ambient temperature either 24 or 72 h post mortem 
prior to sampling.  Theoretically, post-mortem increases in cardiac blood levels can 
occur due to intravascular diffusion out of blood-rich organs such as the liver and the 
lungs (34).  Therefore, in the third group, ligation of the large vessels around the heart 
was performed (immediately after killing) and these rabbits were further treated as in the 
second group.   
In humans, who mainly take MDMA orally, it is important to investigate whether 
a “reservoir” in the stomach influences post-mortem blood and tissue concentrations 
when the subject dies shortly after ingestion, and - as a result – the distribution is not yet 
completed.  In addition, drug levels can be affected by agonal vomit aspiration or post-
mortem regurgitation in the airways.  The influence of the gastric reservoir function (43) 
and vomit aspiration or regurgitation (44) has previously been proven for ethanol. This 
was simulated in another rabbit animal model (Chapter 5): post-mortem infusion of an 
MDMA solution was performed either in the trachea or in the stomach and the diffusion 
was studied up to 72 hours after administration.  In both groups, MDMA and MDA 
levels were determined in various fluids and tissues using the same HPLC method. 
 
 In Part Three, the animal experimental data are compared with the human 
findings. The post-mortem distribution of MDMA (and its metabolite MDA) and some 
other amphetamine derivatives in the human body was investigated.  In order to evaluate 
which fluid and/or tissue sampled after death most closely represents the ante-mortem 
concentration,  two different - but complementary – approaches were examined.   
In Chapter 6, the thanato-toxicological approach is taken.  The concentrations 
determined in various fluids (blood sampled on different locations, vitreous humour, 
urine and bile) and tissues such as cardiac muscle, lungs, liver, kidneys, spleen, ilio-
psoas muscle, and brain in subjects who died following exposure to MDMA and/or 
derivatives are discussed.  Apart from MDMA and MDA, some other amphetamine 
derivatives, namely 4-methylthioamphetamine (4-MTA) and para-methoxyamphetamine 
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(PMA) are considered.  For the relatively new derivative, 4-MTA, the data of persons 
who survived after ingestion are presented and the clinical observations are commented 
too.    
Chapter 7 takes an anatomo-pathological/thanatological approach, with 
emphasis on immunohistochemistry.  Thus, a semi-quantitative visual presentation of the 
distribution of MDMA in tissues is obtained and correlated with the toxicological 
findings.  The question is posed whether immunohistochemical detection could be either 
an alternative or a supplementary tool in the forensic inquiry when the toxicological 
determinations are interfered with or have become impossible.  In particular, the brain – 
being an important target organ for MDMA – is a difficult matrix for chromatographic 
extraction due to the lipid fraction.  In this thesis, an immunohistochemical method for 
the detection of MDMA and MDA in human brain tissues and the pituitary gland is 
reported. However, immunohistochemical detection is restricted due to the fact that only 
the fraction bound to tissues can be demonstrated since the unbound fraction is washed 
out during the preparation procedure.  This is a fundamental difference with the 
toxicological quantitation in tissue homogenates, in which both the bound and the 
unbound fraction are measured.  
 
Finally, Summary and Conclusions provides the main findings of our research 
work. 
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PART ONE   Review of the medico-legal literature and survey of 
amphetamine-related fatalities at the Department of 
Forensic Medicine (Ghent University) 
 
Chapter 1 Review of the medico-legal literature:   
focus on 3,4-methylenedioxymethamphetamine (MDMA) 
 
In this chapter, a summary of the pharmacology of the amphetamine derivative 3,4-
methylenedioxymethamphetamine (MDMA, “ecstasy”, XTC) will be presented, followed 
by a discussion of the epidemiological setting.  In addition, the medico-legal implications of 
these drugs with regard to the manner of death will be considered.  Finally, the available 
thanato-toxicological literature data will be discussed.  
 
The chemical structure of MDMA or N-methyl-3,4-methylenedioxyphenyl-
isopropylamine is presented in Figure 1.1 (a);  it is a racemic mixture and is used as a 
hydrochloride. The asymmetric carbon atom is indicated in Figure 1.1 (a).  
The structure of 3,4-methylenedioxyamphetamine (MDA) - which is closely related to 
MDMA and is one of its metabolites – is presented in Figure 1.1 (b). 
There is an important difference in the structure of MDMA compared with amphetamine 
and methamphetamine.  MDMA contains a methylenedioxy(-O-CH2-O-)ring attached to 
positions 3 and 4 of the aromatic ring of the amphetamine molecule resulting in a “ring-
substituted” amphetamine derivative which resembles the hallucinogenic substance 
mescaline.  Therefore, the pharmacological effects of MDMA and its closely related 
analogue 3,4-methylenedioxyethylamphetamine (MDEA) are a blend of those of 
amphetamine and mescaline.  In addition, these products and/or their metabolites are 
chemically similar to the natural neurotransmitters adrenaline (epinephrine), serotonin and 
dopamine (1).  MDMA was first designed in 1914 as an appetite suppressant, though it was 













3,4-methylenedioxyamphetamine (MDA) (b) 
 
Figure 1.1  Chemical structure of 3,4-methylenedioxymethamphetamine (MDMA (a))  
and 3,4-methylenedioxyamphetamine (MDA (b)). 
(* indicates the asymmetric carbon atom) 
 
 
I Pharmacology of MDMA: human and animal experimental data 
 The effects following administration of a drug are related to two successive events: 
first a pharmacokinetic and then a pharmacodynamic phase. The available pharmacokinetic 
data of MDMA describing the relationship between a given dose, the blood (or plasma) 
level and the concentration at the site of action - in connection with drug absorption, 
distribution and elimination in the human body - are presented.   Thereafter, the clinico-
pathological effects related to the concentration of MDMA at the sites of action (or 
pharmacodynamics) - are discussed.  In an attempt to explain the recorded effects in 
humans, relevant data established in animal experimental models are commented. 
 
I.1  Pharmacokinetics of MDMA in humans 
Due to the risk of adverse reactions following administration of MDMA, problems 
of medical ethics arise when performing research in the healthy human.  Nevertheless, a 
few data on the pharmacokinetics of MDMA in humans are available.   Vereby et al. were 
the first to report on pharmacokinetic data in a human subject.  Following oral intake of 50 
mg MDMA, the peak plasma MDMA and MDA levels were found after 2 and 4 h, 
respectively, and the half-life was 7.6 h.  Unchanged MDMA was the most important 
excretion product (± 65 %) in urine and the amount of MDA found in urine was about 7 % 
of the initially ingested dose (3).  Helmlin et al. found that a single oral dose of 1.5 mg/kg 
MDMA in adults (n = 2) resulted in mean peak plasma levels of 331 ng/ml MDMA and 15 






observed after 21.5 h (4).  In addition, it was confirmed that conjugated 4-hydroxy-3-
methoxymethamphetamine (HMMA) and 3,4-dihydroxymethamphetamine (HHMA) are 
the main urinary metabolites of MDMA (4,5).  About ten years after the initial experiment 
by Vereby et al., the half-life of about 8 hours and the easy absorption of MDMA after oral 
intake resulting in a peak plasma concentration about 2 hours after ingestion were both 
confirmed (6,7).  Figure 1.2 shows the mean plasma concentrations of MDMA and its 
metabolites MDA, HMMA and 4-hydroxy-3-methoxyamphetamine (HMA) as a function of 
time after oral intake (n = 8; reproduced from de la Torre et al.(7)).  The corresponding 
pharmacokinetic parameters are summarized in Table 1.1 (reproduced from de la Torre et 

























Figure 1.2 Plasma concentration time course for MDMA and its metabolites after oral 
ingestion of 100 mg MDMA in human, expressed as mean ± SE (n = 8). 




Table 1.1   Pharmacokinetic parameters for MDMA and metabolites following oral  
  ingestion of 100 mg, administered to 8 subjects. 
  Abbreviations:  Cmax : peak plasma concentration 
      tmax : time of peak plasma concentration 
      t ½: elimination half-life 
  [reproduced from de la Torre et al. (7)] 
 
   Cmax tmax t ½  
   (ng/ml) (h) (h) 
MDMA    
          mean  222.50 2.3 8.96 
          ± SD  26.06 1.1 2.27 
MDA    
          mean  13.13 6.7 24.89 
          ± SD  4.47 2.6 14.53 
HMMA    
          mean  236.66 2.3 11.25 
          ± SD  87.12 0.9 2.86 
HMA    
          mean  7.50 8.2 37.37 
          ± SD  4.00 1.67 17.93 
 
 
An enantioselective disposition of MDMA was demonstrated, following oral administration 
of racemic MDMA in volunteers (8): the plasma concentrations of (R)-MDMA exceeded 
those of the (S)-enantiomer, and the plasma half-life of (R)-MDMA was significantly 
longer than that of the (S)-enantiomer (5.8 ± 2.2 h and 3.6 ± 0.9 h, respectively).  More 
recent studies have demonstrated that MDA is not a major – though it is an active - 
metabolite in humans (9,10) (see Figure 1.2 and 1.3).  At present, several metabolic 
pathways including demethylenation and N-dealkylation (11) and enzymes (CYP 
isoenzymes) intervening in the metabolism of MDMA have been postulated (12,13).  Kreth 
et al. were able to identify the human cytochrome P450 (CYP) isoenzymes that catalyze the 
oxidative metabolism of MDMA and its analogues MDEA and MDA: they concluded that 
in addition to CYP2D6, as the sole high-affinity demethylenase, several other P450 
isozymes have the capacity to contribute to microsomal oxidative metabolism of 
methylenedioxyamphetamines (13).  Maurer et al. demonstrated that in humans 
demethyl(en)ation was mainly catalyzed by CYP2D6 or CYP3A4, but also by CYP 
independent mechanisms (12).  Demethylenation was followed by catechol-O-methyl-
transferase (COMT) catalyzed methylation and/or glucuronidation/sulphation (12).  The 
scheme in Figure 1.3 shows a proposed metabolic pathway of MDMA in humans 
(reproduced from de la Torre et al.(10)).  Some of the enzymes involved in this process can 
be saturated at relatively low concentrations of the drug which results in disproportionately 
large increases in blood and brain concentrations of the drug when higher doses are 




time curve following oral ingestion of 50, 100 and 150 mg MDMA, respectively, is shown 
(reproduced from de la Torre et al.(10)).  Therefore, relatively small increases in dosage can 
give rise to significant increases in toxicity risk.  In addition, the fact that it takes about 5 
half-lives (for MDMA, i.e. about 40 hours) to clear more than 95 % of the drug explains the 



























Figure 1.3 Proposed metabolism of 3,4-methylenedioxymethamphetamine in human. 

































Figure 1.4 MDMA (+) and HMMA (? ) plasma concentrations (µg/l) versus time curve 
in three subjects administered 50 mg, 100 mg, and 150 mg (one subject per dose). 
  [reproduced from de la Torre(10)] 
 
 
Furthermore Kalant specifies that some of the metabolites of MDMA, especially its first 
metabolite MDA, are still pharmacologically active so that the duration of action of 
MDMA may be somewhat longer and therefore can in part explain the “delayed effects of 
MDMA” (1).  Hernández-López et al. demonstrated that MDMA consumption in 
association with alcohol induced a 13 % increase in plasma concentrations of MDMA (14). 
The mechanism of this interaction is not known; a change in ethanol absorption or initial 
distribution was postulated, but the authors note that the changes in pharmacokinetics – 
though statistically significant - were mild in magnitude and therefore could be considered 





The pharmacokinetic data of MDMA can be compared with those of amphetamine 
and methamphetamine.  The half-life of amphetamine and (+)-methamphetamine is 7 – 34 
h and 6 – 15 h, respectively.  The renal excretion of both is dependent on the urinary pH.  In 
the 24 h following intake, 30 % of unchanged amphetamine can be retrieved, but 
alkalinization of urine substantially decreases the fraction found, even to about 1%.  To our 
knowledge, the influence of the urinary pH on the excretion of MDMA is not studied, 
though can be assumed. On the other hand,  acidification of urine can result in retrieval of  
about 74 % of the initial dose (15).  For S(+)-methamphetamine, the average elimination 
half-life in human volunteers (following oral administration) was 10.1 h (range 6.4 – 15.1 
h) (16). At present, the above-mentioned pharmacokinetic parameters have not yet been 
fully elucidated for MDA, but the half-life for MDA is assumed to be longer than that of 
MDMA (17).  Similarities have been noted in the metabolism of amphetamine-derived 
designer drugs: these substances undergo predominantly two overlapping metabolic 
pathways, namely O-demethylenation to dihydroxy derivatives (catechols), followed by 
methylation of one of the hydroxy groups, and successive degradation of the side chain to 
N-dealkyl and deaminooxo metabolites (18).  
 
 
I.2  Pharmacodynamics of MDMA 
I.2.1  Animal experimental data 
As mentioned above, human experimental studies with MDMA give rise to 
problems of medical ethics.  Therefore, standardized animal models are required to solve 
some questions.  However, it often remains difficult to extrapolate conclusions obtained 
from animal experiments to humans due to a variety of factors which influence the kinetics 
and metabolism of substances, such as species, strain, gender, route of administration, dose, 
frequency and time of administration, temperature, coadministration of drugs and surgical 
manipulation (19).  The central nervous system is the predominant target site of MDMA 
and will therefore be discussed more in detail.   In this section, only literature data with a 
clear link to the human clinico-pathological findings will be referred to.   
 
I.2.1.1  Cardiovascular effects 
The sympathomimetic properties of MDMA resulting in increased heart rate and 
blood pressure is hypothesized to be mediated by MDMA-induced monoamine release in 
both the central and the peripheral nervous systems, and perhaps also by the direct effect of 
MDMA on α2-adrenergic receptors (20,21).  For methamphetamine, rat cardiomyocytes 





I.2.1.2  Hepatotoxicity 
The mechanism of MDMA-induced liver injury has still not been clarified.  In 
experiments using rats, Beitia et al. described histological findings ranging from foci of 
individual cell necrosis to centrilobular necrosis and from mild to moderate lobular 
hepatitis (23).  In addition, features of massive hepatic parenchymal collapse with areas of 
nodular regeneration can be observed (23).  Following acute MDMA administration in rats, 
hepatocyte necrosis particularly in portal areas with inflammatory infiltrate consisting of 
lymphocytes and macrophages was found (23).  Repeated intraperitoneal injection of 
MDMA in the rat produced hepatocyte necrosis and inflammatory infiltrate around the 
hepatic vein  (23).  In these animal experiments, there was no clear evidence that 
glutathione (GSH) depletion with free radical-induced toxicity is responsible for overt liver 
cell death (23).  Hyperthermia-induced oxidative stress which comes to expression as GSH 
depletion was found in vitro following d-amphetamine exposure (24). In addition, 
catecholamines and hyperthermia were postulated to contribute to the mechanism of 
hepatotoxicity (24).   Hyperthermia as a triggering factor for hepatotoxicity induced by 
MDMA was recently assumed by Carvalho et al. (25). 
 
I.2.1.3  Cerebral effects and neurotoxicity 
On the basis of the clinical effects described in humans (see below) which 
demonstrate that the brain is an important target organ, one would think that MDMA passes 
easily through the blood-brain barrier.  However, the pharmacokinetics of MDMA with 
respect to the distribution into the brain are not yet elucidated.  Due to the high pKa of this 
weak base (10.38) (26), MDMA is found totally in ionized form at physiological pH and, as 
a result,  MDMA is in fact not expected to diffuse easily to the brain.  Therefore, it may be 
that transport to the brain takes place via an active mechanism.  For several substances such 
as anticonvulsants, efflux mechanisms protecting the homeostasis of the brain can 
significantly interfere with the functioning of these drugs (27).  On the contrary, for 
MDMA, Mann et al. suggested that P-glycoprotein plays a facilitating role in the entry of 
this substance via the blood-brain barrier (28).  The rapid partitioning of (+)-
methamphetamine which is closely related to MDMA in the rat brain, can also partially be 
explained in terms of physicochemical properties (such as small molecular weight) of that 
substance (29), and therefore in view of the chemical structure of MDMA (see Figure 1.1), 
this may also be applicable to MDMA.  In addition, data from rats indicate that metabolites 
of MDMA (such as glutathione conjugates) enter the brain via a transporter and are 
subsequently metabolized to thioether conjugates, which contribute to the serotonergic 
neurotoxicity (30,31); thus, the metabolite HHMA may play a role in the neurotoxicity (31-
33).  In rats, the regional distribution of [3H]-MDMA and [3H]-MDA in brain and a few 
peripheral tissues was studied following a single subcutaneous injection of 20 mg/kg [3H]-
MDMA or [3H]-MDA.  Table 1.2 shows that the distribution of MDMA and  MDA  was 
fairly comparable in all brain regions.  The highest levels were found in the liver and the 




Table 1.2  Regional distribution of [3H]-MDMA and [3H]-MDA in rat brain and 
peripheral tissues following a single subcutaneous injection of 20 mg/kg  
[3H]-MDMA or [3H]-MDA and sacrificed 45 minutes later.  
[reproduced from Battaglia et al. In: Peroutka (34)] 
 
 
region [3H]-MDMA  [3H]-MDA  
             (µmol/g tissue) 
frontal cortex 0.22 0.42 
rest of cortex 0.19 0.32 
striatum 0.22 0.42 
hippocampus 0.22 0.44 
thalamus 0.21 0.44 
hypothalamus 0.18 0.37 
midbrain 0.17 0.36 
cerebellum 0.15 0.39 
brainstem 0.15 0.23 
pituitary gland 0.31 - 
liver 0.48 1.26 
spleen 0.25 0.56 
 
 
MDMA is known as serotonin (5-HT) neurotoxin.  Serotonin is widely distributed 
in different organ systems, including the blood and digestive tract, spleen, liver, lung, skin, 
the pineal gland and brain (35).  Ninety percent of the serotonin in the human body is 
believed to be present in the mucosae of the gastrointestinal system, 8 to 10 % in the blood 
platelets and 1 to 2 % in the central nervous system (35).  The main site of toxicity of 
MDMA is assumed to be within the serotonergic pathways in the central nervous system 
(36).  These pathways are present in the raphe nuclei (37) which are located in the midline 
region of the brainstem and which receive afferent fibers from the prefrontal cortex and 
send axons to the forebrain (prosencephalon), cerebellum and spinal cord (35). Together 
with the locus ceruleus, the raphe nuclei are considered to be part of the reticular formation 
(38).  The locus ceruleus has widespread connections with virtually all parts of the brain 
and has noradrenaline as catecholamine neurotransmitter substance (38).  The scheme in 
Figure 1.5 (a) shows the reticular formation consisting of groupings of neurons  including 
the raphe nuclei in humans (38).  In Figure 1.5 (b) and Figure 1.5 (c), an overview of the 
serotonergic fiber projections to the spinal cord and the forebrain (mainly consisting of the 
basal ganglia and the neocortex), respectively, in humans is presented (35).   Serotonin is 
evenly distributed throughout the brain, but high levels are found, for example in the raphe 
nuclei and hypothalamus (37). The location of serotonergic cell bodies and pathways in the 




their widespread connections, the serotonergic pathways influence for example affective 
behaviour, food intake, hormone secretion, sexual behaviour, and thermoregulation (36). 
The synthesis (a) and catabolism (b) of 5-HT is presented in Figure 1.7 (reproduced from 
Feldman (35)). Up to the present, several serotonin receptor types have been discovered.  In 




















Figure 1.5 (a) Scheme of the reticular formation consisting of grouping of neurons within the     
brainstem.  The raphe nuclei form a distinct subset of serotonergic neurons.  

































Figure 1.5 (b)    Scheme of the serotonergic projections to the spinal cord (descending pathways). 
Figure 1.5 (c)    Scheme of the serotonergic fiber system projections to the forebrain. 





Figure 1.6 Scheme of the location of serotonergic cell bodies and pathways in the rat central 
nervous system  (B1 to B9 refers to 5-HT cell groups).  





























(a)      (b) 
 
 
Figure 1.7  Synthesis (a) and catabolism (b) of serotonin (5-HT).  The enzymes catalyzing the 
reactions and the interfering co-factors are indicated. 








Figure 1.8 Scheme of the serotonergic synapse illustrating the serotonin synthesis and 
metabolism, presynapsic and vesicular 5-HT uptake, and vesicular 5-HT release.  
Pre- and postsynaptic 5-HT receptors are shown.   
(Try H = tryptophan hydroxylase; AADC = aromatic L-amino acid decarboxylase: 
see also Fig 1.6)  







Animal experiments showed that MDMA induced serotonin neurotoxicity can be 
manifested by following mechanisms: reduced cerebral 5-HT content, decreased numbers 
of identifiable 5-HT-uptake sites and transporter molecules, reduced activity of tryptophan 
hydroxylase (TPH ; the rate-limiting enzyme in the 5-HT synthetic pathway), and 
degenerating cerebral serotonergic axons and axon terminals (1,39,40).   
Frederick et al. observed altered behavioural effects (including memory and 
attention) in rhesus monkeys (41).   These effects were associated with significant 
decreases of about 50% in serotonin levels in frontal cortex and hippocampus 
approximately six months after a short-course high-dose MDMA treatment (41).  In rats, 
changes in 5-HT levels in other regions were demonstrated, such as in the nucleus 
accumbens and striatum (42), and in the raphe nuclei (43).  The  nucleus accumbens 
contains neurons that are part of the basal ganglia.  Its function has not yet been elucidated 
but it is assumed to be involved in integrating certain cognitive aspects of a situation with 
the emotional component, and in addiction behaviour in animals - and likely in humans as 
well (44).  The human basal ganglia and the nucleus accumbens are presented in Figure 1.9 





Figure 1.9 Schematic view of the various nuclei located in the basal forebrain area  including 
the basal ganglia .  




Regional differences in serotonin neurotoxicity have been reported: e.g. the number 
of cortical 5-HT uptake sites in rats (measured by specific binding to the transporter) 
completely recovered at 52 weeks post-treatment, while at the same time the hippocampal 
5-HT uptake sites were still significantly decreased (45).  The effects of MDMA on 5-HT 
neurons in specific neuroanatomic loci were studied in the rat using autoradiography.  
Marked decreases in 5-HT uptake sites in several regions known to receive projections of 
5-HT neurons, such as the cerebral cortex, caudate nucleus, hippocampus, and most 
thalamic nuclei, were observed (46,47).   
The underlying mechanism that would explain neuronal cell death is still not yet 
fully understood, but a few hypotheses have been presented, including hydroxy radical 
formation (48), and tryptophan hydroxylase inactivation, for instance by increasing the 
intracellular calcium ion concentration (49).  Huether et al. postulated a profound wastage 
of energy on a 5-HT cellular basis (50). 
Histological and immunohistochemical evidence of the degeneration of serotonergic 
axons has been reported (51-54). In addition, dopamine (DA) is believed to play an 
unmistakable role in MDMA-induced damage to 5-HT axons (55-57).      
When considering the serotonergic neurotoxicity of MDMA, the more pronounced 
sensitivity of monkeys compared to rats was demonstrated by neurochemical and 
neurohistological experiments (58).  This could indicate species-dependent differences to 
MDMA-induced toxic effects. 
Figure 1.10 shows the integrated hypothesis as explanation for the serotonergic 
neurotoxicity proposed by Sprague et al. (59).  The authors describe the following 
sequence: MDMA induces an acute release of 5-HT and DA, which is followed by 
depletion of intraneuronal 5-HT stores. Thereafter, the initially released 5-HT activates 
post-synaptic 5-HT2A/2C receptors located on γ-aminobutyric acid (GABA) interneurons, 
resulting in a decrease in GABA-ergic transmission and increased DA release and 
synthesis.  The excessive DA released may then be transported into the depleted 5-HT 
terminal.  The DA is then deaminated by monoamine oxidase B (MAO-B) located within 
the 5-HT terminal.  This results in free-radical formation and the selective degeneration of 
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Figure 1.10  An integrated hypothesis for the development of selective 5-HT terminal 
degeneration following MDMA.  
[reproduced from Sprague (59)] 
 
 
In rats, stereochemical differences in the potency of MDMA were demonstrated by 
Fitzgerald et al. and the S(+) isomer is believed to be more neurotoxic than R(-)-MDMA 
(60), this toxicity being produced by stimulation of the 5-HT2 receptors, which are assumed 
to be important in the psychoactive effects of the hallucinogenic substances (61) .   
Apart from stimulating 5-HT and DA release, MDMA can induce noradrenaline 
release, e.g. from hippocampal slices (62).   
 
An interesting review of the literature data is available, which focuses on the 
correlation between the effects that MDMA exhibits and different brain regions, as studied 
in various laboratory animals (55).  Several clinical effects can at least partially be 
explained, for example jaw clenching is an expression of the influence of MDMA on motor 
neurons in the hypoglossal nucleus (55).     
 The euphoric effects produced by MDMA are related to increasing extracellular 
levels of DA and 5-HT in the nucleus accumbens (55).  The hallucinogenic effects of 
MDMA are assumed to be correlated with the serotonergic circuits originating in the raphe 
nucleus and extending into the neocortex, thalamus and hippocampus (63).   
Kalivas et al. demonstrated in rats that paranoia and psychosis could be explained 
by behavioural sensitisation and enhanced dopamine transmission in the nucleus 
accumbens (64). 




Callaway et al. demonstrated that locomotor hyperactivity induced by MDMA 
administration in rats was dependent upon serotonin (5-HT) rather than dopamine release 
and therefore a central role for 5-HT release in the stimulant-like behavioural effects of 
MDMA was assumed (65).   In addition, McCreary et al. supported a role for the 5-HT1B/1D 
receptor in mediating  acute hyperactivity induced by (+)-MDMA (66).   
Moreover, MDMA-induced hyperthermia and locomotor hyperactivity in laboratory 
animals can be inhibited by drugs that prevent MDMA-induced 5-HT release and can be 
attenuated by administering 5-HT receptor antagonists (55).  Pederson et al. proved in a 
rabbit animal model, that sympathetically mediated cutaneous vasoconstriction is one 
mechanism contributing to MDMA-induced hyperthermia (67).  Therefore, drugs acting as 
5-HT2A receptor antagonists (such as clozapine) can be therapeutically important in treating 
severe life-threatening hyperthermia (67).   Darvesh et al. proposed - as possible 
mechanism important for the development of  hyperthermia -  the influence of MDMA on 
brain energy regulation: they were able to demonstrate MDMA-induced glycogenolysis in 
rat brain and that this process involves 5-HT2 receptor activation.  Therefore, they 
concluded that MDMA promotes energy dysregulation and that hyperthermia may be an 
expression of MDMA-induced alterations in cellular energetics (68).  In rats,  Mechan et al. 
demonstrated that MDMA-induced hyperthermia could rather be explained by the increased 
release of dopamine acting at D1 receptors than by 5-HT release as such (69). As dopamine 
and serotonin are important mediators of body temperature - lowering and raising, 
respectively - drugs with antidopaminergic or serotonin releasing properties can be 
responsible for hyperthermia syndromes (70).  By this means, MDMA-induced 
hyperthermia can be partially understood.   Malpass et al. proposed that, being cytochrome 
P-450 2D6 deficient, human poor metabolizers may be genetically predisposed towards a 
fatal outcome, but comparison of deficient and normal rats revealed that this cannot be 
explained by a simple increased hyperthermic response to the drug (71).  Malberg 
demonstrated in rats that high ambient temperatures are required to induce neurotoxicity, 
and therefore ambient temperature has a significant influence on MDMA-induced 
neurotoxicity, body temperature and thus thermoregulation (72).  In mice, Carvalho et al. 
were able to support the hypothesis that oxidative stress is important in the first stage of 
MDMA-induced liver damage and that liver antioxidant status is deteriorated by high 
ambient temperature.  Therefore they concluded that increased ambient temperature may 
potentiate MDMA-induced hepatotoxicity by increasing body hyperthermia (73). This 
confirms that in humans, promoting environmental conditions are important (such as high 
ambient temperature in dancings) to induce toxicity (1,74). 
 
I.2.2  Desired effects in humans 
First we summarize the desired clinical effects in recreational use.  Minor and 
severe adverse effects are discussed thereafter (see I.2.3). 
MDMA is sometimes classified as a hallucinogen, though it can also be classed with 
the central stimulants. In view of the psycho-pharmacological effects, MDMA can be rated 
among the “entactogens”, a term which refers to the feeling of enhanced closeness and 




The typical dosage range for recreational use of MDMA is 50 to 150 mg (1).  
However, the content of an “ecstasy” tablet may vary enormously: different amphetamines 
can be found and the amount of MDMA can vary significantly.  For example, an 
examination of tablets sold as “ecstasy” revealed that only about the half of them actually 
contained MDMA and the mean content was 91.3 mg with a wide range (2 – 149 mg) (78).    
The clinical effects of MDMA after oral ingestion – which is the most common route of 
administration in recreational use – start at about 20 to 60 minutes.  Initially, the user 
experiences a brief “rush” of energy, which is often described as mild, but euphoric.  This 
“rush” is followed by a more comfortable episode lasting 2 to 3 hours which is then 
followed by a gradual “coming down” sensation or feeling of fatigue (79).   Questionnaires 
for the purpose of obtaining more information about the desired effects of MDMA use 
revealed that physically, MDMA produces a feeling of increased alertness, energy, and 
sexual arousal (80).  Psychologically an increased feeling of “closeness” and “peace” with 
other people, well-being, and euphoria, were commonly mentioned (76,80).   These feelings 
of increased empathy gave rise to the name “entactogens” or “empathogens” (77).  In other 
words, the primary reported effects of MDMA are a “positive mood state” and feelings of 
intimacy and closeness to others (81).  The secondary effects described refer to the 
stimulant properties - namely feelings of energy and activation - and to the psychedelic 
effects of insight and perceptual and sensual enhancement (81). 
Hallucinogenic effects have only been described following ingestion of high doses 
(82).  Gender differences have been reported: women were found to be more susceptible 
(for example to hallucinogenic-like perceptions) than men (83).  In addition, MDMA has a 
much shorter action than MDA, which is known to cause hallucinogenic effects similar to 
those of mescaline or LSD.   Therefore, it can be generally assumed that the additional N-
methyl group in the chemical structure of MDMA limits the duration of action and 
attenuates or even abolishes the hallucinogenic properties described after MDA use (75,77).    
Combining MDMA with alcohol may result into a longer lasting euphoria and sense 
of well being, and may partially reverse the subjective alcohol-induced sedation, but not 
reduce drunkenness feelings (14). 
 
I.2.3  Human toxicity 
Important interindividual differences exist between MDMA plasma concentrations 
and the clinical symptoms, and as a result, adverse effects are correlated not only with the 
ingested amount.  Side effects are due mainly to the sympathomimetic and/or the neuro-
toxicological effects of MDMA.  As tolerance to the effects of MDMA develops rapidly, 
more frequent use requires larger doses to achieve the desired effects, but then the 
unpleasant side-effects increase as well (81,84).  MDMA is generally considered as non-
addictive, although some cases of dependence are described (85).  
In this section, we first describe relatively minor acute and chronic adverse effects 
(most of which were noticed clinically) of MDMA use, classified by organ system.  In 
addition, more pronounced adverse reactions in some cases involving life-threatening 
effects are commented upon.  Finally, the correlation between the MDMA plasma or blood 




I.2.3.1  Symptoms 
I.2.3.1.1  Cardiovascular effects 
Frequent acute, relatively minor unpleasant effects of MDMA – which indicate the 
sympathomimetic involvement – include tachycardia, palpitations, hypertension, mydriasis, 
and dry mouth (6,7). In addition, gender differences have been observed following MDMA 
exposure: e.g. men showed higher increases in blood pressure than women (83).  
Hypertensive crises and cardiac dysrhythmia (like ventricular tachy-arythmias) are 
commonly reported acute severe cardiovascular symptoms (86).   Hypertensive crises may 
cause cerebrovascular accidents and other complications from end-organ vasospasms.  A 
few cases of cerebral haemorrhage or infarction following MDMA intake were reported 
(87-92).  Intracerebral haemorrhage was also described in amphetamine and cocaine users 
(93,92).  Hypertensive surges and cerebral angiitis have been postulated as mechanisms 
causing intracerebral haemorrhage following amphetamine and methamphetamine use (89).   
Both, severe hypertension with increased risk for haemorrhages on the one hand, 
and tachycardia or cardiac dysrythmia on the other hand, can develop into heart failure (1). 
 
 I.2.3.1.2   Hepatotoxicity 
There is a broad spectrum of hepatotoxic effects induced by MDMA: jaundice, 
hepatomegaly, hepatitis and extensive fibrosis (87-97). In young people presenting with 
unexplained jaundice or hepatomegaly, questions regarding (mis)use of MDMA should be 
posed (87).  The interval between drug consumption and jaundice is variable and therefore 
the link between the two can be obscured (98).  Hepatitis is the most frequently reported 
manifestation of MDMA induced liver damage (98-101).  In most of the reported hepatitis 
cases, biochemical tests for viral hepatitis are negative.  Rarely, hepatitis due to MDMA 
exposure can result in fulminant hepatic failure (102) which can require liver 
transplantation (103). 
Proposed hypotheses to explain the hepatotoxic effects include an allergic drug 
reaction (such as idiosyncratic toxic hepatitis), a toxic contaminant, autosomal recessive 
inheritance of gene mutations (lack of cytochrome P450 oxidase CYP2D6) resulting in 
impaired metabolism of the drug, or a secondary effect of hyperpyrexia (87,96,104).  
Whether an idiosyncratic toxic hepatitis is due to MDMA itself or to a metabolite, a 
contaminant in MDMA manufacture, or to an additive in the tablets is not yet clear (87).  In 
the case reported by Khakoo, an idiosyncratic reaction was assumed to be the underlying 
mechanism of ecstasy-induced accelerated hepatic fibrosis (including a predominantly 
eosinophilic inflammatory infiltrate; 95).  Schwab et al. believing that inherited CYP2D6 
deficiency is unrelated to MDMA-induced hepatotoxicity, suggested an idiosyncratic 
reaction because there is no correlation between the severity of liver damage and either the 
amount of MDMA ingested or the frequency of MDMA use (105).   A fatality presenting 
with hyperthermia and fulminant liver failure – which originated following a single 





I.2.3.1.3  Central nervous system effects 
Relatively minor adverse sequelae experienced during the 24 hours following 
MDMA ingestion, include lack of energy and appetite, insomnia, jaw clenching, occasional 
concentration problems, brooding (108). Other reported side-effects are tremor, diaphoresis, 
trismus (tight jaw) and bruxism (jaw clenching), impaired gait, and restless legs (107,108).  
Rebound depression and lethargy has been reported in about 80 % of the subjects, in the 
days following MDMA use, due probably to monoaminergic depletion (109).  Following 
short-term administration of MDMA, a slight impairment in the performance of 
psychomotor tasks was noticed (110). 
Hyperthermia is one of the most feared acute toxic life-threatening complications of 
MDMA exposure. Biochemical analyses indicating metabolic acidosis, increased creatine 
kinase activity and hyperkalaemia are compatible with hyperthermia.  It has been postulated 
that dehydration could precipitate MDMA-induced hyperthermia (86).  Dysregulation of 
the thermoregulatory center is promoted when profuse sweating and intense physical 
activity in a hot environment occurs (1). Hyperthermia as part of a MDMA-induced 
serotonin syndrome has been postulated (111).  Neurotoxicological effects can also 
manifest themselves indirectly: e.g. signs of multiple organ failure such as acute hepatic or 
renal failure due to hyperthermia.  
It is not excluded that excessive drinking of water following MDMA ingestion can 
result in dangerous hyponatraemia (112,113) and cerebral oedema (114,115) which can 
develop into coma (116) and death (117).  The mechanism by which excessive fluid 
consumption occurs is not yet understood.  An additional mechanism that can aggravate 
hemodilution and hyponatraemia is the inappropriate secretion of antidiuretic hormone 
(118,119).     
The long-lasting effects of MDMA, even after abstinence, are not yet completely 
understood. A few reported cases suggest that these effects should not be underestimated. 
Verbal and visual memory impairment in abstinent MDMA users (120-124), and long-term 
memory problems related to storage and retrieval difficulties (125) were reported.  In 
addition, in chronic MDMA users - followed over the course of one year – progressive 
decline in terms of immediate and delayed recall were noticed (126).  The extent of the 
impairment correlated with the degree of MDMA exposure and the decrements in 5-
hydroxyindoleacetic acid [5-HIAA; metabolite of 5-HT (or serotonin)] concentrations 
determined in cerebrospinal fluid (120).   
  A case of pure amnesic syndrome after ingestion of half an MDMA tablet was 
reported and brain magnetic resonance imaging disclosed symmetric lesions in the globus 
pallidus (which were clinically silent) (127).  Spatt et al. assumed alterations in the 
hippocampi as cause of persistent memory problems in their case (127). 
There have been several reports of lasting adverse neuropsychiatric sequelae in 
humans who have chronically ingested (usually high) doses of MDMA. Moreover, it was 
suggested that individuals with prior psychiatric medical history can be more susceptible to 
MDMA’s adverse effects, such as acute (128) and chronic (129,130) paranoid psychosis, 
panic attacks (131), panic disorder with secondary depression (132) and depression with 




broad spectrum of psychiatric morbidity (134-136). Neuropsychiatric signs have also been 
reported following single or brief MDMA use such as panic disorder (137) and prolonged 
psychosis (138,139). As there is evidence that serotonin (5-HT) has a role in mediating 
antipsychotic drug effects (140), the involvement of 5-HT into the psychotomimetic and 
psychotogenic properties of MDMA can be assumed.  In addition - similar to the 
observation in memory impairment (120) - a decreased concentration of the 5-HT 
metabolite 5-HIAA in cerebrospinal fluid - as an index of brain monoaminergic function – 
was found in MDMA users (141,142).   
Brain-imaging studies are provided in the last few years to investigate the 
neurotoxic effects of MDMA.  For example, a reduced density of 5-HT uptake sites in 
several brain regions of MDMA users was found, as well as deficits in brain 5-HT 
transporter molecules (143,144) and altered blood flow in certain parts of the brain (145).  
Single-photon emission CT studies suggest that MDMA users may be at risk for 
cerebrovascular accidents due to alterations in the 5-HT-neurotransmission system (down-
regulation of 5-HT2-receptors implicating vasoconstriction) (146).  A case of toxic 
leukencephalopathy following a single MDMA use – confirmed by computed tomography 
and magnetic resonance – has been reported; the dose ingested neither a blood or plasma 
MDMA level were available (147).  Damage of serotonergic afferents could possibly 
mediate long-lasting alterations of cerebral glucose metabolism as a secondary effect (148).  
Moreover, a reduction in brain glucose metabolic uptake has been noted, for example, in 
the hippocampus of regular users (149).  Thus memory deficits in MDMA users could 
possibly be explained on the basis of alteration of the hippocampal function by MDMA. 
The gender difference, namely that women might be more susceptible to the neurotoxic 
effects of MDMA, was also noticed by means of single-photon-emission computed 
tomography (SPECT) (150).  Brain anomalies including cerebellar atrophy and thalamic 
dysfunction have been proven using imaging techniques such as magnetic resonance, but it 
is difficult to distinguish the relationship of these lesions to the effect of MDMA, on the 
one hand, and hypoxia and ischaemia, on the other (168).   
  
I.2.3.1.4  Uro-genital effects 
As MDMA is a potent α-adrenergic agonist, acute urinary retention can occur, and 
therefore MDMA (ab)use should be considered in young people presenting with 
unexplained acute urinary retention (151). 
Acute renal failure is often described in MDMA-related multiple organ failure 
originating from hyperthermia with rhabdomyolysis (86,152).  Sometimes haemodialysis is 
required (87). However, it has been hypothesized that rhabdomyolysis - which is a common 





I.2.3.1.5  Various symptoms 
Spontaneous pneumomediastinum - which is usually not life-threatening, but can 
require medical attention - is a rare complication after MDMA abuse (154-156).  Levine et 
al. postulated an increased intrathoracic pressure due to vomiting as a possible mechanism 
(154).  Pittman et al. proposed that the pneumomediastinum was caused by repeated 
Valsalva type maneuvers that resulted in episodes of increased intra-alveolar pressure, 
because their subject was repeatedly blowing a whistle during an eight-hour dancing 
session (155).   In the case reported by Quin, none of these mechanisms were present and 
therefore the authors concluded that the nature of physical exertion accompanying ecstasy 
intoxication led to the causative barotrauma (156). 
A few reports of aplastic anaemia following exposure to MDMA, which can be 
fatal, were published (157). 
In addition, a few cases of keratopathy after MDMA ingestion were reported (158); 
the mechanism of this corneal epitheliopathy remains unexplained. 
 
I.2.3.1.6  Multiple organ failure 
The above-mentioned commonly observed severe acute toxic effects such as 
hyperthermia, metabolic disturbances, seizures, hypertensive crises, cardiac dysrhythmia, 
and cerebrovascular accidents can escalate in severity and result in multiple organ failure.  
Feared complications include rhabdomyolysis, disseminated intravascular coagulation 
(DIC), adult respiratory distress syndrome (ARDS) and acute renal failure.  Hepatic failure 
is often part of multiple organ failure originating from hyperthermia.  Multiple organ failure 
is often the mechanism of death, even when intensive monitoring and therapy is performed 
(see below: IV.1.2. and IV.2.).  Figure 1.11 presents an integrated scheme of the 
mechanisms which can be involved in major MDMA-induced complications such as 
multiple organ failure (159).   For example, the complex cascade occurring in the clinical 
pattern in which MDMA ingestion leads to prolonged hyperactivity and hypovolaemia 
(resulting from insufficient volume repletion), which are important factors in the 
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Figure 1.11  Mechanisms by which MDMA may produce major complications.  Hyperthermia is 
more commonly an indirect effect, mediated through hyperactivity, rather than a 
direct pharmacological effect. 
Abbreviations: DIC: disseminated intravascular coagulation 
    ARDS: adult respiratory distress syndrome 
[reproduced from Henry JA In: Hopkins & Ellis (159)] 
 
 
I.2.3.2  Correlation between blood levels and clinical effects 
Important inter-individual differences in effects and adverse reactions following 
MDMA ingestion have been noted.  Therefore, the toxicity of MDMA in humans is an 
object of current debate (160).  It has been postulated that the striking inter-individual 
differences in intensity, time course and toxicity may be related to individual differences in 
the metabolic handling of the MDMA isomers (1).  Moreover, as cytochrome P450 
enzymes are important in the metabolism of MDMA (12), persons who have a genetic 
defect of these enzymes - and therefore are poor metabolizers – may be particularly 
sensitive to MDMA and hence be at more risk of toxicity (157,161).  In addition, referring 
to the illicit source of MDMA, it cannot  be excluded that unpleasant side-effects or even 
toxicity are – at least  partially – mediated by contaminants (162). 
In fatalities solely following MDMA ingestion, a wide range of blood levels has 
been reported with values ranging from 0.04 to 18.50 µg/ml (94,163, see also below).  This 
inter-individual difference is illustrated by Randall: a patient with an MDMA plasma level 
of 7.72 µg/ml after ingestion of 42 tablets only complained of “hangover” with tachycardia 




possible effect of tolerance in chronic MDMA abuse, which could be an explanation for 
this very high plasma level with minor clinical problems. 
A few rare cases of exceptional survival after high doses of MDMA have been 
described indicating the unclear relationship between a specific blood or plasma level and 
the clinical effects.   Brown et al. reported a nearly fatal case following MDMA intake: 1 to 
2 hours after admission to hospital, MDMA plasma levels of 6.5 and 7.0 µg/ml, 
respectively, were found (165).  Roberts et al. reported a subject who presented at the 
emergency department with a core temperature of 38.6 ° C, sweating profusely, vomiting 
and irritable with subsequent convulsions and respiratory problems resulting in the need for 
intubation.  A plasma MDMA level of 4.05 µg/ml - after intentional ingestion of 18 tablets 
– has been reported. The patient recovered within one week, however, although he admitted 
being forgetful, irritable and having flashbacks to events immediately prior to losing 
consciousness (166).  Ramcharan et al. described a case in which unconsciousness, apnea 
and convulsions developed after intake of 50 tablets, but recovery occurred within 2 days 
(74).  Unfortunately in this case, an MDMA blood or plasma level determination was not 
available.  The subject published by Mallick et al. ingested three tablets of ecstasy and 
survived the subsequent hyperpyrexia (42.9 °C) which included convulsions, 
rhabdomyolysis, metabolic acidosis and respiratory failure, but unfortunately, no MDMA 
blood or plasma level is available for this case either (167).   
It should be emphasized that polydrug abuse makes this toxicological discussion 
even more hazardous.  A woman who suffered from a DIC and a brief cardiac arrest 
following the combined intake of MDMA, amyl nitrite, lysergic acid diethylamide (LSD), 
cannabis and alcohol, developed an amnesic syndrome and severe ataxia (168).  This 
question becomes even more complicated to solve when different amphetamines have been 
taken together. For example, Agaba et al. reported a case presenting with massive 
intracerebral hematoma and extradural hematoma after “amphetamine” ingestion (169): the 
composition of the tablets taken was not known, but a combination of pure amphetamine 
and MDMA was postulated and therefore the impact of the two on the symptoms is not 
clear (169).  This remark can also be applied to the case presenting with chronic renal 
failure (due to necrotizing vasculopathy) after ingestion of methamphetamine and MDMA 
(170). 
 
II Epidemiological data on the use of MDMA 
There are no clear epidemiological data on (ab)use of amphetamine and derivatives.  
This is probably due to the fact that there are no specific international directives mandating 
systematic screening for these substances.  This also holds for Europe, though efforts have 
been made to map the use of drugs among the population, including the use of 
amphetamines and “ecstasy”. In addition, guidelines have been presented for ensuring 
quality and for comparing the studies performed in the various European member states 
(171).   





II.1  Europe 
II.1.1  Belgium 
Epidemiological data on MDMA use in Belgium are scarce, although such data are 
being collected by the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA). The use of amphetamines and “ecstasy” in Belgium shows the same evolution 
as in the other European countries: an obvious increase was observed between 1994 and 
1998 in the numbers of 15 to 16 years-old who have ever used MDMA (from 4.1 to 6.2 %) 
and from then on a plateau phase was recorded (172).  In addition, the lifetime prevalence 
of MDMA and amphetamines for young people aged 15-16 and 17-18 is higher in the 
French Community than in the Flemish Community (173).  Recently, the drug-related 
medical problems due to the use of recreational drugs during two famous events (‘I love 
techno’ and ‘De Nacht’) were studied: in the patients evaluated in an emergency 
department (Ghent), the dominant drug abused was ecstasy (174).   
 
II.1.2  Other European countries 
In England, an informal survey of undergraduates more than 10 years ago revealed 
that  about 40 % admitted having used MDMA at least once (76,175).  The frequency of 
use by the subjects varied significantly, and ranged from 1 to 38 times. The median amount 
of MDMA usage reported by these undergraduates was four doses, while the mean number 
of doses taken was 5.4.  The amount of drug taken in a single dosage ranged from 60 to 250 
mg (approximately 1 to 4 mg/per kilogram bodyweight) (175).   
In the European studies, amphetamine and MDMA use is usually classified as being 
part of a subgroup such as the “synthetic drugs” or “hallucinogens” (171).  It has been 
noted that the spread of synthetic drugs in the European Union has stabilized, though the 
use of ecstasy is still increasing in certain locations (cities, holiday resorts, youth cultures) 
(171-177). It was reported that in 1998 0.5 – 3 % of the adult European population (mainly 
young people, of course) had at one time or another used ecstasy (178).  In the Health 
Behaviour of School-aged Children (HBSC) survey, repeated community surveys are 
performed in schools among young people aged 15 to 18 years: cannabis has been found to 
be the most popular drug, though until 1999 MDMA was the second most used product; 
since then a trend toward stabilisation - or perhaps even a slight decrease - has become 
apparent (173).  
More recently, in the UK, the ecstasy-induced death rate in 1996 per 10 000 15-24-
year-old users was defined as between 0.2 and 5.3; the death-rate from road traffic 
accidents in the same age-group was 1.0 (179).   
Non-published data in Switzerland indicate that the age of the subjects at first 
consumption was obviously lower in 1999 than 1996.  Forty-five percent of first-time 
consumers were 17 years of age or younger in 1999, whereas in 1996, about 28 % were 
younger than 18 (180). 
A school-based survey in Oslo of adolescents between 14 and 17 years of age 
disclosed that ecstasy is used in a polydrug-use pattern (181).   
An overview of the available epidemiological data in Italy and other European 




II.2  USA and the rest of the world 
Surveys in the USA examining the prevalence of MDMA use among high school 
sophomores and seniors revealed increasing use in the 1990s (183).  For example, for 
seniors in 1999, lifetime prevalence of MDMA use had risen from 5.0 % to 8.0 % in the 
previous three years (183 ). A study performed in 119 US colleges (involving a study 
population of over 14,000 students) revealed an increase of prevalence from 2.8 to 4.7 % 
between 1997 and 1999 (184).  Furthermore, the results obtained in a smaller sample of 10 
colleges showed that the increase continued in 2000 (184).   
Just as in the European countries, an increase in MDMA use was noted among rave 
club attendees (185). 
To our knowledge, there are no epidemiological data available concerning MDMA 
use in Australia or the Asian countries although a few fatal cases have been described (163, 
186).  
The MDMA fatalities reported in the international literature are summarized below 
(see pag 33- 41).  
 
III  Medico-legal implications of MDMA 
The above-mentioned behavioural and cognitive effects of MDMA can result into 
non-lethal accidents, suicidal behaviour or even crimes. As for all drug fatalities, the 
manner of death can be related to accident, suicide or criminal activity. At present, the risks 
of MDMA (ab)use for humans – to the user him/herself and to his/her acquaintances – are 
difficult to define  (160).  
    
III.1  Accidents  
It is difficult, if not impossible, to determine the boundary between the desired 
effects, such as euphoria, and feelings of closeness, and the adverse effects, such as 
impairment of cognition and co-ordination and - in an advanced phase – hallucinations, 
agitation, abnormal behaviour, and even psychosis.  The majority of the reported 
intoxications are “accidental”, being due to the higher sensitivity of a subject to a “normal” 
recreational dose, though severe adverse effects can sometimes occur due to the content of 
certain tablets (which can be of purer quality than one is accustomed to ingest).  
Furthermore, it is generally accepted that the use of amphetamines and their derivatives can 
increase the risk of being involved in accidents, though the possible increased risk has not 
yet been established (187).   
Over a three-month period, 16 ecstasy abusers were treated in a single emergency 
department for injuries due to traffic accidents; all of which had been caused by reckless 
driving (188).  From 1995 through mid-1996, a prospective multicentre study was 
conducted in hospital emergency departments in Belgium in order to investigate the drug-
related traffic accidents (Belgian Toxicology and Trauma Study or BTT Study): urine 
tested positive for amphetamines in 3 % of all accidents (189).  In this study, amphetamines 
and XTC were detected in urine in 2 % of injured drivers (190).  This is in accordance with 




5 cases in which bizarre and dangerous behaviour was exhibited when driving after MDMA 
ingestion; unfortunately, the MDMA blood or plasma levels were not reported (194). 
Recently, drivers under the influence were studied in Belgium: cannabis and 
amphetamines were obviously the major drugs detected in the impaired driver population 
(195).  Amphetamine as such and combinations (with cannabis and cocaine) accounted for 
about 32 % and about 20 %, respectively, of this population (195). 
Seven non-fatal accidents involving people determined by police officers to be 
“driving while under the influence” were MDMA or MDEA-related (196).  Serum levels of 
MDMA and related compounds in impaired drivers were described: 18 of the 30 cases were 
positive for MDMA, with a concentration range of 1 to 514 ng/ml and  a median level of 76 
ng/ml (197).  Omtzigt et al. reported 39 drivers under the influence of amphetamine and 
derivatives: 9 subjects were MDMA positive and whole blood concentrations ranged from 
0.04 to 0.38 µg/ml (198).  In the 18 cases of apparent MDMA-impaired driving reported by 
Logan et al., most subjects showed muscle twitching and body tremors, dilated pupils and 
slow pupillary reaction to light, increased pulse and blood pressure, problems with balance 
and co-ordination, and profuse perspiration (199).  No clear correlation between the 
MDMA blood level and the specific demeanour of the subject could be demonstrated (199) 
and, as a result, the individual variability was confirmed.   
Easy monitoring techniques, including the use of alternative matrices such as saliva 
and sweat, for detecting drugs of abuse (including amphetamine and derivatives) in drivers 
have been published (200,201). 
A few cases have been reported in which the relationship between MDMA intake 
and traffic accident fatalities has been established (87,188,202,203).  Henry et al. described 
five road traffic accident victims in whom MDMA had been identified; two of these had 
died (87).  In 7 out of the 30 amphetamine-related fatalities reported by Lora-Tamayo et al., 
the subjects had been involved in a traffic accident; in 3 out of the 7, MDMA had been 
found (204). 
For comparison, in the methamphetamine-related fatalities reviewed in Taiwan, the 
majority of the cases were accidental deaths (59 %) (205). 
Workplace drug testing (WDT) has not yet become well regulated and is therefore 
not systematically performed in Europe (206).  Consequently, industrial accidents related 
to drug (ab)use may possibly be underestimated. 
In one of the cases reported by Dowling et al. (207), the subject died due to 
electrocution and multiple injuries.   
Finally, an “accidental ingestion” of MDMA by a 13-month-old boy is reported.  
Fortunately, the convulsions, hypertension (180/70 mmHg) and tachy-arrhythmia (170 
beats/min) were successfully treated with chlormethiazole.  About 90 minutes after 
ingestion of a capsule of MDMA, a serum level of 0.7 µg/ml was found.  The child 
recovered completely within four days and had no short-term neurological deficit, though 





III.2 (Attempted) suicide  
A few suicides and suicide attempts by means of MDMA are described (e.g. 74, 
138, 166, 209-211).  It is not excluded - though it is difficult to prove – that psychiatric 
disturbances resulting from intentional recreational MDMA use can develop into suicidal 
tendencies.  However, it is hardly possible to conclude that MDMA is solely responsible for 
inducing depression and/or suicidal behaviour, though as an association between MDMA 
use and serotonergic alterations was postulated, some connection can be assumed (210).  
Moreover, gender differences were noticed: women are more susceptible than men to mid-
week depression (212). 
Cox reported a suicide case in which a time interval of twelve days between 
ingestion and death took place: a previously healthy 21-year-old man experienced an acute 
paranoid psychotic reaction and was therefore admitted to a psychiatric department.  This 
psychosis apparently resolved spontaneously after 48 h.  On the eighth day after discharge 
he committed suicide by drowning (213). 
Furthermore, it is not excluded that some suicides are - unintentionally – classified 
as accidents: for example one of the cases reported by Dowling et al. (207) died due to 
electrocution and multiple injuries as he climbed up a utility tower.  In that case it was not 
clear whether he fell to the ground following a hallucination (such as thinking he was able 
to fly) or resulting from a severe depression with suicidal behaviour. 
For the sake of completeness, and because “ecstasy” tablets do not necessarily 
contain MDMA alone: suicide has also been reported after intake of  3,4-
methylenedioxyethyl-amphetamine (MDEA or “Eve”) and N-methyl-1-(3,4-
methylenedioxyphenyl)-2-butanamine (MBDB), two compounds closely related to MDMA  
(214-216).  
 
 III.3 Criminal offences 
Aggression and violence associated with substance abuse is well known, having 
been described for stimulants such as cocaine (217).  Literature data on criminal offence 
resulting from (ab)use of MDMA or other amphetamine-related substances are not 
available to our knowledge. For example, incidents of extremely violent behaviour leading 
to fatalities can be assumed to have happened, but have not been confirmed in the literature, 
except for the following cases.   Omtzigt JGC et al. described a man accused of attempted 
manslaughter in whom an MDMA blood level of 0.14 µg/ml was found (198). Bernhard 
presented 25 fatalities (between 1977 and 2001) in which “3 XTC related crimes with 
violence” are noted (180).  Moreover, aggressive behaviour following MDMA use was 
studied in a few clinical trials (212,218-220).  Morgan found that ecstasy users exhibited 
increased impulsivity and that persons having the most elevated trait impulsiveness scores 
had taken the highest amounts (218).  Data indicate that chronic and heavy recreational use 
of MDMA can result not only in a significant risk of persistent cognitive impairment, but 
also disturbances of affect and personality (219). MDMA subjects rated lower levels of 
aggression on the night they used the drug, but both men and women showed significantly 
higher levels of aggression three to four days later (212). Differences in personality 




modulating impulsive and aggressive personality traits (141,221).  In addition, 
aggressiveness in MDMA users was evaluated by quantitation of hormone levels : 
increased catecholamines reactivity, basal hypothalamus-pituitary-adrenal axis 
hyperactivity and blunted ACTH responses could be due to MDMA action on 
monoaminergic pathways and adrenal function (220).  These authors concluded that 
aggressive responses were significantly higher in ecstasy users in comparison with control 
persons (220,222).  However, McCann et al. reported that some MDMA users may have 
decreased impulsivity as well (141).   
MDMA was associated with high-risk sexual behaviours among some gay and 
bisexual men (223) and therefore, theoretically, an increased chance of sexual assaults 
could not be excluded.  In addition, it is advisable also to screen for MDMA in sexual 
assaults or “date-rape” cases (224). 
The question remains open as to whether someone who commits a criminal offence 
under the influence of MDMA can be held responsible for his actions or not.  In other 
words, it is hazardous to declare someone to be of unsound mind or not.  
For comparison, Ellinwood described 13 persons who committed homicide while 
intoxicated with amphetamines (225).  In the majority of these cases, the criminal events 
were related to psychiatric disorders such as amphetamine-induced paranoid thinking and 
panic attacks (225).  In the review of methamphetamine-related fatalities by Zhu et al., 4 of 
the 15 cases were homicides, and the immediate cause of death was related to head injuries 
and stab wounds (226).  In the study group of Shaw, 14 % of the methamphetamine-related 
fatalities were homicides (205).  In these reports, it is not specified whether the subjects 
were victims or aggressors.  
 
IV Thanatological findings 
IV.1  Anatomo-pathological data in MDMA-related fatalities      
IV.1.1  General findings 
The general considerations addressed in dealing with all drug involved victims are 
also applicable to amphetamine-related fatalities (227), namely the person may have died 
due to a very high fatal blood level, but death may also have been the result of medical 
derangements originating from chronic consumption.  The third possibility is that death 
may not have been directly due to the drug concentration itself, but rather to drug-induced 
altered behaviour that can cause a person to take too many risks, thus leading to fatal 
accidents, such as death due to cranio-cerebral trauma or polytrauma following a traffic 
accident.   
In his literature review, Kalant found 87 fatalities involving ecstasy or related drugs 
(1); the mechanisms or manners of death were as follows: 
- cardiovascular and cerebrovascular: n = 8 
- hepatic: n = 4 
- cerebral including hyponatraemia: n = 9 
- hyperpyrexia: n = 30 
- misadventure (suicide, accident): n = 14 




External examination of a “pure” acute drug overdose victim generally reveals only 
non-specific signs which can indicate drug abuse.  As polydrug abuse (including 
amphetamines) is very frequent, non-recent injection marks, caries, pin-point pupils (found 
in opiate intoxications) or mydriasis (typical for central stimulants such as cocaine, 
amphetamines), drug paraphernalia etc. should raise suspicions, thus prompting the 
performance of a toxicological investigation.  A frothy foam on the nose and/or mouth 
resulting from acute pulmonary oedema is often observed in narcotic overdose deaths 
(227), though it may be found in any intoxication.  Cyanosis and congestion of the face, and 
pronounced dark-violet livores - possibly with vibices - indicating acute to subacute 
cardiopulmonary failure are also frequently observed. 
During internal inspection of an acute drug overdose victim, non-specific signs of 
an asphyxial mechanism of death - due to acute to subacute cardiopulmonary failure - will 
be noticed: acute pulmonary oedema and generalized visceral congestion. Tardieu spots on 
the pleurae or epicardium can be found as well (227).   
Pathological consequences resulting from chronic – mainly intravenous - drug 
abuse which can be found at autopsy include aspiration pneumonitis, viral hepatitis, 
aspecific lymphadenitis and bacterial endocarditis (227).  
The microscopical changes found in drug abuse may be attributed to the direct toxic 
effect of the drug on a tissue or to indirect adverse physiologic reactions such as hypoxia, 
which are precipitated by the drug action on the central nervous, respiratory, or 
cardiovascular systems (228). The combination of perivascular fibrosis, microvascular 
disease, and contraction band necrosis in the cardiac muscle is assumed to be nearly 
diagnostic for chronic exposure to high concentrations of catecholamines, which can be 
explained for example by chronic stimulant abuse (17).  As chronic polydrug abuse (and 
thus variable routes of administration including intravenous injection) is frequent, 
pulmonary microscopical complications include pneumonitis, thrombotic or embolic 
phenomena, bronchitis, and diffuse multifocal foreign-body granulomata (228). In these 
granulomata, birefringent and crystalline material is often present (228).  These foreign-
body granulomata can also be found in other organs such as the spleen, lymph nodes, and 
liver (228).   Another even more common finding in the liver pointing to chronic – mainly 
intravenous - polydrug abuse is a chronic inflammatory infiltrate of the portal triads 
composed predominantly of lymphocytes, but also of occasional mononuclear cells, plasma 
cells, neutrophils and eosinophils (228).  The eosinophils indicate an allergic reaction to 
foreign material.  This portal triaditis can be isolated or associated, for example, with 
hepatitis, liver steatosis or even cirrhosis (228).  In addition, aspecific mucosal 
inflammation of the gastrointestinal tract and haemorrhagic gastritis can be retrieved (228).  
In the brain as well, non-specific histological findings predominate: e.g. vascular 
congestion, perivascular haemorrhage, focal cerebral cortical or cerebellar haemorrhage, 
oedema, degenerative neuronal changes, focal necrosis, inflammation, glial reaction and 





IV.1.2 Findings pointing to (ab)use of amphetamine and derivatives  
The pathological findings in deaths associated with the use of amphetamine and 
derived compounds such as methamphetamine (METH), 3,4-methylenedioxyamphetamine 
(MDA), 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”), and 3,4-
methylenedioxyethylamphetamine (MDEA) are not yet completely understood.  Indeed, 
when someone dies after intake, not only can the interpretation of the specific concentration 
be hazardous, but also the macroscopical and microscopical autopsy findings can include a 
broad spectrum of non-specific assessments.  Postulated mechanisms of death include 
cardiovascular failure, toxic liver effects, multiple organ failure induced by hyperthermia 
and disseminated intravascular coagulation (DIC)  (94). 
As mentioned above, cardiovascular complications resulting from MDMA abuse 
can be due to severe hypertension with haemorrhages on the one hand, and cardiac 
arrhythmia (e.g. ventricular tachycardia) on the other.  Both mechanisms can develop into 
heart failure, thus resulting in signs of acute to subacute cardiopulmonary failure at autopsy 
(1). This is in accordance with the findings in methamphetamine fatalities (229).  For 
amphetamines, the cardiopulmonary failure can be induced by the sympathomimetic 
properties, though it can also result from central depression of these vital functions, such as 
when hyperthermia takes place.  Occasionally, a severe hypertensive reaction can occur 
even at recreational doses, particularly in subjects with latent cardiovascular problems 
(108), which can sometimes be an incidental discovery during autopsy.  Noradrenaline 
release can account for these direct cardiovascular effects, which can lead to sudden 
cardiovascular collapse (e.g. due to aortic dissection (230,87,94,231).  Histologically, 
changes induced by MDMA can vary from contraction band necrosis to individual myocyte 
necrosis with a surrounding neutrophil and macrophage inflammatory response (94).  These 
lesions can be correlated to catecholamine induced acute myocardial injury.   It is not 
excluded that the focal subendocardial haemorrhage, which is described in 
methamphetamine-related fatalities (usually surrounding areas of myocyte disruption) 
(232), can also be found in MDMA induced fatalities as a sign of increased catecholamine 
release.   
For stimulants such as cocaine and amphetamines, recent and older macro- and 
micro-infarctions can be found in several organs, though presumably cardiac and cerebral 
(232).  
Haemorrhagic and ischemic stroke have been described following 
methamphetamine use via smoking, oral ingestion or intravenous means (232) - and it can 
be assumed that they have also occurred after the use of other amphetamine derivatives.  In 
amphetamine and methamphetamine abuse it was possible (by means of angiographic 
evidence) to demonstrate that intracranial and subarachnoid haemorrhage could sometimes 
be correlated with arterial spasm (232).  
Small foci of myocardial fibrosis resulting from micro-infarction can indicate non-
recent “ecstasy” use (94 ).  Cardiomyopathy (associated with an enhanced heart weight, but 
normal coronary arteries) seems to be more common in chronic amphetamine than in 




Histologically, in chronic amphetamine or methamphetamine abusers – just as in 
cocaine addicts – interstitial myocardial fibrosis can be a prominent finding (232).  In 
addition, granularity of myocyte fibers, occasional myocyte hypertrophy with disarray, and 
medial hypertrophy of the arterioles have been described (232).    Necrotizing vasculitis 
resulting from amphetamine abuse is histologically almost identical to that seen in 
polyarteritis nodosa, including fibrinoid necrosis of the intima and media with mixed 
cellular infiltrates (232).  Both smaller and larger vessels can be involved.  When found 
following longer survival periods, intimal proliferation associated with marked luminal 
narrowing - especially at the bifurcation of vessels - was noticed.  Moreover, giant cells 
were characteristically absent and the veins were spared (232).    
Pulmonary changes that can be found at autopsy – apart from congestion and 
oedema – include pulmonary infarction, intra-alveolar haemorrhage and inhalation of 
gastric contents (94).  As – to our knowledge - MDMA is principally used orally, the 
thromboembolic arteriopathy (with thrombosis of small vessels, foreign body granulomas) 
usually seen in chronic intravenous users of whatever substance is rare, and therefore 
pulmonary hypertension, which is sometimes described in amphetamine and 
methamphetamine addicts (232), is scarce.   Primary pulmonary hypertension as a 
consequence of serotonin alterations has been postulated for all stimulants regardless of the 
means of administration (232).  As recreational use of MDMA alone or in combination with 
alcohol can alter the immunological status, i.e. result in immune dysfunction (233,234), a 
greater susceptibility to infections can be assumed.  In methamphetamine-related fatalities, 
pneumonia was the most obvious finding capable of evoking natural death (235). 
Possible hepatotoxic effects have already been described above (including hepatitis 
as the most frequently found hepatic lesion; see I.2.3.1.2), but can logically also be found at 
autopsy.  During histological inspection, hepatocellular necrosis (either focal or massive 
with confluent lytic necrosis of zones 2 and 3) expanded portal tracts due to oedema and 
inflammatory infiltrates (rich in eosinophils), sinusoidal dilatation, canalicular bile plugs 
(occasionally) and/or microvesicular fatty degeneration of the hepatocytes can be observed 
(94,96,100).  As mentioned above, there is no clear relationship between the amount 
ingested or frequency of MDMA use and the degree of liver damage found, and therefore 
an idiosyncratic type of reaction – whether fatal or not - is hypothesized (97).  Moreover, 
methamphetamine may enhance the toxicity of other hepatotoxic agents, such as carbon 
tetrachloride (232). 
When hyperthermia occurs, apart from acute congestion, brain oedema is obvious. 
Hyperthermia is frequently followed by multiple organ failure with evidence of 
rhabdomyolysis often resulting in acute renal failure (152), adult respiratory distress 
syndrome (ARDS), and DIC (209,236,237).  In addition, immunohistochemical 
demonstration of myoglobin in the kidneys (238) and depletion of myoglobin in the cardiac 
muscle can confirm the hyperthermia (239).  Similar findings have been described in 
MDEA fatalities (240,241). 
The neuropathological findings have been studied using animal experiments, but 
are hardly known in MDMA users.  However, Kish et al. found that striatal (caudate, 




hydroxyindolacetic acid were decreased by 50 to 80 % in the autopsied brain of a chronic 
MDMA user (242).  Dopamine concentrations were only moderately depressed (by 47 %) 
in the nucleus accumbens of this subject and unaffected in the caudate nucleus and 
putamen, suggesting that the nucleus accumbens – which is a limbic striatal subdivision - 
might be more sensitive to the dopamine-releasing action of the drug (242).  
Macroscopically and microscopically, acute congestion and oedema of the brain is often 
found.  Apart from signs of DIC, possible histological findings include, foci of 
haemorrhage, perivascular haemorrhages, and degeneration of neurons, which can be 
particularly apparent in the locus ceruleus in the upper pons (94).   
Squier et al. described a subject who took a combination of “ecstasy”, amphetamine, 
heroin and alcohol (243).  He was found unconscious and admitted to hospital, where he 
remained comatose and pyrexial (38.5°C) till his death five weeks later.  At autopsy, 
bronchopneumonia and pulmonary embolism were determined to be the immediate causes 
of death.  Brain dissection revealed bilateral necrosis of the globus pallidus and small foci 
of necrosis in the white matter.  This was confirmed by histological examination and, in 
addition, mild astrocytic gliosis was found in the amygdala and hypothalamus.  Moreover, 
the cerebral white matter showed diffuse gliosis and spongy change without myelin debris 
or inflammation, with only the subcortical zones being spared.  The cerebral cortex, 
hippocampus, brainstem and cerebellum were normal (243).  Bearing in mind the combined 
intake of several drugs, it is unfortunately uncertain that the bilateral necrosis of the globus 
pallidus – though this area is rich in serotonergic and dopaminergic nerve terminals - can be 
fully attributed to the “ecstasy” and/or amphetamine intake. Referring to the findings in 
animal experiments (42) in which changes in the nucleus accumbens (which is adjacent to 
the globus pallidus) have been demonstrated, the hypothesis of Squier et al. can be 
assumed.  However, bilateral globus pallidus necrosis is classically described in carbon 
monoxide intoxications with prolonged survival, but also in opiate overdoses.  Damage to 
the globus pallidus can be observed in hypoxic-ischaemic cerebral injury, but then almost 
always in association with damage of the hippocampus or other areas of the cerebral cortex, 
a condition which was not observed in the case just described (243). 
To our knowledge, there are no other data available of neuropathological findings in 
humans that can be related to the serotonergic toxicity of MDMA. 
 
A summary of possible histological findings in MDMA-related fatalities is presented in 
Table 1.3 (reproduced in part from Fornes: 244).  Although the mechanism of MDMA-
induced  hyperthermia is different, the clinical manifestations and anatomo-pathological 
findings are to a great extent comparable with those described in exertional heat stroke (see 





Table 1.3  Survey of the histological findings which can be observed in MDMA-induced 
fatalities.  
[in part reproduced from Fornes (244)] 
 
organ pathology 
heart acute to subacute lesions 
 - individual myocyte necrosis, possibly with inflammatory response 
 - contraction band necrosis 
 non-recent lesions 
 - foci of fibrosis 
 - myocyte hypertrophy 
  
lungs acute lesions 
 - congestion 
 - oedema (sometimes with haemorrhagic component) 
 - alveolar haemorrhage 
 - vomit aspiration 
 - diffuse alveolar damage (DAD)  
  
liver acute to subacute lesions 
 - centrolobular and midzonal necrosis 
 - portal and sinusoidal inflammation (mainly neutrophilic infiltration) 
 - steatosis 
 - focal or fulminant hepatitis 
 - signs of disseminated intravascular coagulation (DIC) 
 chronic lesions 
 - cholestasis 
 - chronic portitis (infiltrate consisting of lymphocyte, eosinophils, macrophages)  
 - chronic hepatitis 
  
kidneys  acute lesions 
 - acute tubular necrosis; myoglobin observed in tubuli related to rhabdomyolysis 
 - signs of DIC: e.g. fibrin thrombi in the glomeruli 
  
skeletal muscle  acute lesions 
 - necrosis related to rhabdomyolysis 
  
brain acute to subacute lesions 
 - moderate to severe oedema 
 - intense vascular congestion, possibly associated with perivascular haemorrhage 
 - subarachnoid haemorrhage 
 - intracerebral haemorrhage or infarction 
 - signs of DIC 
 - necrosis of the globus pallidus 
 - seldom: leukoencephalopathy, necrosis of the locus ceruleus 
 non-recent lesions 




Table 1.4  Survey of the complications of heat stroke (clinico-pathological findings).   
[reproduced from Dickinson (245)] 
 
organ pathology effects 
brain - oedema - convulsions 
 - petechial haemorrhages - coma 
 - congestion 
  
muscle  - rhabdomyolysis - acute renal failure 
  - hyperkalaemia  
  - hyperuricaemia  
  - hypocalcaemia  
  - hyperphosphataemia  
  - enzyme release, esp. creatine kinase 
  - possibly disseminated intravascular 
  coagulation (DIC) 
  
blood - lactic acidosis - fragmentation of red blood cells 
 - DIC - acute renal failure 
  - thrombocytopenia  
  - haemorrhage 
  - thrombosis 
  - haemolysis 
  
liver - centrilobular necrosis - liver cell failure: 
     jaundice 
     haemorrhage 
     hypoglycaemia 
     enzyme release 
  
kidneys  - acute tubular necrosis - acute renal failure: 
     oliguria 
     acidosis 
     hyperkalaemia  
  
lungs - respiratory alkalosis - tetany 
 - aspiration pneumonia  - hypoxia 
 - haemorrhagic pneumonia  
  
heart - haemorrhagic myocarditis - shock 
  
gastro-intestinal - non-specific general bleeding - nausea, vomiting, diarrhoea 





IV.2  Thanato-toxicological data in MDMA-related fatalities 
The pharmacokinetics of drugs taken in overdose may differ from those observed 
following therapeutic doses and therefore may result into a poor correlation between the 
clinical findings in overdose patients and the blood concentrations of ingested drugs (246).  
Clinically, blood levels in intoxicated persons may thus be difficult to interpret, though 
after death, this interpretation becomes even more tenuous.  In addition, post-mortem blood 
levels can be influenced by post-mortem processes such as instability, redistribution and 
even neoformation. 
 
IV.2.1  Animal experimental data 
 To our knowledge, animal models investigating post-mortem distribution and re-
distribution of MDMA are not available and therefore this will be investigated (see part 
two). 
 For methamphetamine, Nagata et al. studied post-mortem rabbit tissue 
concentrations in vitro for up to a period of 2 years after death, and demonstrated that 
skeletal muscle and bone marrow are the most appropriate specimens for assessing toxicity 
of methamphetamine and its metabolite amphetamine (247). 
 For amphetamine and methamphetamine, animal experiments dealing with this 
subject in situ are scarce (248, 249).  Hilberg et al. administered amphetamine to rats by a 
gastric tube and the animals were killed 90 minutes later.  Cardiac blood was sampled 
immediately before sacrifice and 2 h post mortem (248).  Post-mortem blood samples from 
the inferior vena cava, the vitreous humour and various tissues were tested.  The authors 
concluded that the amphetamine level in the vena cava blood was more closely related to 
the ante-mortem blood level, confirming that a peripheral blood sample is recommended.  
However, in the data presented, the difference between amphetamine levels in cardiac 
blood and vena cava inferior is rather minor (see Table 1.5).  The ratios of post-mortem 
tissue concentrations of amphetamine to the ante-mortem blood level are presented in Table 
1.5 (248). The similar mean ratio calculated for the vitreous humour level was 1.1 ± 0.2 
(see Table 1.5).  Obviously higher amphetamine levels in tissue compared to ante-mortem 
blood were found in the kidneys, and less pronounced though also elevated tissue levels 
were seen in liver, lungs, and brain (248) indicating tissue accumulation of the substance.  
Vitreous humour and muscle amphetamine levels were more closely related to the ante-
mortem blood concentration.   
Moriya et al. studied the redistribution of methamphetamine in the early post-mortem 
period in the rabbit following intravenous administration and compared the blood and tissue 
levels with (Group I) or without (Group II) ligation of the large vessels around the heart 
(249).  The lung levels were the highest of all, followed by the blood and myocardium 
concentrations, and the liver levels.  The mean ratios of the cardiac blood concentrations 6 
h post mortem to the level at the time of death were for group I in the left and right 
chambers 1.13 ± 0.42 and 1.07 ± 0.04, respectively.  The analogous ratios for group II were 




methamphetamine can be redistributed rapidly into the pulmonary venous blood and then 
into the left cardiac chamber (249). 
 
 
Table 1.5  Post-mortem blood, vitreous humour and tissue amphetamine levels in the rat, 2 
hours after in vivo gastric infusion.  
[reproduced from Hilberg et al. (248)] 
 
 ratio of post-mortem fluid or tissue amphetamine level to 
 antemortem blood concentration (mean ± SE) 
cardiac blood 2.4 ± 0.2 
vena cava blood 2.3 ± 0.3 
vitreous humour 1.1 ± 0.2 
carcass homogenate 1.0 ± 0.2 
lung 1.8 ± 0.1 
myocardium 0.9 ± 0.1 
liver 2.0 ± 0.7 
kidney 6.3 ± 2.0 
thigh muscle  0.8 ± 0.2 
brain 1.8  ± 0.6 
 
 
IV.2.2  Survey of MDMA-related human fatalities 
 At present the interpretation of a specific post-mortem MDMA blood level should be 
made in the light of the available case reports.  Relevant data are summarized in Table 1.6. 
Unfortunately, the blood sampling site is often not mentioned, though when it is available, 
it is indicated. 
 
Abbreviations:  
PM: post mortem; 
AM: ante mortem; 
MDMA: 3,4-methylenedioxymethamphetamine; 
MDA: methylenedioxyamphetamine;  
MDEA: 3,4-methylenedioxyethylamphetamine; 
AMP: amphetamine;  
PMA: para-methoxyamphetamine;  
METH: methamphetamine;  
ARF: acute renal failure;  
DIC: disseminated intravascular coagulation;  
TA: traffic accident;  
NA: not available;  
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1  Blood level expressed in µg/ml for all drugs, unless stated and except for ethanol concentrations 
(g/l). 
2  When “accidental” is not specified, an unintentional death after recreational use (e.g. long-term 
dancing at a “rave party”) is assumed. 
3  Femoral blood levels.  Cardiac blood levels of MDMA, MDA and AMP are 9.10, 0.83 and 0.11 
µg/ml, respectively.  Brain MDMA concentrations were 10 µg/g in the medulla (not specified) 
and 14 µg/g in the cerebellum.  In his hair (0 to 6 cm), 6.70 µg/g was found.  
4  Femoral blood levels. Cardiac blood levels of MDMA and MDA are 0.42 and 0.04 µg/ml, 
respectively. 
5  Femoral blood level. Cardiac blood concentration: 3.51 µg/ml. 
6  Femoral blood level. Cardiac blood concentration: 5.38 µg/ml. 
7  Serum MDMA level upon admission to hospital; the man died 5 hours after arrival. 
8  Woman admitted to hospital a few hours after ingestion of one “ecstasy” tablet; she died 36 h 
later.  Blood and stomach MDMA levels on admission were 0.42 and 28 µg/ml, respectively. 
9  Woman ingested one tablet; died 9 days after admission to hospital.  A toxicological screening 
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Cox (213) 21 M blood PM <LOD
10 
drowning suicide asphyxia  
Cox (251) 
 





























































































of 0.25 µg/ml; neither at what time this concentration was found, nor the origin of the blood 
sample are specified.   
10  The man committed suicide on the eighth day after an acute psychosis (see also III.2). 
11  Femoral blood concentrations. MDMA and MDEA concentration in blood sampled upon 
admission to hospital: 0.55 and 0.49 µg/ml, respectively. 
12  MDMA concentration in clotted and anticoagulated cardiac blood: 2.32 and 2.14 µg/ml; vitreous 
humour and urine MDMA levels: 1.11  and 118.8 µg/ml, respectively.  MDA level in blood and 
vitreous humour was < 0.25 µg/ml and 3.86 µg/ml in urine. 
13  Man died 6 h after initial presentation in hospital.  He ingested 10 tablets of ecstasy.  Liver 
MDMA concentration:1.2 µg/g. 
14  The man climbed a high voltage utility tower to a height of 13 m, was electrocuted and fell to the 
ground.  MDMA was positive in blood, but unfortunately not quantified. 
15   The man was found dead beside his car, with an inhaler in his hand.  Two hours before, he “had 
been drinking alcohol with his friends”.  Post-mortem examination revealed features of acute 
and chronic bronchial asthma. No theophylline was detected. 
16  Toxicological analysis of both ante- and post-mortem blood revealed the same MDMA 
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17  Sampling at about 6 hours following ingestion of ecstasy.  She died in spite of a liver 
transplantation. 
18  Woman took MDMA on a regular basis and even continued to use it when obvious jaundice 
occurred.  There is no information available about the last ingestion.  Arrived at hospital in 
encephalopatic (grade II) condition due to MDMA-induced acute liver failure.   
19  Woman presented to hospital with a six-day illness (jaundice, nausea etc).  Ten days before the 
onset, she had taken a single ecstasy tablet.  A few days later, she developed encephalopathy as 
part of an acute hepatic failure and died in spite of a liver transplantation. 
20  A woman, who had been using MDMA for the previous 6 months, consulted a physian following 
a three-week history of worsening jaundice associated with nausea and vomiting.  She developed 
an acute liver failure and died in spite of a liver transplant. 
21  The authors presented ten PMA-related fatalities.  Only the cases in which MDMA could also be 
quantified in blood are reported. 
22  MDMA, PMA and AMP liver concentrations: 3.2, 7.4, 0.45 µg/g, respectively. AMP was not 
detected in blood. 
23  MDMA, PMA, METH, and AMP liver levels: 3.2, 5.6, 0.26, and 0.35 µg/g, respectively. 
24  MDMA, PMA, and METH liver levels: 3.0, 2.7 and 0.76 µg/g, respectively. 
25  Person died four hours following arrival at hospital.  MDMA, MDA and MDEA concentrations: 
263.13, 5.25, and 183.73 µg/ml in urine and 27.34 < LOQ, and 21.93 µg/ml in bile, respectively.  











level  cause of 
death 














accidental acute to subacute 
cardiopulmonary 
failure, deep 






















































































































respectively. The corresponding MDEA levels: 10.68, 8.04, 8.03, 8.43, and 7.05 µg/g, 
respectively.  MDA could only be quantified in liver and kidney: 0.17 and 1.36 µg/g, 
respectively. 
26  Witness saw the subject ingesting “numerous” tablets of ecstasy for the entire duration of the 
party.  An accidental overdose can be assumed, though a suicidal attempt cannot be excluded. 
Urine and bile MDMA concentrations: 31.00 and 2.50 µg/ml, respectively. MDMA 
concentrations in liver, kidney, lung, brain, and spleen: 5.10, 8.70, 6.75, 7.10, and 5.00 µg/g, 
respectively.  MDA was only quantifiable in blood, urine and kidney: 0.85, 0.25 and 0.97 µg/ml 
or µg/g, respectively. 
27  Blood sampled from the brachiocephalic vein.  MDMA, MDEA, MDA and AMP concentrations 
in stomach content: 96, 324, 299, and < 0.1 µg/ml, respectively.  All amphetamines were 
detected in urine, but not quantified. 
28  Sampling location is not specified. MDMA, MDEA and MDA levels: 2.18, 60.42, and 2.62 
µg/ml in urine and 2.33, 18.88, and 1.18 in bile, respectively.  The corresponding levels in hair: 
1.66, 29.5, and 1.10 µg/g. 
29  This man is the brother of the 24-year-old man mentioned just above. The type of blood 
specimen is also not specified.  MDMA, MDEA and MDA levels: 1.40, 60.60, and 1.43 µg/ml in 
urine and 2.43, 32.38, and 6.60 in bile, respectively.  The corresponding levels in hair: 2.70, 
50.98, and 2.14 µg/g. 
30 MBDB: N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine (or Methyl-J, “Eden”).  In 
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31  Upon arrival at the hospital – a few hours after ecstasy ingestion - a CT scan revealed a large 
frontal haematoma and an angiogram showed a left frontal arteriovenous malformation.  In spite 
of a craniotomy, he was brain dead the following day. 
32  Driver of car in head-on collision. 
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34  Man treated with ritonavir for AIDS, took 2 ½ MDMA tablets and died.  Ritonavir is a potential 
inhibitor of CYP2D6 (principal in the metabolism of MDMA).  The toxic effects were attributed 
to impaired metabolism.  
35  Blood concentration on admission to hospital. Man fell to ground during “car-surfing”. 
36  Femoral blood level.  Worked at a nightclub. Mechanism of death is not clear: cardio-pulmonary 
failure, hyperthermia or an allergic reaction (idiosyncrasia) were postulated.  MDMA 
concentration in liver: 39.7 µg/g.  MDMA was still present in stomach but not quantified. 
37  Subject became agitated after ingestion of “pills” and jumped out of a window. 
38  There are hardly any data available: death was attributed to stabbing.  It is not clear whether this 
was criminal or accidental (such as self-mutilation or suicide). 
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40   Suddenly died when dancing in a “disco”.  At autopsy, an ischemic heart disease, occlusion of 
two main coronary branches and an old left ventricular infarction were found. 
41  Cocaine and benzoylecgonine concentration 0.04 and 0.13 µg/ml, respectively. 
42  Man was found dead in open space.  The morphine concentration refers to the free morphine 
level (µg/ml). 
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44   Syndrome of inappropriate antidiuretic hormone secretion.  
45  Man suddenly collapsed and died in the street; no medical antecedents; only traces of MDMA 
and MDA in urine 
46  Benzoylecgonine concentration of 0.97 µg/ml; cocaine itself not quantified any more.  Total 
MDMA and MDA level in vitreous humour: 1.9 and 0.24 µg/ml, respectively. The R(-) and S(+) 
MDMA concentrations in vitreous humour: 1.2 and 0.7 µg/ml, and the corresponding MDA 
enantiomers: 0.2 and 0.04 µg/ml, respectively. 
47  Person died 4 ½ hours after presentation in hospital.  
48  Person complained of retrosternal pain.  THC, 9-COOH-THC and 11-OH-THC were 1.90, 4.80 
and 0.70 µg/ml. 
49  Died in hospital about 24 h after ingestion of MDMA. 
50  Femoral and heart blood levels: 2.8 and 10.9 µg/ml, respectively.  The liver and brain MDMA 
concentrations: 20.0 and 13.7 µg/g, respectively.  MDA level was < 0.5 µg/ml in heart blood and 




























































51  Liver and brain MDMA levels: 1.8 and < 1.6 µg/g, respectively.  The MDA concentration was < 
0.33 µg/g in liver and not detected in brain. Benzoylecgonine, diazepam and nordiazepam were 
present in blood, but not quantified. 
52  The man remained comatose for five weeks prior to death; no blood level available. 
53  Man with Wolff-Parkinson-White syndrome and therefore an increased risk for dying suddenly 
(e.g. due to ventricular fibrillation), in particular when sympathomimetic substances such as 
MDMA are used. 
54  Sampling site at autopsy not specified.  Man died following 5 days of hospitalization during 
which he received many units of plasma, red blood cells and platelets (48, 7 and 14 units, 
respectively).  MDMA, METH and AMP but no MDA were detected in urine. 




IV.3  Discussion of the human thanatological literature data 
In this literature review, 76 fatalities in which MDMA was involved were identified.  
Figure 1.12 shows the age (a) and sex (b) distribution.  The majority of the reported victims 
were below the age of 25 and the subject group younger than 21 was the largest.  The males 





Figure 1.12 Age (a) and sex (b) distribution of the MDMA-related fatalities reported in the  
  literature (n = 76) 
  
 
Figure 1.13 presents the causes (a), manners (b) and mechanisms (c) of death.  
“Pure” MDMA fatalities account for about one third of the total.  It can be observed in 
Figure 1.13 (a) that often a combination of amphetamines was used and polydrug abuse 
(viz. combined use of MDMA and e.g. ethanol, benzodiazepines etc.) was not infrequent.  
When considering the manner of death, accidental fatalities are the most significant group 
(see Figure 1.13 (b)).  Hyperthermia is the most frequent mechanism of death in the 
reported victims (32 %); cardiac and pulmonary complications each account for about one-
quarter of the total numbers (see Figure 1.13 (c)).  Moreover, the mechanism of death is 
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Figure 1.13   Distribution of the cause (a), manner (b) and mechanism (c) of death of the  




The anatomo-pathological findings in MDMA-related fatalities - either macroscopically or 
microscopically – are non-specific.  A whole range of possible pathological observations 
can be found, such as hepatotoxicity, cardiomyopathy, acute to subacute cardiopulmonary 
failure, brain oedema, signs of multiple organ failure, and DIC. In fact, the anatomo-
pathological disorders in MDMA-related fatalities cannot easily be distinguished from 
those described in the abuse of amphetamine (or other derivatives) and other stimulant 
drugs such as cocaine.  Bearing in mind the above-mentioned assessments, some anatomo-
pathological anomalies can raise suspicions which needs to be confirmed by toxicological 
investigation. 
Referring to the available thanato-toxicological literature data – indicating a wide 
range of concentrations -, the interpretation of the MDMA blood level after death remains a 
debatable question.  Indeed a broad range of concentrations is found, viz. between 0.04 
µg/ml and 18.5 µg/ml (94,163). In the latter case, reported by Lo et al. (163), a femoral 
blood level of 18.5 µg/ml is extraordinary as the majority of the blood MDMA levels being 
between 0.5 and 4 to 5 µg/ml.  For the most part, blood MDMA levels are given; when 
persons are admitted to the emergency service, serum or plasma is more frequently used for 
MDMA quantitation.  For all amphetamines, the serum/blood conversion factor is assumed 
to be nearby or somewhat higher than 1 and therefore the sample type is usually not taken 
into account (260).  However, Garrett found a red blood cell-plasma partition coefficient of 
1.48 and 1.45 for MDMA and MDA, respectively, indicating a certain accumulation of 
MDMA and MDA in red blood cells (26).   For amphetamine and methamphetamine, the 
blood sampling site in human fatalities was proven to be important for the interpretation of 
a quantified level (261,262).  For example, for methamphetamine, concentrations measured 
in the left heart of human fatalities are about two times higher than those quantified in the 
right heart (262).  Blood collected from the pulmonary vessels sometimes showed 
concentrations that were many times higher than blood sampled from the heart and, as a 
result, diffusion out of the lungs into the pulmonary circulation was demonstrated (262). 
Although elaborate studies dealing with the post-mortem phenomena in MDMA-
related fatalities are at present not available, it is obvious that a peripheral sampling site 
(such as the femoral vein; see Table 1.6) is recommended.  Toxicologists should be aware 
of the blood sampling location and whether a peripheral blood sample is available.  They 
should be cautious in their conclusions as to whether or not the quantified level is either 
toxic or lethal.   
In conclusion, though the literature data on amphetamine and methamphetamine 
indicate that post-mortem redistribution can take place, a few questions such as whether 
MDMA is liable to post-mortem redistribution remain to be elucidated.  It is mandatory to 
consider the anatomo-pathological findings and the toxicological data as a whole in order to 
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Chapter 2  Survey of amphetamine-related fatalities at the Department of 
Forensic Medicine, Ghent University, between January 1976 
and April 2002 
 
I  Introduction 
Between January 1976 and the end of April 2002, twenty-two amphetamine-related 
fatalities were examined at the Department of Forensic Medicine (Ghent University) and a 
review of these victims (external and often internal examination, microscopical study, and 
toxicological investigation) was performed.  The inquiries originated predominantly from the 
Judicial District of Ghent, though a few cases were from Dendermonde and Veurne.  During 
this period, 1617 external examinations and 2452 autopsies were performed.  The number of 
amphetamine-related fatalities and the respective total number of fatalities investigated each 
year (external and internal examinations) are shown in Figure 2.1 and 2.2.  These figures 
demonstrate that the annual rate of amphetamine-related fatalities has been increasing since 
about 1995. 
 
Figure 2.1 Total number of amphetamine-related fatalities encountered at the Department of 
Forensic Medicine, Ghent University, between January 1976 and the end of April 








































Figure 2.2 Total number (sum of external and internal examinations) of all fatalities examined at 
the Department of Forensic Medicine, Ghent University, between January 1976 and 
the end of April 2002. 
 
 
In order to obtain a relevant study population group, the study population consisted of 
victims due to the (ab)use of amphetamine and all its derivatives. The amphetamine-related 
fatalities will be examined in accordance with the usual line of medico-legal reasoning, viz: 
was the death of the victim accidental, can suicide be the explanation or did the subject die 
due to a criminal offence?   
In addition, the anatomo-pathological and thanato-toxicological findings will be 



























II Case studies 
Twenty-two cases were discovered between January 1976 and April 2002.  In the case 
history, relevant data such as information obtained from the police inquiry (if available) and 
medical precedents are specified.  Thereafter, the findings obtained during the external 
examination and autopsy followed by the histological data will be summarized.  The 
biometrical data, the organ weights and the reference weight of each organ at various ages are 
presented in Table 2.1 (a) and Table 2.1 (b), respectively (1).  An increased organ weight can 
be correlated with the mechanism of death (e.g. pulmonary congestion and oedema, brain 
oedema) or with pre-existing pathology (e.g. cardiomyopathy, liver steatosis). The 
toxicological data are summarized below (Table 2.2). 
 
 II.1  Case 80/181 
This 15-year-old boy suddenly collapsed about 15 minutes after the start of a football 
game.  There were no surrounding players involved at the very moment of his collapse. 
Intensive reanimation was performed for a period of about 1.15 h. 
During external examination, signs of intensive reanimation were found.  There were no 
other traumatic lesions. 
During autopsy, red-brownish mucus was seen in the trachea. Bloody fluid was present in the 
thoracic cavities (300 ml). Tardieu spots were noted on the pleurae and pericardium.  
Inspection of the lungs revealed overwhelming pulmonary congestion and oedema.  A 
generalized visceral congestion was present.  Finally, a somewhat narrowed aortic ring 
(perimeter of 5 cm) was observed. 
Histological examination disclosed the following findings: 
heart :congestion, slight focal fatty infiltration, no inflammatory infiltrates 
lungs: congestion and oedema 
liver: vacuolisation of the hepatocytes but no fatty infiltration with Scharlach red staining; 
slight non-specific portitis (lymphocyte infiltration) 
kidney: congestion 
brain and brainstem: congestion, a few perivascular bleedings in the brainstem. 
 
 II.2  Case 89/88 
A 28-year-old man ate mussels on the evening of the 20th of May.  He had diarrhoea 
the following night and died on the 21st between 5.45 and 8.10 a.m. 
During external examination, obvious signs of cardiopulmonary failure (e.g. pronounced 
cyanotic face), a few small skin lesions consistent with a slight fall or impact and signs of 
reanimation were observed. 
At autopsy, vomit was present in the trachea. Overwhelming pulmonary congestion and 
oedema, and brain oedema were observed. 
Histological examination disclosed the following findings: 
heart: signs of ischemia, slight myocardosis, arteriolar media hypertrophy 
lungs: severe congestion and oedema, neutrophilic sludging, focal subpleural bleeding 





brain and brainstem: congestion and oedema, a few perivascular bleedings in the brainstem 
 
II.3  Case 94/15 
A 19-year-old man took 10 “XTC” pills at about 10:00 a.m.  He became comatose 
and was admitted to hospital at 2:00 p.m.: his temperature was 41.7°C and epileptic fits were 
noticed.  He died at about 10:30 p.m. following DIC and multiple organ failure. Ante-mortem 
samples taken on two different times were available. Toxicological analysis of the serum and 
urine samples taken upon arrival at the hospital disclosed MDEA concentrations of 2.22 and 
24.15 µg/ml, respectively.  A few hours later, blood and urine samples were again taken in 
the hospital and immunoassay determined the following concentrations: amphetamines 0.120 
µg/ml, cocaine 0.500 µg/ml, cannabinoids: 0.022 µg/ml, benzodiazepines: 0.224 µg/ml.  The 
corresponding urine levels were 2.400 µg/ml, 6.000 µg/ml, 0.210 µg/ml, and 0.181 µg/ml, 
respectively.  Ethanol was only present in urine (0.54 g/l). The MDEA blood and urine levels 
were 1.28 and 24.84 µg/ml, respectively.  Analysis of a pill disclosed that it contained 119 
mg of MDEA.  
The external inspection showed signs of intensive reanimation, a few slight skin lesions and 
bleeding out of the nose. 
During autopsy, 400 ml of bloody fluid were found in the thoracic cavities, as well as Tardieu 
spots on pleurae and pericardium. A tongue bite was present.  On incision, overwhelming 
pulmonary congestion and oedema were seen. In addition, obvious brain congestion and 
oedema were observed. 
Histological examination disclosed the following findings: 
heart: slight myocardosis 
lungs: obvious congestion and haemorrhagic oedema 
liver: slight steatosis (degree I) 
kidney: acute tubular necrosis 
brain and brainstem: moderate oedema. 
 
 II.4  Case 95/271 
A 19-year-old female was found unconscious in bed; intensive reanimation failed.   
External examination revealed signs of intensive reanimation, scars of automutilation, and 
obvious signs of cardiopulmonary failure (e.g. cyanotic face). 
At autopsy, yellowish mucus and foamy fluid in trachea, pus plugs in the lungs, zones of 
dysaeration, and pulmonary congestion and oedema were observed. Tardieu spots on pleurae 
and pericardium and generalized visceral congestion were noticed.  Brain congestion and 
oedema were remarked. 
Histological examination disclosed the following findings: 
heart: congestion 
lungs: pulmonary hypertension, acute bronchiolitis, onset bronchopneumonia, foreign body 
granulomata (cf. chronic intravenous drug (ab)use) 
liver: sign of  shock: centrolobular atrophia, vacuolisation of the hepatocytes; moderate non-
specific portitis (lymphocyte infiltration) 




brain and brainstem: congestion and oedema, a few perivascular haemorrhages in the 
brainstem. 
 
 II.5  Case 96/26 
A 22-year-old man who had joined the Navy, was found dead in his room.  He had no 
medical antecedents. 
During the external examination, a few skin lesions consistent with a slight fall or impact and 
signs indicating reanimation were noted.  
At autopsy, Tardieu spots on pleurae and pericardium, and obvious pulmonary congestion 
and oedema were found.  A somewhat enlarged heart and brain oedema were seen. 
Histological examination disclosed the following findings: 
heart: pronounced vascular congestion, slight endocardial fibrosis 
lungs: pronounced congestion and oedema, slight bone marrow embolisation (in the absence 
of fractures, assumed to be resulted from severe hyperthermic convulsions), obstruction of 
smaller bronchi by mucoid material, chronic bronchitis (lympho-plasmocytic and 
eosinophilic infiltrates) 
liver: steatosis (degree I to II), acute congestion 
kidney: acute tubular necrosis, acute congestion 
brain and brainstem: congestion and oedema. 
 
 II.6  Case 96/96/1 
This 21-year-old woman was found dead in bed, in the arms of her friend.  They  
were recently discharged from hospital for detoxification therapy.  They committed suicide 
together. 
In this case, the investigation was restricted to an external examination.  At external 
inspection moderate putrefaction was found.  Dried oedema around the mouth was noted. A 
puncture wound at the left wrist was assumed.  
 
 II.7  Case 97/35 
This 19-year-old man was murdered by a thoracic gunshot following an altercation.  
MDMA use was an incidental discovery. 
During external examination, signs of reanimation and a few skin lesions consistent with a 
fall or impact were noted.  A thoracic shotgun lesion ("à bout touchant") and subcutaneous 
emphysema were observed. 
At autopsy, a haemothorax (1600 ml), a cardiac laceration and blood aspiration were found.  
The abdominal organs were obviously anemic. In addition, a galea ecchymose (cf. fall) and 
some brain congestion and oedema were seen. 
Histological examination disclosed the following findings: 
heart: normal myocardial tissue apart from anemia 
lungs: intra-alveolar bleeding (blood aspiration) 
liver: normal but anemic 
kidney: normal, anemic 




 II.8  Case 97/134 
This 19-year-old man was found dead lying in a sofa.  He was known to have had an 
allergic constitution (atopic eczema) and at the scene a bronchodilator was found. An erosion 
of the nasal septum was noted, which indicated sniffing.  A prolonged survival following  
polydrug abuse was assumed.  MDEA was found positive in urine and below the limit of 
detection in blood (< LOD).  
During the external inspection, reanimation signs, an obvious cyanotic face and eczema on 
the right elbow and poplitea (cf. allergic constitution ?) were found. 
During autopsy, Tardieu spots on pleurae and pericardium were observed. Mucus and vomit 
plugs in the bronchi were found.  Upon incision, obvious pulmonary congestion and oedema 
was seen.  Apart from generalized visceral congestion, brain congestion and oedema were 
noticed. 
Histological examination disclosed the following findings: 
heart: pronounced vascular congestion, slight myocardosis 
lungs: dysaeration, subacute vascular congestion and haemorrhagic oedema, acute bronchitis 
and onset bronchopneumonia, onset diffuse alveolar damage (DAD; shock lungs) 
liver: congestion 
kidney: pronounced acute vascular congestion 
pituitary gland: congestion 
brain and brainstem: acute congestion and oedema, a few perivascular bleedings, signs of 
onset hypoxia in the hippocampus.  
 
II.9  Case 97/156 
A 32-year-old man was detained by the police for “drunkenness”.  In jail, he was very 
aggressive and disoriented for a few hours and finally he hung himself (using his shirt fixed 
on the bars) while still in custody. The neuroleptic sulpiride (Dogmatil®) and acetaminophen 
with codeine (Dafalgan Codeine®) were in his home. 
At external examination, a ligature mark at the neck and various fresh ecchymoses and 
excoriations on the limbs (consistent with repeated falls or impacts) were observed. 
At autopsy, Tardieu spots on pleurae and pericardium, obvious pulmonary congestion and 
generalized visceral congestion were noted.  Slight brain congestion and oedema were found. 
Histological examination disclosed the following findings: 
heart: acute vascular congestion, slight myocardosis 
lungs: pronounced acute vascular congestion and haemorrhagic oedema; chronic bronchitis, 
chronic pleuritis 
liver: pronounced acute vascular congestion 
kidney: acute congestion 
skin right arm and left elbow: subcutaneous ecchymoses (> 5 hours old) 
pituitary gland: acute congestion 
brain and brainstem: acute congestion and oedema; a few perivascular bleedings; sludging 
and localized perivasculitis in caudate nucleus, sludging in brainstem, obvious perivascular 





II.10  Case 98/14 
This 40-year-old man died in a traffic accident following an argument.   
Upon external examination, scattered abrasions and ecchymoses on head, limbs and thorax 
were found. 
At autopsy, pleural Tardieu spots, pulmonary congestion and an enlarged heart were noticed. 
Multiple fractures of the skull and the skull base associated with a subdural and arachnoideal 
bleeding were observed. In addition, an epi- and subdural bleeding of cervical spine was 
found. 
Histological examination disclosed the following findings: 
heart: acute vascular congestion, moderate myocardosis, signs of protracted hypoxia 
lungs: emphysema with pulmonary hypertension, slight chronic bronchitis, obvious blood 
aspiration, pronounced congestion and oedema, sludging with onset shock lungs 
liver: acute vascular congestion, steatosis (3rd degree) 
kidney: acute vascular congestion, signs of shock 
pituitary gland: traumatic haemorrhagic zone in neurohypophysis with slight inflammatory 
infiltration (some hours old) 
skin occiput: abrasion (ca. 10 hours old) 
brain and brainstem: acute congestion and oedema; periventricular bleeding in brainstem 
(possibly of traumatic origin), recent cerebellar and cerebral contusions, signs of hypoxia in 
lentiform nucleus, thalamus, cortical regions and hippocampus, recent contusion of the 
cervical medulla. 
 
 II.11  Case 98/41 
This 22-year-old driver suddenly left the main road without immediate cause.  He was 
admitted to hospital where he received 10 units of packed cells and several units of plasma 
expanders as part of the treatment for haemorrhagic shock.  He died a few hours later.  At 
autopsy, an extremely tiny man was found (BMI = 17) and Graves’ disease was incidentally 
discovered. 
Upon external examination, apart from signs of intensive reanimation, scattered abrasions, 
lacerations and ecchymoses were found.  
At autopsy, a haemothorax (290 ml), lung contusions and pulmonary oedema were observed.  
About 750 ml blood in the abdomen due to a laceration of the liver and small bowel 
perforations were seen. Stress ulcerations in the stomach mucosa were present. Subdural 
bleeding, brain contusions and oedema, associated with an epidural bleeding of the cervical 
spine were found. 
Histological examination disclosed the following findings: 
heart: some congestion and some sludging, a few small focal lymphocyte infiltrates, slight 
myocardosis 
lungs: obvious chronic bronchitis, sludging as part of onset shock lungs, a few scattered 
foreign body granulomata, obvious fat embolisation 
liver: findings of protracted shock 
kidney: normal, anemic 




thyroid gland: chronic lymphocytic thyroiditis compatible with Graves' disease 
pituitary gland: acute congestion 
brain and brainstem: oedema, subarachnoideal bleeding, a few small recent brain contusions, 
commotio of the brainstem, signs of hypoxia in pons and hippocampus. 
 
II.12  Case 98/239 
This 24-year-old man had antecedents of drug abuse and was treated with a few 
benzodiazepines; the narcotic analgesic piritramide (Dipidolor®) was found.  He was found 
dead lying in an armchair on his back.  No reanimation took place.  Glucose was strongly 
positive in urine (++++). 
External inspection demonstrated signs of cardiopulmonary failure. Scars of automutilation 
and a small ecchymose on the left forearm possibly compatible with a intravenous puncture 
were observed. 
At autopsy, mucus and cloudy oedema in bronchi, hepatisation regions of the left lung, and 
overwhelming pulmonary congestion and oedema were found. About 175 ml of bloody fluid 
was present in the thoracic cavities. Some brain oedema was also observed. 
Histological examination disclosed the following findings: 
heart: pronounced acute vascular congestion; small scattered subepicardial bleedings 
lungs: onset bronchopneumonia, obvious vascular congestion and a few microthrombi, 
polynuclear macrophages with crystalline inclusions (cf. chronic intravenous drug abuse). 
liver: acute vascular congestion 
kidney: acute vascular congestion 
carinal lymph node: acute reactive lymphadenitis 
skin of left forearm: recent subcutaneous bleeding 
pituitary gland: acute congestion 
brain and brainstem: acute congestion and oedema, scattered small perivascular bleedings, 
signs of protracted hypoxia in cerebellum, pons, cortical regions, hippocampus. Small 
hippocampal bleedings (cf. increased intracranial pressure). 
 
II.13  Case 98/251 
This 31-year-old man suddenly collapsed in a discotheque. His friends declared that 
he had used XTC and marihuana on a regular basis.  Analysis of a tablet found on this person 
demonstrated an MDMA content of 9 % or 25.23 mg MDMA.  It is not known how many 
pills he may have ingested. 
External examination showed signs of intensive reanimation and obvious signs of 
cardiopulmonary failure. 
During autopsy, an obviously enlarged heart and a recurrent myocardial infarction on an old 
lesion associated with a recent coronary thrombosis was found.  For his age, a moderate 
atherosclerosis of all coronary arteries was observed. Overwhelming pulmonary congestion 
and oedema as well as generalized visceral congestion were present.  In addition, brain 




Histological examination disclosed the following findings: 
heart: extensive transmural infarction, which is at least ca. 5 weeks old; smaller recent 
infarction zone, ca. 5 days old; also more recent cellular hypoxia, and recent thrombosis of 
ramus circumflexus. 
lungs: pronounced acute vascular congestion and haemorrhagic oedema; chronic bronchitis, 
deep vomit aspiration, bone marrow embolisation (cf. rib fractures due to reanimation) 
liver: acute vascular congestion 
kidney: intima fibrosis; signs of onset shock 
pituitary gland: acute congestion 
brain and brainstem: congestion and oedema, signs of protracted hypoxia in cortical regions, 
cerebellum and hippocampus. 
 
II.14  Case 99/231 
This 18-year-old man was found dead in bed.  He was known to be addicted to drugs 
and had therefore been receiving treatment with methadone and benzodiazepines.  Oedema 
and vomit was present on his bed linen.  In his pocket, a small box containing numerous 
tablets, mainly medication, was retrieved. 
The investigation was restricted to an external examination. Obvious signs of 
cardiopulmonary failure were found (e.g. obvious pulmonary oedema, cyanosis). 
 
 II.15  Case 99/235 
This 27-year-old drug dealer died following ingestion of about 6 pills.  In his pockets, 
a note describing the effects of 4-MTA was found.   
Upon external inspection, besides signs of reanimation, slight ecchymoses on limbs 
consistent with a minor fall or impact were observed. 
Autopsy showed Tardieu spots on pleurae and pericardium associated with obvious 
pulmonary congestion and oedema. Stress ulcerations in the stomach mucosa were present. 
Histological examination disclosed the following findings: 
heart: acute vascular congestion, slight myocardosis 
lungs: overwhelming vascular congestion and haemorrhagic oedema, some chronic 
bronchitis 
liver: acute vascular congestion 
kidney: acute vascular congestion 
spleen: acute vascular congestion 
pituitary gland:  congestion 
brain and brainstem: congestion and oedema; a few perivascular bleedings in pons and brain. 
Somewhat decreased number of Purkinje cells, perivascular lymphocyte and macrophage 
infiltration in brainstem and lentiform nucleus. 






II.16  Case 00/112 
This 23-year-old man was found dead in a bar, sitting on a chair.  
External examination showed obvious signs of cardiopulmonary failure (e.g. pronounced 
cyanotic face) and reanimation signs. 
At autopsy, a great deal of bloody oedema was present in trachea and bronchi. Numerous 
Tardieu spots on pleurae and epicardium, and an overwhelming lung congestion and oedema 
were found. A persistence of a left superior caval vein was an incidental discovery.  Apart 
from generalized visceral congestion, congestion of the arachnoidea was found. 
Histological examination disclosed the following findings: 
heart: acute vascular congestion, moderate myocardosis, signs of diffuse hypoxia 
(subendocardial); some fatty infiltration and slight bleedings in the right ventricle 
lungs: overwhelming vascular congestion and haemorrhagic oedema 
liver: acute vascular congestion, slight steatosis (1st degree) 
kidney: acute vascular congestion 
spleen: acute vascular congestion 
pituitary gland:  congestion 
brain and brainstem: congestion and oedema; a few perivascular bleedings in pons and brain, 
perivasculitis (lymphocyte infiltration); no obvious signs of protracted hypoxia (normal 
hippocampus). 
This case is also studied in detail in Chapter 6 of this thesis (4). 
 
II.17  Case 01/29 
According to the statements of his family and friends, this 17-year old man was not 
obviously depressive, though he was somewhat down at times.  His motorbike and a bottle of 
Dutch gin were retrieved nearby the train rails. Marihuana was found in his pockets. It was 
assumed that he threw himself in front of a passing train.   
The investigation was restricted to an external examination.  A severe cranio-cervical 
destruction and multiple fractures (thorax, limbs) were found.  Inguinal lacerations indicate 
that he was hit in standing position.  Due to the severe cranio-cerebral destruction (including 
orbital fractures), there was no vitreous humour available.  The urine was very bloody (cf. 
pubic fractures).  
 
II.18  Case 01/34 
A 23-year-old man was found dead at home, lying in an armchair.  Police inquiry 
revealed that he had many visitors and therefore he was suspected to be a drug dealer, which 
was – to our knowledge – not confirmed.   
At external examination, onset of putrefaction (onset epidermolysis, dehydration of the eyes, 
mummification of the fingers and toes), a few small excoriations on the forearms were 
observed.   
At autopsy, emphysema of the lungs due to putrefaction, oedema in the trachea and bronchi 
and obvious pulmonary congestion were noticed.  About 250 ml bloody fluid was present in 
the thoracic cavities.  In addition to generalized congestion of all organs, obvious brain 




Histological examination disclosed the following findings: 
heart: acute congestion, signs of shock (signs of diffuse protracted hypoxia, neutrophylic 
sludging). 
lungs: pronounced acute vascular congestion and haemorrhagic oedema; signs of shock and 
DIC (sludging, microthrombi) 
liver: acute vascular congestion, onset of autolysis 
kidney: obviously autolytic, signs compatible with ATN (acute tubular necrosis), myoglobine 
staining non-conclusive 
spleen: acute vascular congestion, signs of shock 
adrenal gland: signs of shock (eosinophylic coagulation necrosis) 
pituitary gland:  congestion 
brain and brainstem: obvious congestion and oedema; a few perivascular bleedings; obvious 
sludging in cerebellum, thalamus and hippocampus; cortical microemboli; perivasculitis 
(lymphocytic) in lentiform nucleus; hippocampus shows signs of hypoxia. 
This case is also investigated and discussed in detail in Chapter 6 of the present work (5). 
 
II.19  Case 01/122 
This 18-year-old man had been drinking a lot, together with a friend.  He spent the 
night at his friend’s house.  He had been snoring the whole night, but was found dead in the 
morning, lying in ventral position.  
During external examination, onset of putrefaction was observed.  A cyanosis of the 
face and upper thorax was noted.  A few slight abrasions in his face (possibly agonal or post 
mortem) and a slight abrasion on the knee consistent with a fall or impact were found. 
At autopsy, 160 ml bloody fluid was present in the thoracic cavities. Tardieu spots on 
pericardium and pleurae, obvious pulmonary congestion and oedema, and some pus in the 
distal bronchial branches were found.  Apart from generalized visceral congestion, brain 
oedema and a tongue bite were observed. 
Histological examination disclosed the following findings: 
heart: acute vascular congestion, slight myocardosis 
lungs: pronounced acute vascular congestion and haemorrhagic oedema; sludging; onset of 
shock lungs 
liver: acute vascular congestion, microvacuolar steatosis (1st to 2nd degree) 
kidney: acute congestion; pronounced autolysis hampering the interpretation (such as ATN) 
pancreas: slight focal fibrosis and chronic infiltration 
pituitary gland:  congestion 
brain and brainstem: obvious congestion and oedema; a few perivascular bleedings, obvious 
sludging in caudate nucleus en thalamus; signs of protracted agony found in hippocampus. 
This case is discussed together with case 01/158 in Chapter 6 of this work. 
 
 II.20  Case 01/142 
This 28-year-old man was extremely confused and agitated. He had inflicted several 
cut and stab wounds on himself.  Thereafter, he ran into the house up to the 3rd floor, where 




then tied the rope around his neck and jumped down.  The rope broke, however, and he fell to 
the ground, where he died. 
The inquiry was restricted to an external examination.  Slight linear abrasions (cf. 
attempted hanging) were seen, as well as several abrasions associated with cut and stab 
wounds in the precordial region, abdomen, forearms and neck (including hesitation cuts).  In 
addition, contusions on the head were present. Some deeper precordial wounds (cf. 
subcutaneous emphysema) and abdominal fecaloid material indicated severe internal trauma. 
 
 II.21  Case 01/158 
This 31-year-old man was found dead at home next to his bed, in an advanced state of 
putrefaction.  He was known to have an alcohol abuse problem.  
Upon external examination, severe putrefaction was found. 
At autopsy, 600 ml bloody fluid was present in the pleural cavities. Putrefaction of all organs 
was found.  However, pulmonary congestion could still be observed. Generalized visceral 
congestion could be assumed. The brain was very weak (cf. putrefaction). 
Histological examination disclosed the following findings: 
heart: pronounced putrefaction hampering a detailed diagnosis; only significant scars (old 
infarctation) could be excluded 
lungs: pronounced putrefaction, arguments for congestion, oedema and deep vomit 
aspiration. A few Prussian blue positive macrophages were observed 
liver: pronounced putrefaction hampering a detailed diagnosis 
kidney: pronounced putrefaction hampering a detailed diagnosis 
pituitary gland:  pronounced putrefaction hampering a detailed diagnosis 
brain and brainstem: pronounced putrefaction hampering a detailed diagnosis; no significant 
scars or traumatic bleeding. 
Due to the severe putrefaction, vitreous humour was not available for toxicological analysis. 
As mentioned above, this case is considered together with case 01/122 in Chapter 6. 
 
II.22  Case 01/197 
This 32-year-old man arrived in custody, the morning of the day he died.  He was 
manic-depressive and had consulted a psychiatrist, who prescribed him benzodiazepines and 
carbamazepine.  He hung himself by means of a kitchen towel. 
The investigation was restricted to an external examination.  Signs of reanimation 
were found.  A typical ligature mark in the neck was observed. Old scars compatible with 






Table 2.1 (a) Biometrical data and organ weights of the amphetamine-related fatalities at the 
Department of Forensic Medicine, Ghent University (n = 17).  
(BMI: body mass index)  
 
case  age length weight BMI brain heart lungs liver  kidneys  spleen 
number (years) (cm) (kg)  (g) (g) (g) (g) (g) (g) 
80/181 15 182 65 19.6 1355 290 1375 1720 338 235 
89/88 28 169 62 21.7 1470 295 1085 1510 220 100 
94/15 19 183 72 21.4 1440 300 1960 1430 300 100 
95/271 19 164 53 19.7 1200 315 955 1370 320 215 
96/26 22 172 87 29.4 1350 437 1358 1550 310 150 
97/35 19 174 55 18.1 1410 243 440 1100 220 90 
97/134 19 169 55 19.2 1430 280 1290 1745 250 170 
97/156 32 176 65 20.9 1500 335 1350 1510 300 100 
98/14 40 177 81 25.6 1465 480 1605 1900 480 90 
98/41 22 178 57 18.0 1385 254 1550 1255 245 245 
98/239 24 170 61 21.1 1560 345 1495 1545 320 85 
98/251 31 171 75 25.6 1580 460 1300 2235 460 180 
99/235 27 171 55 18.8 1320 255 970 1300 280 200 
00/112 23 186 95 27.5 1545 405 1620 1950 265 275 
01/34 23 175 56 18.3 1405 315 1410 1160 190 235 
01/122 18 177 61 19.5 1445 270 1280 1470 250 200 
01/158 31 178 85 26.8 1300 350 1230 1250 325 120 
           
mean   175 67 22 1421 331 1310 1529 298 164 
(SD)  (5.7) (13.1) (3.7) (98.9) (73.5) (332.8) (302.3) (77.3) (64.3) 
 
 
Table 2.1 (b)  Reference weights of the organs at various ages (in grams).  
[reproduced in part from Boyd E. (1)] 
 
age        brain         heart         lungs        liver      kidneys       spleen 
(years) men women men women men women men women men women men women 
15 - 16 1407 1271 258 238 692 709 1315 1330 229 230 135 127 
16 - 17 1419 1300 282 243 747 626 1380 1360 244 236 145 134 
17 - 18 1409 1254 300 247 777 650 1450 1380 260 240 152 140 
18 - 19 1426 1312 310 250 875 655 1510 1395 270 244 157 146 
19 - 20 1430 1294 318 251 1036 785 1580 1405 282 247 160 151 







III Toxicological data 
III.1  Drug assays 
For most cases, screening tests were performed using immunoassay techniques and 
confirmation occurred by means of high-performance liquid chromatography with 
photodiode-array detection (HPLC-DAD) (6) and gas chromatography/mass spectrometry 
(GC/MS) (7). In one of the older cases (89/88), quantification of the levels was performed by 
spectrophotometry.  For cases 00/112, 01/122 and 01/158 an HPLC procedure with 
fluorescence detection was applied (4).  For case 01/34, a method using HPLC coupled to ion 
trap based mass spectrometry (LC/MS) was used (8). 
 
III.2  Results 
The toxicological data from samples obtained during external (n = 5) and internal 
examination (n = 17) are presented in Table 2.2.  Four “pure” MDMA fatalities were found 
and six victims in which MDMA was present, having been ingested together with other 
substances (such as ethanol, benzodiazepines).  The broad range of blood concentrations 
noted in the “pure” MDMA victims ran from 0.27 to 13.51 µg/ml.   Amphetamine and 
MDEA were involved in nine and three cases, respectively.  Both PMA and 4-MTA were 
found in one case.  In only about half of the cases was a vitreous humour level of 
amphetamine or its derivative available.  Urine and (sometimes) stomach content and bile 
concentrations were detected, being relatively high for all amphetamines.  A few tissue 
concentrations were determined: substantial levels of all amphetamines were found in liver 
and kidney. 
Toxicological analysis of various tissues was performed for cases 99/235, 00/112, 
01/34, 01/122 and 01/158.  The distribution of MDMA and related compounds in the human 
body is discussed in detail in the third part of the present work. 
Two blood samples, subclavian and femoral in particular, were taken during the 
external examination of case 01/142.  These amphetamine blood levels were 1.30 µg/ml and 




Table 2.2.  Toxicological data obtained from the amphetamine-related fatalities at the Department of 
Forensic Medicine, Ghent University (n = 22).  
 
case  substances blood blood  vitreous urine  stomach liver bile  kidney 
number   sample  humour  content    
  (µg/ml)1 type  (µg/ml) 1 (µg/ml)1 (µg/g) 1 (µg/g) 1 (µg/ml)1 (µg/g) 1 
80/181 amphetamines 2   2.13 3 - - - - 4.10 - 0.80 
 ethanol < LOD  - - - 0.48 - 0.43 
89/88 AMP  - - - 20 13 9 - - 
 ethanol 0.70  - 2.40 - - - - 
94/15 MDEA  3.88 - 2.36 46.75 1.27 - - - 
 ethanol < LOD  - 0.50 - - - - 
 cocaine 4 0.39  - 0.30 - - - - 
 cannabinoids 0.05  - < LOQ - - - - 
95/271 AMP 0.20 VS - 0.50 - - - - 
 bromazepam 0.86  - 0.38 1.58 - - - 
 cannabinoids < LOD  - 0.03 - - - - 
96/26 amphetamines 2 0.24 VS 0.45 21.60 - - - - 
 AMP  < LOQ  < LOQ 14.80 - - - - 
96/96/1 amphetamines 2 0.86 VS - - - - - - 
 ethanol 0.07  - - - - - - 
 methadone 0.28  - - - - - - 
 bromazepam 0.27  - - - - - - 
 nordiazepam 0.33  - - - - - - 
 diazepam 0.15  - - - - - - 
97/35 MDMA 0.20 IC - 26.00 6.60 - - - 
 LSD 0.002  - 0.02 - - 0.114 - 
97/134 MDEA < LOD VCI 0.18 + - - - - 
 benzodiazepines 5 5.04  < LOD 6.840 - - - - 
 nordiazepam < LOQ  0.01 0.630 - - - - 
 diazepam 0.11  < LOD 0.530 - - - - 
 dihydrocodeine < LOQ  0.44 46.10 - - - - 
 cocaine 4 0.32  0.13 20.60 - - - - 
 opiates 0.96  1.01 181.40 - - - - 
 free morphine 0.02  < LOQ 0.216 - - - - 
97/156 MDMA < LOD VCI < LOD 0.43 - - - - 
 MDEA < LOD  < LOD 3.16 - - - - 
 ethanol 1.14  0.56 1.47 - - - - 
 opiates 6 0.40  0.09 0.056 - - - - 
 benzodiazepines 0.19  < LOD 2.10 - - - - 
 lormetazepam < LOQ  < LOD 0.475 - - - - 
 salicylates 8.20  < LOD 8.2 - - - - 




Table 2.2.  Toxicological data obtained from the amphetamine-related fatalities at the  
Department of Forensic Medicine, Ghent University (n = 22) (continued). 
 
case  substances blood blood  vitreous urine  stomach liver bile  kidney 
number   sample  humour  content    
  (µg/ml) 1 type  (µg/ml) 1 (µg/ml)1 (µg/g) 1 (µg/g) 1 (µg/ml)1 (µg/g) 1 
98/14 AMP  0.07 VCI 0.24 + - - - - 
 ethanol 1.69  ND 2.24 - - - - 
 cocaine  < LOD  < LOQ + - - - - 
 cannabinoids < LOD  < LOQ + - - - - 
98/41 AMP  0.15 VCI < LOQ - - - - - 
98/239 AMP < LOD VS 0.06 ++ - - - - 
 ethanol < LOD  N.D. 0.42 - - - - 
 cocaine < LOD  < LOD + - - - - 
 benzoylecgonine < LOD  < LOD + - - - - 
 cannabinoids 0.04  < LOD ++ - - - - 
 methadone < LOD  < LOD + - - - - 
 opiates < LOD  < LOD ++ - - - - 
 codeine < LOD  < LOD + - - - - 
 morphine 5 0.02  < LOD 2.5 0.15 - 7.6 0.4 
 benzodiazepines +  < LOD + + - - - 
 nordiazepam 0.60  < LOD + - - - - 
98/251 MDMA < LOD VS 0.83 - 1.90 - - - 
99/231  amphetamines  - VS - 0.80 - - - - 
 MDMA < LOQ  - 2.65 - - - - 
 ethanol 0.06  - 0.16 - - - - 
 cannabinoids 0.02  - 1.08 - - - - 
 methadone < LOQ  - 2.50 - - - - 
 diazepam 0.71  - 15.58 7 - - - - 
 nordiazepam 2.27  - < LOQ - - - - 
 bromazepam 0.94  - 8.96 - - - - 
 7-aminofluni-
trazepam 
< LOD  - 1.24 - - - - 
 amitriptyline 0.40  - 2.45 - - - - 
 nortriptyline < LOQ  - 2.82 - - - - 
99/235 MTA 5.23 VF 1.31 95.50 - 30.80 36.40 2.88 
 MDMA  0.01  0.068 4.93 - 0.089 0.231 0.033 
 cannabinoids < LOD  - + - - - - 
00/112 MDMA 3.10 VF 3.400 170.9 118.10 26.20 14.20 13.9 
 MDA 0.09  0.060 4.00 0.448 1.20 0.32 3.022 
01/29 MDMA 4.22 VF NA + - - - - 




Table 2.2.  Toxicological data obtained from the amphetamine-related fatalities at the  
Department of Forensic Medicine, Ghent University (n = 22) (continued). 
 
case  substances blood blood  vitreous urine  stomach liver bile  kidney  
number   sample  humour  content    
  (µg/ml)1 type  (µg/ml) 1 (µg/ml)1 (µg/g) 1 (µg/g) 1 (µg/ml)1 (µg/g) 1 
01/34 PMA 1.63 VF 2.101 0.932 73.103 8.904 50.012 5.669 
 MDMA 1.13  1.633 0.791 33.168 6.657 25.420 4.058 
 MDA 0.44  0.577 0.369 14.308 0.744 11.655 3.888 
 AMP 0.20  0.292 0.522 5.478 0.857 9.425 0.746 
01/122 MDMA 0.27 VS 0.361 3.640 10.518 4.867 22.075 1.848 
 MDA 0.01  0.015 0.110 0.581 0.093 0.764 0.089 
01/142 AMP 0.30 VF 1.80 775 - - - - 
01/158 MDMA 13.51 VF NA 71.56 2310.71 103.496 86.954 155.293 
 MDA 0.04  NA 3.48 3.940 0.828 1.782 6.678 
01/197 AMP < LOD VS 1.42 36.00 - - - - 
 carbamazepine 7.97  1.38 2.62 - - - - 
 benzodiazepines 12.0  1.42 18.00 - - - - 
 nordiazepam 5.27  0.125 1.04 - - - - 




< LOD: below limit of detection 
< LOQ: below limit of quantitation 
-: not available 
+: detected, but not quantified 
VS: subclavian vein 
IC: intracranial 
VCI: inferior vena caval vein 
VF: femoral vein 
 
1 for ethanol: g/l or g/kg 
2 amphetamines: total amount of amphetamines (screening test result) 
3 screening test result (Abuscreen) 
4 metabolite of cocaine 
5 screening test result (radio-immunoassay or enzyme-immunoassay) 
6 identified as codeine 
7 diazepam benzophenone in hydrolysed urine.  Other compounds in hydrolysed urine: 
- bromazepam benzophenone: 18.08 µg/ml 
- oxazepam benzophenone: 19.67 µg/ml 




IV     Summary of the cases 
The age distribution of the amphetamine-related fatalities is presented in Figure 2.3.  
The majority of the victims were younger than 25, and the subjects in the largest group were 
below 21. 
A survey of the cases including the cause, manner and mechanism of death is shown 
in Table 2.3; the data present in this table are summarized and visualized in Figure 2.4.  
Figure 2.4 (a) shows the distribution of the causes of death: “pure” overdose victims due to 
the ingestion of amphetamine and/or derivatives comprise only about one-third of the 
fatalities.  Fatal combinations such as abuse of several drugs at the same time, and poly-
trauma (e.g. resulting from traffic accidents) make up a significant part of the study group.    
The proportion of each manner of death (accidental, suicidal, and criminal) is presented in 
Figure 2.4 (b).  The majority of the fatalities were due to an unintentional overdose (about 
60% of the study population).  Suicides were the second largest group, followed by 
accidental traumatic deaths. The various mechanisms of death are shown in Figure 2.4 (c). 
Acute to subacute cardiopulmary failure was the most frequently observed mechanism of 
death, followed by polytrauma lesions (e.g. haemorrhagic shock, cranio-cerebral lesions) and 
hyperthermia. 
 
Figure 2.3 Age distribution of amphetamine-related fatalities at the Department of  


















aged 15 – 20 years 
aged 21 – 25 years 
aged 26 – 30 years 
aged 31 – 35 years 




Table 2.3 Survey of the amphetamine-related fatalities at the Department of Forensic Medicine, 
  Ghent University (n = 22). (PMI: post-mortem interval in days; TA: traffic accident). 
 
case  age sex PMI inquiry cause of death manner of mechanism of death 
number (y)  (d)   death  
80/181 15 M 2.5 autopsy AMP intoxication accidental ventricular fibrillation 
89/88 28 M 1 autopsy AMP intoxication accidental cardiopulmonary failure 
94/15 19 M 1.5 autopsy MDEA intoxication suicide hyperthermia, MOF, DIC 
95/271 19 F 1 autopsy polydrug intoxica-tion 
including AMP 
accidental acute bronchiolitis and 
bronchopneumonia 
96/26 22 M 1 autopsy AMP intoxication accidental hyperthermia  
96/96/1 21 M 3 external  polydrug intoxica-tion 
including AMP 
suicide cardiopulmonary failure ? 
97/35 19 M 3 autopsy Shotgun, MDMA and 
LSD 
murder internal bleeding 
97/134 19 M 1 autopsy polydrug intoxica-tion 
including MDEA 
accidental cardiopulmonary failure onset 
of bronchopneumonia 
97/156 32 M 1 autopsy hanging following 
ingestion of MDMA, 





mechanical asphyxia  





98/41 22 M 3.8 autopsy polytrauma (TA), AMP accidental 
(TA) 
haemorrhagic shock due to 
multiple fractures; con- tusions 
of brain and cervical spine 
98/239 24 M ± 4.5 autopsy polydrug intoxica-tion 
including AMP 
accidental  cardiopulmonary failure; onset 
of bronchopneumonia 
98/251 31 M 2.2 autopsy natural disease and 
MDMA ingestion 
accidental cardiac arrhythmia, non-recent 
myocardial infarction 
99/231 18 M 0.3 external  poly-drug intoxication 
including MDMA 
accidental  cardiopulmonary failure ? 
99/235 27 M 2 autopsy MTA, MDMA, 
intoxication 
accidental fatal cardiac arrhythmia ? fatal 
epileptic insults not excluded 
00/112 23 M 1.2 autopsy predisposing natural 
disease and MDMA 
intoxication 
accidental  cardiopulmonary failure 
01/29 17 M 0.3 external  polytrauma (TA), 
MDMA  
suicide  cranio-cervical trauma, 
multiple fractures (thorax, 
limbs) 
01/34 23 M ± 3 autopsy PMA, MDMA, AMP 
intoxication 
accidental hyperthermia, DIC 
01/122 18 M ± 5 autopsy MDMA intoxication accidental hyperthermia, MOF 
01/142 28 M 1.3 external  polytrauma and AMP suicide internal bleeding ? 
cranio-cervical trauma ? 
01/158 31 M ± 7 autopsy MDMA intoxication accidental cardiopulmonary failure 
01/197 32 M 0.13 external  hanging following 
AMP ingestion 












Figure 2.4 Distribution of the cause (a), manner (b) and mechanism (c) of death of the  
  amphetamine-related fatalities at the Department of Forensic Medicine, Ghent  
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Figure 2.1 shows that the number of amphetamine-related fatalities has increased 
since about 1995.  The peak year in our study population is 2001.  However, it should be 
noted that some bias could have taken place during the last few years due to the 
establishment of a system for the systematic screening of medico-legal fatalities, with 
specific attention being given to amphetamine-related victims.  
The age and sex distribution of our study group was well in line with the world 
literature data (see Figure 1.12 and Figure 2.3).  The same applies to the distribution of the 
causes and manners of death. However, besides pure intoxications, polydrug (ab)use was 
frequent (see Figure 2.4 (a)). Accidental overdoses comprised the majority of deaths (see 
Figure 2.4 (b)).  In addition, in our study group, the number of suicides is substantial (23 %).  
In 2 out of 5 suicide cases (case 97/156 and 01/142) severe confusion was noted.  In the 
subject dying in a train accident (case 01/29) it cannot be excluded that an acute psychotic 
syndrome was the immediate cause of his decision.  Cardiopulmonary failure is the most 
important mechanism of death (see Figure 2.4 (c)).  It should be noted that the distribution of 
cases is not fully comparable with the literature data, as in the literature review specifically 
MDMA-related fatalities were described and in our study population all amphetamine-related 
fatalities were considered.  
Our data confirm that the autopsy findings in “pure” amphetamine and polydrug 
overdoses are non-specific: e.g. signs of cardiopulmonary failure (overwhelming pulmonary 
congestion and oedema), generalized visceral congestion sometimes interfered by intensive 
cardiopulmonary reanimation, and non-specific brain oedema were often found.  This is in 
accordance with the increased lung weights (see Table 2.1).  
The microscopical findings are also non-specific, though as mentioned in Chapter 1, 
some indications, such as pulmonary foreign body granulomata, can point to regular drug 
(ab)use.  In order to conclude that hyperthermia was the cause of death, the data of the 
external examination at the scene, and the macroscopical and microscopical findings must be 
considered as a whole. 
Unfortunately, pathological data on chronic amphetamine and – specifically - on 
MDMA users, are hardly available from our cases.  However, referring to the young subject 
in whom a recurrent acute myocardial infarction based on an acute coronary thrombosis and 
an old  transmural infarction (case 98/251) was observed, it is obvious that MDMA (or other 
analogues) - just like amphetamine - can be cardiotoxic.  However, it was assumed that 
cardiomyopathy in chronic amphetamine and methamphetamine abuse was mainly 
catecholamine-related and that these lesions can be differentiated from ischemic cardiac 
necrosis.  The catecholamine-induced myocardial injury is not restricted to a “zone” of 
injury, as is found in ischemic necrosis (related to the supply of the coronary branch 
involved) (9).  However, we cannot exclude the possibility that the subject (case 98/251) had 
a genetic predisposition (such as hyperlipemia) or that he had frequently used cocaine.  An 
enlarged heart can point to chronic stimulant abuse (see Table 2.1) but, unfortunately, we 
have little data on the antecedents of our subjects. 
When drug (ab)use is suspected, toxicological investigation should be performed.  




trauma due to a traffic accident), toxicological screening can be indicative, especially in 
young subjects.  Of our fatalities, 14 % involved traffic accidents.  As mentioned above, the 
dangers of driving under the influence of amphetamines should not be underestimated (see 
Chapter 1).  Moreover, drug use can be an explanation for bizarre behaviour, even when 
traffic accidents are not involved (see e.g. cases 97/156 and 01/142).   
The toxicological data in our cases confirm the broad range of post-mortem 
concentrations: for the “pure” MDMA overdoses, blood values of between 0.27 and 13.51 
µg/ml were found.  In a few cases, the amphetamines were below limit of detection in blood 
and were only barely detected in urine.  Prouty and Anderson were able to demonstrate that 
the interference of post-mortem phenomena such as post-mortem redistribution can be 
avoided by sampling blood as soon as possible after death from an isolated peripheral vein 
such as the femoral vein (10).  It should be noted that in the older cases (cases 80/181, 89/88, 
and possibly also in case 94/15) the blood sampling site is not known and it cannot be 
excluded that cardiac blood was used.  For this reason, and also because the analytical 
techniques in that period might have been less sensitive and/or specific, these levels should 
be interpreted with caution.  Blood sampling from the inferior vena cava was performed in 
the lower abdomen and thus not nearby the liver, which explains why these levels are not 
unexpectedly high.  The discrepancy between the subclavian and the femoral blood AMP 
concentration in case 01/142 might be explained by contamination of the subclavian sample.  
In that case, several stab wounds were found associated with important thoracic and 
abdominal lesions.  An autopsy was not performed, however. 
Unfortunately, the available vitreous humour concentrations are restricted and the 
number of samples is too small to interpret the possible correlation between blood and 
vitreous humour levels.  The data indicate that the vitreous humour levels were still positive 
when the persons were already in an advanced elimination phase (see cases 97/134, 98/14, 
98/239), which can be interpreted in the light of the pharmacokinetics in which the vitreous 
humour levels lag somewhat behind the blood concentrations.  As the vitreous fluid is to a 
minor extent influenced by the autolytic processes, it is worthwhile to study the value of this 
specimen (see Chapter 3 and part 3 of this work).   
The amphetamine concentrations in urine, bile and liver indicated a possible  
elimination via hepatic biotransformation and excretion via bile and  kidneys.  The available 
stomach content levels pointed to a possible reservoir function, which could give rise to post-
mortem redistribution. 
In view of our data, the impact of the blood sampling location in the interpretation of 
the toxicological results is not clear.  It will be necessary to study the distribution – and 
possible redistribution - in various fluids and tissues, to reach a conclusion on this issue.  In 
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I Abstract  
As drug instability and redistribution are factors known to affect the interpretation 
of post-mortem blood levels, we questioned whether post-mortem vitreous humour 
concentrations could be useful as predictors for the MDMA load at the time of death. In a 
first series of in vivo experiments using rabbits, 3,4-methylenedioxymethamphetamine 
(MDMA) concentrations in plasma, blood and vitreous humour were studied as a function 
of time after intravenous (iv) administration of MDMA. Equilibration between the vascular 
compartment and vitreous humour was attained about 1 h after iv MDMA administration.  
In a second series of experiments, the post-mortem stability of MDMA in vitreous humour 
in relation to ambient temperature was investigated. Post-mortem MDMA concentrations 
in vitreous humour were closer to the ante-mortem blood levels when compared to cardiac 
blood samples.  
These preliminary investigations in the rabbit model indicate that measurements of 
vitreous humour concentrations could also be of interest for predicting the blood 
concentration at the time of death in humans.  
 
Key words : 3,4-Methylenedioxymethamphetamine (MDMA) - Vitreous humour – 
Pharmacokinetics - Post-mortem stability - Rabbits 
 
II Introduction 
As post-mortem drug levels in blood do not necessarily reflect the concentration at 
the time of death, the question whether a detected level played an important role in the 
mechanism of death,  remains a complex problem in the forensic practice.  In particular, 
post-mortem instability and redistribution of drugs are important thanato-chemical factors 
(1).  This “toxicological nightmare” is an established fact for various drugs e.g. cocaine 
(2), and many therapeutic drugs such as barbiturates (1) and digitalis (3,4).  To a certain 
extent, the influence of these post-mortem phenomena can be avoided by sampling blood 
as soon as possible after death from an isolated peripheral vein such as the femoral vein 
(5).  However, bearing in mind this general recommendation, a single blood sample is 
often insufficient to draw appropriate conclusions.  Another sample (tissue or fluid) should 
not only be used as an analytical control for the blood level determined, but could also 
provide information on the pharmacokinetic phase and as a result the time of drug intake.  
Vitreous humour is one of these supplementary samples and is an interesting medium 
because the vitreous fluid is less influenced by autolytic processes and is convenient (e.g. 
simple to sample and not affected by hemolysis).  Formerly, vitreous humour 
determinations have been performed in order to detect various drugs, in particular ethanol 
(6), morphine (7), cocaine (8), and amitriptyline (9), for example. 
To our knowledge, the post-mortem drug distribution in humans has barely been 
explored for amphetamines and analogues, or for MDMA in particular, with the exception 
of a few case reports (10-12). 
To investigate whether vitreous humour concentrations could be more helpful than 




rabbits were carried out.  Rabbits were chosen as the animal model because they have a 
vitreous volume of about 1.4 ml (13) which is much larger than in rats, and the chemical 
characteristics of vitreous humour in rabbits are comparable to those in humans (14).   As 
pharmacokinetic data for MDMA in the rabbit are lacking, we first investigated this after 
intravenous (iv) administration.  We then studied whether determination of MDMA in 
vitreous humour is possible and whether there was a correlation in vivo between the 
vitreous humour levels and the plasma or blood concentrations.  Finally, to explore 
whether the post-mortem vitreous concentrations could be useful to estimate the blood 
MDMA levels at the time of death, the influence of the post-mortem interval and the 
ambient temperature was examined. 
 
III Materials and methods  
The study protocol was approved by the Ethics Committee for animals of the 
Medical School, Ghent University (request number ECP 98/1 and ECP 99/9). 3,4-
Methylenedioxymethamphetamine hydrochloride was provided by Sigma-Aldrich 
(Belgium). 
 
III.1   Animals and procedures   
Female white New Zealand rabbits (weight 2050 – 4500 g) were purchased from 
Iffa Credo Belgium. The animals were  fasted overnight before the experiment but were 
allowed free access to water.   
 
III.1.1   In vivo experiments 
The broad study design is shown in Figure 3.1.  
A polyethylene catheter (P.E. 50) filled with heparin solution (100 IU/ml) was 
implanted (xylocaine 1 %) into the main central artery of the right ear in 18 rabbits under 
local anaesthesia.  
In one group of six rabbits (t = 120 minutes), arterial blood samples (2 ml) were 
taken at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120 minutes after drug administration for the assay 
of MDMA and MDA (3,4-methylenedioxyamphetamine) concentrations in plasma.  
Additional samples (1ml at 10, 20, 60, 120 minutes) were taken for whole blood 
determinations. Pentobarbital anaesthesia was induced according to Prince (30 – 35 mg/kg 
body weight (15)).  
In all cases, sampled blood was replaced by the same amount of saline.  Blood 
samples were centrifuged at 3500 rpm for 10 minutes, and plasma and whole blood 
samples were frozen at – 30°C until analysis.   Both eyes were immediately frozen after 
enucleation by immersion in liquid nitrogen for 1 – 2 minutes.  The eyes were preserved at 
–30°C until the vitreous bodies were dissected as described by Abel and Boyle (16).   
Finally, in three rabbits the urinary excretion of  MDMA and MDA was followed 
for  96 hours after MDMA iv administration (1 mg/kg).  Urine was collected in a 





III.1.2   Post-mortem experiment 
The broad study design is shown in Figure 3.1. Sample preservation and dissection 




 in vivo experiments     post-mortem experiments 
  n = 18       n = 12 
      at t = 120:  - blood sample right ear vein (3 ml) 
       + - immediate killing  
n = 6  n = 6  n = 6    (neck concussion + air embolism) 
t = 30   t = 120   t = 240    + - immediate enucleation of one 
        eye (left or right eye, at random) 
 at t = 30, 120 or 240: 
- last arterial blood sampling (3 ml) 
+ - pentobarbital anaesthesia     n = 6   n = 6 
+  - immediate enucleation of both eyes T   2 °C   17 °C 
 
       n = 3  n = 3   n = 3            n = 3 
      PMI 25 h  73 h 25 h 73 h 
 
At PMI = 25 or 73 h: cardiac blood sampling and 
enucleation of the second eye 
 
 Abbreviations: t:  time expressed in minutes 
   T: Temperature in degrees Celsius 
   PMI: post-mortem interval (hours) 
 
 




III.2   Protein binding  
Protein binding of MDMA was determined by ultrafiltration using Amicon 
centrifuge micropartition system and YMT membrane discs (Grace, Amicon Division, 
Beverly, Mass).  Blank rabbit plasma samples were spiked with 400 ng/ml MDMA; 1 ml 
plasma samples were transferred to the micro-partition system and centrifuged at 1500 rpm 
for 30 minutes resulting in a volume between 100 and 200 µl.  MDMA concentration was 
measured, in a 50 µl aliquot of the ultrafiltrate with HPLC.  Adsorption of MDMA to the 





III.3   Drug assay 
Concentrations of MDMA and MDA were determined using a fully validated 
HPLC (high pressure liquid chromatography) procedure with fluorescence detection (λex 
288, λem 324 nm) .  The samples (250 µl) were liquid/liquid extracted with 
hexane/ethylacetate (70:30, v/v) at pH 9.5 using MDEA (3,4-
methylenedioxyethylamphetamine) as the internal standard.  Chromatographic separation 
was achieved using Hypersil BDS C18 columns (3 µm, 100 x 2.1 mm, Alltech, Deerfield, 
Il.) isocratically eluted at 0.2 ml/min with a mixture of water/methanol/acetonitrile 
containing 0.1 M ammonium acetate.  The method proved linear from 2 to 1000 ng/ml (2 
ng/ml being the quantitation limit both for MDMA and MDA, between-day reproducibility 
< 25 %).  With each batch of samples, a calibration curve prepared in the corresponding 
blank matrix (except for the vitreous humour which was substituted with water for reasons 
of practical unavailability) and quality control samples (7 and 500 ng/ml) were analysed.  
Accuracy was between 97 – 102 % (n = 7) and total precision (CV, coefficient of 
variation) was lower than 13 % (n = 7).  
  
III.4   Analysis of data 
The results are expressed as means (± SD).  
The plasma concentration-time profiles of MDMA after iv administration were 
individually analysed using a pharmacokinetic computer programme (WinNonlin version 
1.5 – Scientific Consulting, Inc.) and were best characterized on the basis of the Akaike 
Information Criterion (17), by a 2-compartment model using the equation C = A e -αt + B e 
-β t, where C is the plasma concentration at time t, α and β  are hybrid rate constants and A 
and B are the coefficients of the exponential terms. Calculation of the pharmacokinetic 
parameters (half-life, volume of distribution at steady state, volume of distribution of the 
central compartment, clearance, area under the curve (AUC) and mean residence time) was 
done according to Gibaldi and Perrier (18).  
Statistical processing of the data was performed using non-parametric tests.  The 
Wilcoxon Rank test was used for analysis of interindividual differences in concentrations 
between the left and right eyes.  The Friedman test for repeated measurements was used to 
compare the ratios of blood to plasma MDMA concentrations (10, 20, 60 and 120 minutes 
after infusion). The ratios between the vitreous humour MDMA concentration and the 
corresponding plasma or blood level sampled 30, 120 and 240 minutes after 
administration, were compared using the non-paired Kruskal-Wallis test; and, when 
appropriate, this was followed by the Mann-Whitney U Test.  The correlation between 
vitreous humour and plasma or blood levels was investigated with the Spearman 







IV.1   In vivo experiments 
Figure 3.2 shows the time course of the mean plasma concentrations of MDMA 
following  a 1 mg/kg iv dose (n = 6). The data from each animal were well fitted according 
to a two compartment model.  The corresponding pharmacokinetic parameters are 
summarized in Table 3.1.  The mean blood/plasma ratios calculated at 10, 20, 60 and 120 
minutes after infusion, were 1.2 ± 0.1, 1.2 ±  0.2, 1.3 ± 0.5 and 1.3 ±  0.2, respectively.  
Statistical analysis did not reveal significant differences. 
 
 
Figure 3.2  Plasma concentrations of MDMA as a function of time in rabbits after an iv dose of 
  1 mg/kg MDMA (n = 6). 

























Table 3.1  Pharmacokinetic parameters of MDMA in rabbits after an iv dose of 1 mg/kg.  
(Results are expressed as means ± SD) 
 
 
AUC (Area under the curve;µg.min/l)    16937 ± 7849 
Alpha half-life a (min)      5.0 ± 1.8 
Beta half-life b(min)      63.5 ± 34.2 
Systemic clearance (l/kg per h)    4.1 ± 1.4 
Volume of distribution of the central compartment (l/kg) 1.9 ± 0.8 
Volume of distribution at steady state (l/kg)   4.9 ± 2.6 
Mean residence time (min)     78.1 ± 46.7 
 
a half-time in the distribution phase 
b half-time in the elimination phase 
 
 
MDMA concentrations were measured in the vitreous fluid 30, 120 and 240 
minutes after administration (n = 6 for each time point; see Figure 3.3).  As there were no 
statistical differences in MDMA concentrations between the left and the right eyes (n = 




Figure 3.3  Mean vitreous humour MDMA concentrations as a function of time in rabbits after 
an iv dose of 1 mg/kg MDMA (n = 6 for each time point). 































The ratios of the vitreous MDMA concentrations (MDMAvitreous) to the plasma 
(MDMAplasma ) (see Figure 3.4 (a)) or whole blood (MDMAblood) concentrations 30 
minutes after administration (see Figure 3.4 (b)) were less than one and significantly 
different from the values obtained at 120 and 240 minutes when both ratios were higher 
than one, but no significant difference was observed between both values (ratios: at t = 120 

















(a)                    (b) 
 
Figure 3.4 Individual and mean ratios of the vitreous humour MDMA concentrations to 
plasma (a) or blood (b) concentrations as a function of time in rabbits after an iv 
dose of 1 mg/kg MDMA (n = 18). 
 
Figure 3.5 shows the scatterplot of the MDMAvitreous versus MDMAplasma (Figure 
3.5 (a)) levels or MDMAblood (Figure 3.5. (b)) in the elimination phase.  The Spearman (rs) 
correlation coefficients for the MDMAvitreous and MDMAplasma  or  MDMAblood  in the 
elimination period (at t = 120 and 240 min) were 0.981 and 0.950, respectively.  These 
correlations were significant at the 0.01 level.  The correlation performed without the 
outlier did not change significantly these correlation coefficients being 0.984 and 0.945, 
respectively. 
MDA plasma and blood concentrations were low, ranging between 2 ng/ml and 6 
ng/ml.  The MDA levels in the vitreous humour were below the limit of quantitation (2 
ng/ml). 
The percentages of the administered MDMA dose recovered in urine of three 
rabbits were 12.9, 3.4 and 4.1 %, respectively.   MDA levels were below the limit of 
quantitation.  The mean unbound fraction of MDMA in plasma was 63 % ± 3 (n = 6) at a 










































































(a)                    (b) 
 
Figure 3.5 Scatter plot of vitreous humour versus plasma (a) or blood (b) MDMA 
concentrations (120 and 240 minutes after an iv dose of 1 mg/kg MDMA).  
(n = 12)  
 
 
IV.2   Post-mortem experiment (see Figure 3.6) 
The mean plasma, blood levels and the vitreous humour concentrations of one eye 
120 minutes after MDMA infusion (just prior to killing of the animals) were 32 ± 17, 42 ± 
16, and 27 ± 7 ng/ml, respectively (n = 12). 
 Blood MDMA concentrations were clearly increased post mortem compared to the values 
obtained ante mortem, whereas the vitreous MDMA concentrations did not change 
substantially post mortem. An overall slight increase in vitreous MDMA levels was 
observed, somewhat more pronounced at 17°C 73 h post mortem and vitreous MDMA 
levels tended to be more stable at 2°C. 
 


































































































Figure 3.6 Individual blood and vitreous humour MDMA concentrations (ng/ml) in rabbits 
  120 minutes after an iv dose of 1 mg/kg MDMA (ante-mortem values; blood out of 
  ear artery) and preserved at 2°C (left panel) and 17°C (right panel), either 25 or 73 
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In this study, we examined whether determination of vitreous MDMA levels can be 
useful to predict the MDMA blood concentrations at the time of death with the help of a 
rabbit experiment. 
In order to interpret the post-mortem concentrations of MDMA in the rabbit, we 
first investigated the pharmacokinetics of MDMA after an intravenous dose of 1 mg/kg.  
The plasma concentration versus time curves of MDMA were fitted according to a 2- 
compartment model. MDMA has a high volume of distribution (5 l/kg), a high systemic 
clearance (4.1 l/kg per h) and a relatively short half-life (1 h).  Our results were fairly 
consistent with previously reported pharmacokinetic parameters of MDMA after 
intravenous (iv) and subcutaneous (sc) administration in rats (19). 
The mean blood/plasma ratios in the distribution as well as the elimination phase 
indicate a certain accumulation of MDMA in red blood cells. 
In our experiments, only 6 % of the MDMA dose was found unchanged in urine 
and MDMA is probably eliminated by biotransformation or by excretion via the bile. In 
addition, MDA concentrations in rabbit plasma were very low (below 6 ng/ml) and were 
below the limit of  quantitation in urine. In rats and mice, MDA was identified in plasma as 
an important metabolite (20) whereas in rat urine, either R(-) MDA  and S(+) MDA were 
rarely found (19).   In humans, MDA was originally assumed to be the major metabolite 
(21), but  it was demonstrated that conjugated HMMA (4-hydroxy-3-methoxy-
methamphetamine) and HHMA (3,4-dihydroxymeth-amphetamine) were the main urinary 
metabolites of MDMA (22-25). 
The mean binding of MDMA in rabbit plasma (37 %) is similar to that in dogs [26]. 
In our experiments, after a single intravenous dose, equilibration between plasma 
and vitreous humour was obtained between 30 and 120 minutes, as the MDMAvitreous / 
MDMAplasma ratios did not differ significantly between 120 and 240 minutes post 
administration.  Physiologically, the blood-retina barrier can be compared with the blood-
brain barrier and Chu et al. (27) demonstrated that an equilibration between plasma and 
brain concentrations of MDMA was obtained within 30 minutes after sc administration of 
MDMA in rats.  The  MDMAvitreous / MDMAplasma ratios at 120 (1.4 ± 0.3) and 240 minutes 
(1.6 ± 0.2) and the corresponding ratios of MDMAvitreous to MDMAblood (1.1 ± 0.3 and 1.1 
± 0.4, respectively) indicate a slight accumulation of MDMA in the vitreous compartment.  
The accumulation is in fact even more important as the plasma protein binding of MDMA  
is ± 30 %.   A possible explanation could be binding to the vitreous humour, but in vitreous 
fluid protein concentration is only 1 - 3 % of the total serum protein concentration (14).  
For some drugs with an important level of plasma protein binding, such as fleroxacin (28), 
vitreous to plasma concentration ratios lower than 1 were seen.  However, higher vitreous 
humour levels compared to serum concentrations were noticed in rabbits for fluconazole 
(29).  For ethanol too, a higher vitreous humour level compared to blood concentration at 
steady state was observed (6) which was explained by the smaller  dry matter content of 




To our knowledge, there are only two case reports of MDMA determination in 
human vitreous humour; both revealing a vitreous humour/blood concentration ratio below 
1.  Crifasi and Long (31) published a traffic accident fatality attributed to the use of 
MDMA.  The vitreous/blood ratio was 0.5 and very little  MDA was detected.  These 
authors concluded that their results support an acute event (i.e. that death occurred before 
distribution was complete).  In the second case report, (an acute poisoning, probably 
accidental, due to combined intake of MDMA, cocaine and heroin) (32), the ratio of total 
vitreous/blood MDMA levels was calculated as 0.66; an analogous explanation for their 
results could be assumed. 
Since ambient temperature and post-mortem interval are important thanato-
chemical factors, four different conditions, 2°C or 17°C and 25 or 73 hours post mortem, 
respectively, were investigated in the second part of our study.  We demonstrated that 
MDMA concentrations in cardiac blood  increased post mortem, whereas vitreous MDMA 
levels were much more stable and thus more representative of the ante-mortem blood 
levels.  Relatively small differences were noticed between  the peri- and post-mortem 
vitreous values obtained at ambient temperatures of either 2°C or 17°C.  The elevation of 
the vitreous MDMA concentration 73 hours after death in rabbits preserved at 17°C could 
partially be explained by the dehydration which occurred and, theoretically, a low level of 
post-mortem redistribution. On the other hand, the MDMA concentration increase in our 
rabbit heart blood samples, taken 73 hours post mortem in particular, points to a post-
mortem redistribution.  Moriya and Hashimoto (33) demonstrated post-mortem diffusion 
of methamphetamine from lung tissue in rabbits. In humans, post-mortem cardiac blood 
levels of amphetamine (5) and methamphetamine (34,35) were found to be higher than 
femoral blood concentrations and in one of the cases reported by Rohrig and Prouty, the 
MDMA concentration in heart blood was reported to be 5 times higher than in femoral 
blood (11).   However, recently, in two human fatal cases associated with amphetamine 
intake (36), a post-mortem increase in amphetamine concentrations of 50-60 % in femoral 
blood was noticed. Further thanato-chemical experiments are needed to explore the 
mechanism of these increases. Instability of MDMA itself is not very likely as in vitro 
stability studies of MDMA and MDA in aqueous solutions and dog plasma demonstrated 
that these products are fairly stable (26).  Human blood samples containing amphetamine 
and methamphetamine, stored in preservation products, are  sufficiently stable up to 5 
years (37).  Nagata and colleagues (38) investigated the stability of amphetamine and 
methamphetamine in post-mortem rabbit tissues and concluded that these products are 
sufficiently stable.  
 
In summary, after intravenous administration, MDMA can easily be identified in 
the vitreous humour of rabbits and an equilibration between the vitreous humour and the 
vascular compartment was established after about 1 h.  In addition, our results confirm that 
heart blood samples cannot be used for post-mortem toxicological analysis.  In fact rabbit 
vitreous MDMA was more stable than post-mortem cardiac blood levels. 
Vitreous sampling for MDMA determination seems to be a good autopsy practice if 




equilibration, vitreous humour could be a suitable control sample in case of erratic blood 
values due to either sampling site bias or analytical errors.  In fact vitreous humour 
MDMA levels could be more representative than blood MDMA concentrations when there 
is a prolonged post-mortem interval. Further thanato-chemical investigations of routine 
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Chapter 4    Post-mortem redistribution of 3,4-methylenedioxymethamphetamine 
(MDMA, “ecstasy”) in the rabbit   
 Part one: experimental approach after in vivo intravenous infusion. 
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Post-mortem redistribution is known to influence blood and tissue levels of various 
drugs.  An animal model was used in an attempt to elucidate this problem for the 
amphetamine analogue, 3,4-methylenedioxymethamphetamine (MDMA).  Rabbits received 
1 mg/kg MDMA intravenously (iv) and were killed two hours later in order to simulate the 
state of complete distribution in the body. MDMA and 3,4-methylenedioxyamphetamine 
(MDA) concentrations were determined in blood, urine, bile, vitreous humour, and various 
tissues (eye globe walls, brain, cardiac muscle, lungs, liver, kidneys, iliopsoas muscle and 
adipose tissue) using a high pressure liquid chromatographic (HPLC) procedure with 
fluorescence detection.  
In the first group (control group, sampling immediately post mortem) considerable 
MDMA concentrations were found in the brain and both lungs.  In addition, our data indicate 
the elimination of MDMA by hepatic biotransformation and excretion via the bile.  When 
the animals were preserved either 24 or 72 h post mortem (second group), an increase of 
MDMA and MDA levels in the liver and the eye globe walls was noticed.  In the lungs, on 
the other hand, they tended to decline as a function of increasing post-mortem interval.  
MDMA levels in cardiac and iliopsoas muscle were fairly comparable and remained stable 
up to 72 h after death.   In the third group, ligation of the large vessels around the heart took 
place immediately post mortem, but significant differences in blood and tissue MDMA 
concentrations between rabbits of group 2 and 3 could not be demonstrated.  We therefore 
conclude that post-mortem redistribution of MDMA at the cellular level (viz. by pure 
diffusion gradient from higher to lower concentrations) is more important than its 
redistribution via the vascular pathway.  Finally, MDA levels were relatively low in all 
samples, thus indicating that this is not a major metabolite in the rabbit, at least within the 
first two hours after administration. 
 
Key words: 3,4-Methylenedioxymethamphetamine (MDMA) - 3,4-Methylenedioxy-




For many drugs there is a correlation between plasma concentration and 
pharmacological effect.  However, the interpretation of post-mortem concentrations of many 
substances differs substantially from in vivo quantified levels.  In particular, post-mortem 
instability and redistribution can be important interfering factors, as has been demonstrated, 
for example, for ethanol (1) but also barbiturates (2), cocaine (3), and dothiepin (4).  Post-
mortem distribution has also been investigated for more scarcely encountered substances in 
forensic practice such as laudanosine (5 ), dichloromethane  (6 ).  
These thanato-chemical problems have barely been explored for the amphetamine 
analogue, 3,4-methylenedioxymethamphetamine (MDMA, or “ecstasy”), except in a few 
case reports (7-10).  For amphetamine and methamphetamine, more literature data are 
available (11-19).  Animal experiments dealing with this issue for amphetamine or its 




not been thoroughly investigated either in humans or in animal models.  Substances having 
an apparent volume of distribution of more than 3 to 4 l/kg are liable to post-mortem drug 
redistribution (21).  As shown in a previous study using rabbits, MDMA has a volume of 
distribution at steady state of 4.9 ± 2.6 l/kg (23).  Furthermore, we demonstrated that 
MDMA concentrations in cardiac blood increased post mortem and that vitreous MDMA 
levels were more stable (23).  As a result, since substantial post-mortem redistribution of 
MDMA is suspected and thus could be important to deal with and to take into account when 
drawing conclusions in current forensic practice, two experiments have been set up.  Here, 
death in a state of complete absorption of the drug (e.g. when somebody dies due to multiple 
organ failure) was simulated.  In the following experiment in rabbits (24), post-mortem 
redistribution was investigated when someone dies due to MDMA ingestion before complete 
uptake took place and therefore a considerable “reservoir” of the substance is still present in 
the stomach.  Both animal experiments investigate the consequences on sampling and 
interpretation of the toxicologic data, mainly when peripheral blood cannot be taken for 
analysis.  
In this study, the tissue distribution of MDMA and its metabolite 3,4-
methylenedioxyamphetamine (MDA) was studied in the rabbit after intravenous 
administration.    We also investigated the mechanism of the increases in heart blood 
MDMA levels, in particular, the redistribution of MDMA from the surrounding tissues into 
the cardiac blood. Blood and tissue levels were compared both with and without ligature of 
the large vessels around the heart up to 24 and 72 hours after death.  One could expect that 
by simple diffusion across concentration gradients via vascular pathways, blood-rich organs 
such as the lungs and the liver could contribute to post-mortem increases in drug 
concentrations in cardiac blood (2).  
 
III Materials and methods  
The study protocol was approved by the Ethics Committee for Animals of the 
Medical School, Ghent University (request number ECP 99/20).   
MDMA hydrochloride for the rabbit experiments and pure standards (MDA and 
MDMA) were provided by Sigma-Aldrich (St. Louis, Mo). 
 
III.1   Animals and procedures 
Female white New Zealand rabbits (weight 2000 – 2350 g) were purchased from Iffa 
Credo, Belgium.  The animals were fasted overnight before the experiment but were allowed 
free access to water. 
The study design is presented in Figure 4.1.  Fifteen rabbits received 1 mg/kg 
MDMA, slowly infused via the left ear vein, and 2 rabbits received a comparable amount of 
saline and were used as blanks. Blood was sampled after 2 h via the right ear vein (3 ml) for 
determination of whole blood and serum MDMA levels.  Three groups of rabbits were 
randomly created.  In three rabbits (group 1), all samples were immediately taken after death 
(controls).  The remaining 12 rabbits were left in a supine position at an ambient temperature 
of 18 °C and divided into groups 2 and 3, according to whether or not immediate post-




were each divided into two subgroups (n = 3), which were preserved either 24 hours (group 
a) or 72 hours (group b) post mortem.  From each rabbit, cardiac blood and the following 
tissues were sampled: cardiac muscle, right and left lung, liver, kidney (mixture of right and 
left), cerebrum, cerebellum, brainstem, stomach wall and stomach content, abdominal 
adipose tissue, and iliopsoas muscle.  In addition, enucleation of the second eye and 
sampling of urine and bile in toto was carried out.  The eyes were handled as previously 
described (23).  The individual eye globe walls, consisting of the retina, choroidea and 
sclera, were also preserved for toxicological analysis.  In order to avoid contamination of 
these eye globe walls, all inserting muscle fragments were carefully removed.  Aqueous 
humour, cornea and lens were not included in our protocol.  As creatinine is a stable 
parameter post mortem (25), these levels were determined in the vitreous humour samples 
and the ratio of MDMA to creatinine concentration was calculated.  All samples were stored 
at –30 °C until analysis. 
 
 
at t = 0 min:  1 mg/ kg MDMA, iv (n = 15) 
at t = 120 min: - blood sampling 
+ - immediate killing (by neck concussion + air embolism) 
+ - enucleation of one eye (left or right, at random) 
 
  
Group 1    Group 2    Group 3  
n = 3     n = 6         n = 6 
 no ligation      ligation 
 
                  
  
 
           group 2-a         group 2-b         group 3-a         group 3-b 
               n = 3        n = 3            n = 3         n = 3 
   PMI:    0 h              24 h         72 h           24 h         72 h 
 
    At PMI = 0 h:            At PMI = 24 or 72 h: 
 
 
- enucleation of the second eye 
- cardiac blood sampling 
- tissue sampling, and urine and bile in toto. 
 
 
Figure 4.1   Scheme of the study design in rabbits receiving 1 mg/kg MDMA iv.  




III.2   Analytical methods 
III.2.1   Drug assay 
The samples were analyzed using a fully validated procedure developed in our 
laboratory for the analysis of  MDA, MDMA and 3,4-methylenedioxyethylamphetamine 
(MDEA) (26,10) in biological matrices. The essentials of the method are described below. 
Tissue samples were homogenized after a 1:4 dilution in water using an Ultra-Turrax 
homogenizer from IKA (Staufen, Germany). The resulting homogenates or biological 
liquids (serum, whole blood, vitreous humour, urine, bile and stomach content) were 
liquid/liquid extracted with hexane/ethyl acetate (7/3, v/v) at an alkaline pH of 9.5 (using 
K2CO3). For the tissues, the organic layer was transferred to a test tube containing 1 ml of 1 
M hydrochloric acid. After mixing, the organic layer was discarded. The aqueous layer was 
adjusted to pH 9.5 (using K2CO3) and again extracted with hexane/ethyl acetate (7/3, v/v). 
The organic layer was evaporated after the addition of 50 µL methanolic HCl.  
For the chromatographic separation, a narrow-bore (2.1 x 150 mm, particle size 3 
µm) Hypersil BDS C18 column was used with a gradient elution using 0.1 M ammonium 
acetate in water and acetonitrile/methanol. Fluorescence detection was used with an 
excitation and emission wavelength of 288 and 324 nm respectively.  
Calibration curves were prepared in the corresponding blank matrix and extracted 
using the general isolation procedure. When the concentration of an unknown sample 
exceeded the calibration interval, it was reassayed in an appropriate dilution. 
The limit of quantitation (LOQ) was 2 ng/ml for whole blood, serum and vitreous 
humour, 10 ng/g for tissue samples and 0.1 µg/ml for urine. 
 
III.2.2   Quantitation of creatinine 
Creatinine measurements were performed on a Cobas Mira (Basel, Switzerland) 
automated analyzer and were based on the Jaffé reaction (reaction of creatinine and picrate 
in alkaline medium) (27).  
 
III.3   Analysis of data 
Statistical processing of the data was performed using non-parametric tests (using 
the computer programme SPSS, version 10.0 for Windows).  The Wilcoxon Rank test was 
used both for the analysis of intra-individual differences in concentrations between 
cerebrum, cerebellum and brainstem and for comparing the values of the right and the left 
lung.  The Wilcoxon Rank test was also used to compare the individual vitreous humour 
and blood MDMA levels. The Mann-Whitney U-test was used to compare the values of 
groups 2 and 3.   The Kruskal-Wallis test was applied to compare the MDMA and 
creatinine values as a function of post-mortem interval and, when appropriate, this was 
followed by the Mann-Whitney U-Test.  The correlation between blood and vitreous 
humour or tissue MDMA levels was investigated with the Spearman correlation test.  For 





IV Results  
Figure 4.2 shows the mean concentrations of MDMA and MDA in different tissues 
of the rabbits of group 1.  The MDMA and MDA levels in blood and plasma 120 minutes 
after infusion are comparable with those in a previous study (23).  The individual values of 
the cerebrum, cerebellum and brainstem were taken together as there were no statistically 
significant differences.  The mean of these levels is presented as MDMA concentration in 
the brain.  For the same reason, the mean value of both vitreous humour samples, both eye 
globe walls and both lungs was used.  When compared with the blood level, the highest 
MDMA concentrations were retrieved in the lungs, the bile and the kidneys, followed by 
the brain.  The MDMA levels in cardiac and iliopsoas muscle were comparable, but were 
higher than cardiac blood levels.  In contrast, the MDMA levels in adipose tissue were 
mainly below LOQ and only quantifiable in one rabbit.  The MDA concentrations were 
low in blood and in all tissues (< 100 ng/g), and only substantial in the lungs, liver, bile 


























Figure 4.2 Mean MDMA (a) or MDA (b) concentrations in blood, vitreous humour, bile, and 
tissues in rabbits after an iv injection of 1 mg/kg MDMA. Sampling occurred 120 
min after infusion or immediately after killing (group 1, n = 3).  




In Figure 4.3, the individual MDMA concentrations in blood, vitreous humour and 
eye globe walls of groups 1, 2 and 3 (Figure 4.3 (a)) are presented. For group 1, the 
vitreous humour concentration of each individual eye is presented (and not the mean value 
of both eyes as in Figure 4.2).  The Wilcoxon test showed that the post-mortem MDMA 
blood levels differ significantly from the MDMA vitreous humour levels (p = 0.006; the 
blood MDMA concentrations were higher than de corresponding vitreous humour levels).  
The outlier in the blood MDMA levels (R-14) is not relevant, as contamination with 
thoracic cavity fluid during sampling occurred. The Kruskal-Wallis test showed 
significantly different MDMA concentrations for the vitreous humour and the eye globe 
walls of the second sampled eye (p = 0.006 and 0.023, respectively), immediately post 
mortem and 24 h or 72 h after death.  In addition, the individual creatinine concentrations 
and the ratio of the MDMA to creatinine concentration in vitreous humour are shown (see 
Figure 4.3 (b)). The Kruskal-Wallis test showed also statistically significant differences for 
the creatinine values in the second sampled eye (p = 0.002), immediately post mortem and 
24 h or 72 h after death.  The results of all Kruskal-Wallis tests were confirmed by the 
Mann-Whitney U-test.  However, no statistically significant differences were found when 
the ratios of MDMA to creatinine concentration were considered.  The Spearman 
correlation coefficient (rs) for the MDMA concentration in the vitreous humour and the eye 
globe walls of the second eye was 0.64 (p = 0.05).    
In Figure 4.4, the mean MDMA (see Figure 4.4 (a)) and MDA (see Figure 4.4 (b)) 
concentrations in blood and various tissues of groups 1, 2 and 3 are presented.  No 
statistically significant differences between the ligated and non-ligated rabbits were found, 
either for the MDMA or for the MDA concentrations.  The Kruskal-Wallis test, used to 
compare the values as a function of post-mortem interval, was only significant for the 
MDMA concentrations in the liver (p = 0.015). The Mann-Whitney U-test confirmed a 
significant rise in MDMA levels 24 h and 72 h after death.  The rs for the MDMA level in 
post-mortem blood related to cardiac muscle, lungs or liver was 0.64, 0.63 and 0.59, 
respectively.  These correlations were significant at the 0.05 level.   
The MDMA concentration in urine, available in 12 rabbits, varied between 500 and 
8100 ng/ml.  In all rabbits, MDA concentrations in blood and plasma sampled 2 hours after 
infusion, as well as in the vitreous humour and eye globe walls of the first and second 
sampled eye, were very low (< 15 ng/g) or  below LOQ. MDA could not be quantified in 
cardiac or iliopsoas muscle, or in adipose tissue.  In the brain, MDA was mainly below 
LOQ, except for one rabbit (13 ng/g).   However, relatively high MDA levels were found in 










































Figure 4.3    (a)  Individual MDMA concentrations in blood, vitreous humour and eye globe 
walls after iv injection of 1 mg/kg in rabbits (R) of groups 1, 2 and 3. 
(b) Individual creatinine concentrations (mg/dl) and individual ratios of MDMA 
to creatinine concentrations in vitreous humour in rabbits (R) of groups 1, 2 
and 3. The first (ο) and second (•) point represent the ante- or peri-mortem 

















































Figure 4.4 (a)  Mean post-mortem MDMA concentrations in rabbit tissues after iv injection 













































Figure 4.4 (b)  Mean post-mortem MDA concentrations in rabbit tissues after iv injection 





In the control group (group 1, sampling immediately post mortem), MDMA 
concentrations were obviously higher in the brain and both lungs than in blood, thus 
indicating accumulation of the substance in these tissues.  The MDMA levels in cardiac and 
iliopsoas muscle were relatively similar but also higher than in blood, thus indicating 
potential binding of MDMA to these tissues.  The importance of cardiac muscle levels in 
post-mortem toxicology has previously been investigated extensively, for example for 
digoxin (28).  Liver MDMA concentrations were relatively low and MDA levels relatively 
high when compared with the corresponding blood levels.   These findings point to hepatic 
biotransformation and excretion via the bile.  To our knowledge, the metabolism of MDMA 
in rabbits has not yet been elucidated but, in humans, pathways including demethylation to 
MDA and glucuronide and sulphate conjugation have recently been described (29,30).  
Furthermore, biliary excretion of amphetamine and methamphetamine in the rat was 
established many years ago (31). The MDMA concentrations in the kidney are the highest of 
all, but as the kidney tissue itself is extensively permeated by urine, these levels can be 
interpreted as due to “inherent contamination”.  The MDMA levels in adipose tissue were 
very low and often near or just below the quantification limit.  We cannot exclude the 
possibility that sampling 2 h after iv infusion provides insufficient time for MDMA to gain 
access into this tissue.  As the ratio of the tissue MDMA levels to blood concentrations in 
our rabbits is higher than 1 for most organs, accumulation of this substance in these above-
mentioned tissues is established.  When we compare our data with the tissue distribution of 
amphetamine in the rat (21), we notice that the ratios of tissue to blood concentrations of 
MDMA in the rabbit are higher than the corresponding ratios for amphetamine in the rat, 
thus indicating that the binding of MDMA is more pronounced than that of amphetamine. In 
rats, tissue concentrations 2 hours after iv administration of (+)-methamphetamine were 
highest in the kidney, followed by brain, liver and cardiac muscle (32).  Methamphetamine 
concentrations in rabbit liver after iv infusion were also relatively low and even lower than 
in skeletal muscle (33).   
As the pKa of MDMA is 10.38 (34), MDMA will be found totally in ionised form at 
physiological pH, and therefore MDMA would not be able to diffuse fluently to the brain.  
However, referring to the clinical effects, MDMA can easily pass through the blood-brain 
barrier, a fact which suggests that active transport might take place.  A study in mice 
suggested that P-glycoprotein plays a facilitating role in the entry of MDMA via the blood-
brain barrier (35).  In addition, data from rats indicate that metabolites of MDMA (such as 
glutathione conjugates) enter the brain via a transporter and are subsequently metabolised to 
thioether conjugates which contribute to the serotonergic neurotoxicity (36,37).  The rapid 
partitioning of (+)-methamphetamine in the rat brain was also partially explained by other 
physicochemical properties (such as small molecular weight) of that substance (32). 
Our results confirm the findings of our first study: post-mortem vitreous humour 
MDMA concentrations are more stable than cardiac blood levels (23).  Referring to the 
positive correlation between the MDMA levels in post-mortem blood and cardiac muscle, 
lungs and liver, we can assume a post-mortem diffusion between these organs and cardiac 




homogenates of the eye globe walls sampled in relation to the post-mortem interval. The 
reliability of creatinine concentrations in post-mortem vitreous humour was substantiated 
many years ago (25).  The rise in creatinine concentration in vitreous humour at increasing 
post-mortem interval due to dehydration has been confirmed.  As the ratios of MDMA to 
creatinine concentration still show an increasing (though not statistically significant) 
tendency at longer post-mortem intervals, the (relatively minor) increases in MDMA 
vitreous humour levels cannot be due exclusively to dehydration.  Indeed, bearing in mind 
the very high MDMA levels in the globe wall of the second sampled eye and the significant 
correlation between the vitreous humour and globe wall concentration of that particular eye, 
it can be assumed that diffusion out of these “reservoirs” into the vitreous humour can occur, 
and that it will occur mainly at longer post-mortem intervals.    
 Our data are unable to support the findings of Moriya et al (20), who 
demonstrated redistribution of methamphetamine into cardiac blood via pulmonary blood 
vessels in the early post-mortem period.  Indeed, no statistically significant differences 
between rabbits with (group 3) or without (group 2) ligation of the large vessels around the 
heart could be substantiated.  However, we cannot exclude the possibility that the lack of 
significant differences between group 2 and group 3 is influenced by the small number of 
animals.    
The bile MDMA levels tended to decrease at longer post-mortem intervals (see 
Figure 4.4 (a)), although these changes were not statistically significant.  We believe that the 
significant increases in post-mortem MDMA liver concentrations can partially be explained 
as a result of diffusion from the bile.    On the other hand, MDMA concentrations in cardiac 
and iliopsoas muscle are fairly stable post mortem and can be of interest when the usual 
toxicological samples (blood, urine or vitreous humour) are lacking or when advanced 
putrefaction occurred.  This has previously been suggested for methamphetamine and 
amphetamine (38). 
The MDA levels were relatively low in all organs, being below 100 ng/ml. The 
highest levels were found in the lungs, liver and bile.  The high MDA levels in the lungs 
indicate either non-specific binding of MDA (in addition to accumulation of MDMA) or 
local metabolism of MDMA to MDA as the lungs contain enzymes such as cytochromes 
P450. As MDA could be quantified in the eye globe walls of the second sampled eye in 
groups 2 and 3 and not in the eyes immediately taken after killing (data not shown), this 
could indicate that MDA can also be formed post mortem.  
 
VI Conclusion  
In these experiments in rabbits, a state of complete absorption of MDMA was 
simulated by iv administration.  The organ distribution of MDMA and its metabolite MDA 
was presented and the redistribution up to 72 h post mortem was investigated.   
The enhancement of MDMA concentrations in cardiac blood can be due to post-
mortem redistribution from the lungs, in the first place, and – to an obviously lesser extent – 
from the cardiac muscle and liver.  As significant differences between rabbits with and 
without ligation of the large vessels around the heart could not be proven, we believe that 




cellular levels (from higher to lower concentrations) could be predominant.  However, these 
findings cannot be totally extrapolated to humans due to the different topographic anatomy 
of the rabbit, where the organs are inherently closer to one another.   
This animal study confirms the findings in a recent fatality (10) that drug 
concentrations in samples taken for toxicological assay can be influenced by post-mortem 
redistribution, mainly when sampling takes place centrally in the body, and therefore this 
phenomenon should be taken into account when drawing medico-legal conclusions, such as 
whether the MDMA blood concentrations are toxic or potentially lethal.  In addition, when 
an appropriate blood sample is lacking, quantification in the iliopsoas muscle can be helpful 
to solve the question whether the individual died due to a MDMA overdose. 
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Chapter 5   Post-mortem redistribution of 3,4-methylenedioxymeth-
amphetamine (MDMA, “ecstasy”) in the rabbit   
Part two: post-mortem infusion in trachea or stomach. 
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 Drug concentrations in autopsy samples can also be influenced by post-mortem 
gastric diffusion when the stomach contains a substantial amount of the drug or by 
diffusion from the trachea when agonal aspiration or post-mortem regurgitation of vomit 
occurs.  This was studied in a rabbit animal model in which MDMA solutions were infused 
post mortem either in the trachea or in the stomach.  At 24, 48 or 72 hours post mortem, 
samples including cardiac blood, vitreous humour, urine, bile, gastric content and several 
tissues were taken for toxicologic analysis.   
After post-mortem tracheal infusion, MDMA can easily diffuse not only into the 
lungs but also in great quantities into the cardiac blood and – to a lesser extent – into the 
cardiac muscle. MDMA was also found in the closely adjacent diaphragm and in the upper 
abdominal organs, including the liver and the stomach.   
Following post-mortem infusion into the stomach, considerable MDMA levels were 
found in cardiac blood and muscle, both lungs, diaphragm and liver tissue when the 
solution was concentrated nearby the lower oesophageal sphincter.   However, when the 
MDMA solution was present deeper in the stomach, MDMA levels were high in the spleen 
and the liver and relatively low in cardiac blood and muscle.   
In both experiments, MDA levels were in most tissues low or below the limit of 
quantitation, but were substantial in cardiac blood and muscle, lung and diaphragm, 
indicating that MDMA can be metabolised to MDA after death. 
These results in the rabbit model indicate that the diffusion of MDMA out of the 
stomach content, or due to aspirated vomit and gastro-oesophageal reflux can lead to 
considerable post-mortem redistribution and thus should be taken into account in current 
forensic practice in order to draw the right conclusions when a peripheral blood sample is 
not available.   
 
Key words: 3,4-Methylenedioxymethamphetamine (MDMA) - 3,4-Methylenedioxy-
amphetamine (MDA) - Post-mortem tracheal and gastric infusion - Post-mortem 
redistribution - Experiment on rabbits 
 
II Introduction 
Post-mortem drug levels can be difficult to interpret due to interfering thanato-
chemical processes such as drug instability and post-mortem redistribution (1).  These 
processes can result from diffusion of the substance out of adjacent organs.  They can also 
be due to diffusion from high concentrations present in the gastric content and/or from 
vomit aspiration in the airways or even from post-mortem regurgitation (2,3).     
Post-mortem absorption of ethanol, paracetamol and propoxyphene from simulated 
vomit aspiration was found to result in an increase in post-mortem cardiac blood 
concentrations in five human bodies (4). 
Diffusion of ethanol from the stomach cavity after death has been investigated 
extensively for more than 50 years (5).  As this post-mortem diffusion results in an 
elevation of the blood alcohol level in cardiac blood (6) and even in aortic blood (7), 




because it is obviously less liable to post-mortem changes.  Post-mortem diffusion from 
gastric residue into blood and surrounding tissues has also been studied for a few other 
drugs including zopiclone (8), benzodiazepines (9), paracetamol (9) and amitriptyline 
(10,11). 
The amphetamine derivative, 3,4-methylenedioxymethamphetamine (MDMA, 
“ecstasy”) is stable in blood and plasma in vitro (12).  In part one, post-mortem 
redistribution due to diffusion of MDMA out of several organ tissues was evaluated after 
simulation of a complete distribution of the substance prior to death (13).  In this study, 
post-mortem diffusion of MDMA from a “reservoir” in the stomach or from agonal vomit 
aspiration was explored using a rabbit animal model.  This can be compared with the 
condition when somebody dies shortly after MDMA ingestion (e.g. due to cardiac 
arrhythmia) and therefore an incomplete absorption occurred, or when substantial 
regurgitation or vomit aspiration takes place in the peri-mortem period.  When blood and 
tissue concentrations (studied up to 72 hours after death) in both experimental settings 
change substantially, this should be taken into account in the interpretation of the 
toxicologic results in humans.  
 
III Materials and methods  
Provision of MDMA and rabbits as well as handling of the animals prior to the 
onset of the  experiments and preservation of the samples took place as previously 
described (13). 
 
III.1   Animals and procedures 
The rabbits (weight 1900 – 2420 g) were killed using a CO2-O2 gas chamber (70/30 
%).  Thereafter, two groups of rabbits were created: group 1 (n = 6) was used for post-
mortem infusion into the trachea (PIT) and group 2 (n = 6) for post-mortem infusion into 
the stomach (PIS).  Randomisation of the animals occurred and infusion of the MDMA 
solution (diluted in saline; 1 mg/kg) took place within the first hour post mortem.  
The study design is presented in Figure 5.1. After preparation of either the trachea 
or the oesophagus, ligation towards the laryngeal/pharyngeal region took place.  For group 
1 (PIT), a highly concentrated MDMA solution was used in order to reduce the volume of 
fluid to be infused (< 0.5 ml).  The solution was injected into the trachea using a 1-ml 
syringe and 26 G needle.   In group 2 (PIS), a polyethylene catheter (inner diameter of 2.5 
mm) was inserted into the oesophagus up to the lower oesophageal sphincter.  After 
infusion of MDMA, flushing of the catheter with saline took place. All rabbits were left in 
a supine position at ambient temperature (15 °C).   Dissection was carried out in a strict 
manner so as to avoid contamination of the samples and sampling took place in the same 
sequence for all rabbits.  The samples taken in group 1 (PIT) were: cardiac blood and 
muscle, left and right lungs, left and right diaphragm, liver, stomach wall and stomach 
content, spleen, left and right iliopsoas muscle, abdominal adipose tissue, left and right 
kidneys, urine, cerebrum, cerebellum, brainstem, and both eyes.  In the second group (PIS), 
furthermore, lower vena cava blood, duodenal wall and content, distal small bowel and 




were fasted overnight, the stomach was not empty due to coprophagia.  All organs were 
taken in toto for toxicological analysis.  The eyes were handled as previously described 
(14). 
   
       Group 1 (PIT)          Group 2 (PIS) 
 (tracheal infusion, 1 mg/kg MDMA)  (stomach infusion, 1 mg/kg MDMA) 
   n = 6      n = 6 
 
n = 2  n = 2  n = 2  n = 2  n = 2  n = 2 
  PMI 24 h  48 h  72 h  24 h  48 h  72 h 
 
 
    Tissue sampling       Tissue sampling  
 
Figure  5.1 Scheme of the study design of post-mortem infusion in rabbits receiving 1 mg/kg in 
the trachea (Group 1; PIT; left panel) or in the stomach (Group 2; PIS; right panel). 
  (PMI: post-mortem interval expressed in hours) 
 
 
III.2   Analytical methods 
MDMA and MDA concentrations in the tissues were assayed by HPLC with 
fluorescence detection as described earlier (13). 
 
IV Results 
Figure 5.2 shows the individual concentrations of MDMA and MDA in group 1 
(PIT).  The data indicate that the extent of post-mortem diffusion depends mainly on 
whether the MDMA solution flowed into the left (R-PIT-3,-4,-5,-6) or into the right (R-
PIT-1,-2) bronchus. MDMA concentrations were substantial in the organs most directly 
adjacent to the lung containing the highest MDMA levels, such as the corresponding hemi-
diaphragm.  In most rabbits, very high MDMA levels were found in the cardiac blood.  
When the MDMA solution was concentrated in the left lung, MDMA was quantifiable in 
the stomach wall beginning 24 h after administration, and even in the stomach content and 
kidneys after 48 and 72 h.  This is visually represented in Figure 5.3, where the post-
mortem redistribution is shown in 2 rabbits in which the highest MDMA amounts were 
found in the left principal bronchus at 24 and 48 h post mortem. In most tissues, the MDA 
levels were below the limit of quantitation (LOQ; < 10 ng/g), except in those having very 
high MDMA concentrations: cardiac blood and muscle, both lungs and diaphragm.  












































Figure 5.2 Individual MDMA and MDA concentrations in rabbits (n = 6) after post-mortem 







































Figure 5.3  Thoracic and abdominal post-mortem diffusion after tracheal instillation of 1 mg/kg  
MDMA in rabbits (n = 2), in which spreading of the solution occurred 
predominantly in the left bronchus,  24 and 48 h after administration. 
      Labels: RA: right atrium   AO: aorta 
RV: right ventricle VI: inferior vena cava 
LA: left atrium   VS: superior vena cava 
LV: left ventricle   AR: arteria renalis  
TP: truncus pulmonalis  VR: vena renalis  
VP: venae pulmonales D: diaphragm 
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Figure 5.4 presents the individual MDMA and MDA levels in the rabbits of group 2 
(PIS). Two patterns of post-mortem redistribution can be distinguished: an “intra-gastric” 
and a “supra-diaphragmatic” pattern. In the intra-gastric pattern (n = 3; R-PIS-2,-3,-4), high 
MDMA levels were found in the left diaphragm and lung, as well as in the spleen.  In 
addition, substantial MDMA concentrations were present in the liver.  When the MDMA 
solution was concentrated just above the lower oesophageal sphincter (supra-diaphragmatic 
pattern; n = 3; R-PIS-1,-5,-6), high MDMA levels were found in both hemi-diaphragms, 
the liver, the cardiac blood and muscle, and both lungs. These findings are visually 
documented in Figure 5.5:  the two different patterns, viz. intra-gastric (Figure 5.5 (a)) and 
supra-diaphragmatic (Figure 5.5(b)), are presented 72 h after infusion. 
For all rabbits, an inter-individual variation was observed.  As a result, no clear 
relationship between the concentrations and the post-mortem interval can be postulated.   
In all rabbits, the MDMA levels were either very low or below LOQ (< 10 ng/g) in 
the  brain, eye globe walls and vitreous humour, small bowel wall and content, kidneys, 
iliopsoas muscle, abdominal adipose tissue, muscle of the abdominal wall, and urine (max 
500 ng/g).   However, in two rabbits of each group (R-PIT-3 and R-PIT-5, 24 h and 72 h 
after infusion and R-PIS-4 and R-PIS-5, both rabbits 72 h after infusion), MDMA 
concentrations were non-negligible in the eye globe walls and vitreous humour.  In 
addition, the levels in the eye globe walls were obviously higher than in the vitreous 
humour (max 2000 and 360 ng/g, respectively). 
In the rabbits of the intra-gastric pattern, MDA was barely quantifiable and was in 













































Figure  5.4 Individual MDMA and MDA concentrations in rabbits (n = 6) after post-mortem 





































Figure 5.5 Thoracic and abdominal post-mortem diffusion after gastric instillation of 1 mg/kg  
MDMA in rabbits (n = 2), showing the difference between the intra-gastric (a),  
  and supra-diaphragmatic pattern (b) 72 h after instillation. 
      Labels: RA: right atrium   AO: aorta 
RV: right ventricle VI: inferior vena cava 
LA: left atrium   VS: superior vena cava 
LV: left ventricle   AR: arteria renalis  
TP: truncus pulmonalis  VR: vena renalis  
VP: venae pulmonales D: diaphragm 
MDMA levels (ng/ml or ng/g): 
 > 10,000 
 5,000 – 10,000 
 1,000 – 5,000 
 500 – 1,000 
 100 - 500 
 10 - 100 





MDMA tissue levels after post-mortem tracheal instillation depend on the 
dispersion of the solution into either the left or the right bronchus.  In both cases, however, 
the MDMA concentrations were high in the cardiac blood and – to a lesser extent – also in 
the cardiac muscle.  In addition, our data show that MDMA can easily diffuse out of the 
trachea into the thoracic and upper abdominal organs, and the amounts diffused slightly 
increase with the post-mortem interval.  In the lower abdominal tissues, such as the 
kidneys, the iliopsoas muscle and adipose tissue, the MDMA levels were either very low or 
below the quantitation limit.   
After post-mortem instillation in the stomach, two different diffusion patterns were 
observed depending on whether the MDMA solution was concentrated intra-gastrically or 
supra-diaphragmatically.  The supra-diaphragmatic situation is comparable to gastro-
oesophageal reflux, which involves substantial diffusion into cardiac blood and muscle, 
both lungs and liver.  When the MDMA solution was concentrated more deeply in the 
stomach, post-mortem redistribution did affect the thoracic organs to a minor extent, and 
the intra-gastric solution diffused mainly into the closely adjacent spleen.  Our results 
indicate that peri- or post-mortem gastro-oesophageal reflux is obviously more responsible 
for the redistribution of MDMA than a high MDMA concentration in the stomach itself. 
In four rabbits, non-negligible MDMA levels were found in vitreous humour and 
eye globe walls.  These levels were clearly higher than in the corresponding brain, which 
indicates that another mechanism than pure diffusion from the brain should be assumed.  
One possible explanation is that there was direct or indirect reflux into the naso-pharynx 
with diffusion of MDMA into the sinuses, the skull base and the orbitae.  Such diffusion 
has formerly been established for ethanol: in a human model, diffusion from an ethanol 
solution in the mouth and pharynx into the skull and also into the vitreous humour was 
observed, although at relatively longer post-mortem intervals (more than 60 or 72 h) (15). 
In all the experiments in rabbits we performed at present, we observe that the 
MDMA concentrations in the iliopsoas muscle are not subject to post-mortem diffusion, 
and thus remain stable after death.  Therefore, iliopsoas muscle can be an interesting 
specimen when the usual samples for drug assay are lacking.  However, muscle sampling is 
not recommended for some other substances (such as temazepam, prothiaden, paracetamol 
and amitriptyline) (16,17).  These studies did not include concentrations in iliopsoas 
muscle, however.   
In both post-mortem instillation experiments, the MDA levels were only 
quantifiable when very high local MDMA concentrations were found, which proves that 
MDMA can be metabolised post mortem into MDA.  The MDA concentrations were lower 
when the MDMA solution was concentrated intra-gastrically instead of supra-
diaphragmatically.  This is in accordance with a previous study in which we hypothesized 





VI Conclusion  
 In this experiment, we used tracheal instillation of MDMA to demonstrate that 
agonal vomit aspiration can lead to substantial post-mortem redistribution, mainly into 
cardiac blood and muscle, and into both lungs.  To a less pronounced extent, MDMA also 
diffused to the liver tissue and the lower abdominal organs. Using infusion into the 
stomach, we proved that peri- or post-mortem gastro-oesophageal reflux gives rise to 
significant post-mortem diffusion of MDMA.  When the MDMA reservoir is concentrated 
in the stomach itself, the thoracic organs are not substantially affected by redistribution up 
to 72 h post mortem.  These rabbit experimental results could be extrapolated to humans as 
agonal aspiration in the lungs or post-mortem regurgitation frequently occurs in medico-
legal practice. Our results demonstrate once more that peripheral sampling should be 
recommended in current practice.  However, when this is not possible, the MDMA and 
MDA levels should be interpreted with great caution, especially regarding toxic or lethal 
levels.  Finally, as in all experiments performed at present, the iliopsoas muscle 
concentrations remain stable post mortem, this specimen can be useful in current forensic 
practice when an appropriate blood sample is lacking. 
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In this study, regional tissue distributions of the amphetamine analogue,  3,4-
methylenedioxymethamphetamine (MDMA, “ecstasy”) and its metabolite 3,4-
methylenedioxyamphetamine (MDA) in a fatal overdose are presented.  Quantitation of 
MDMA and MDA levels occurred in blood samples taken centrally (right and left heart and 
main adjacent great vessels) and peripherally (subclavian and femoral blood).  In addition, 
MDMA and MDA concentrations were determined in cardiac and iliopsoas muscle, both 
lungs, liver, both kidneys, spleen, the four brain lobes, cerebellum and brainstem, and 
adipose tissue.  Finally, MDMA and MDA levels were determined in serum, vitreous 
humour, urine and bile.  For all samples, a fully validated high-pressure liquid 
chromatography procedure with fluorescence detection was used.  The found substances 
were also identified with liquid chromatography-tandem mass spectrometry.  
Our data confirm that blood sampling from an isolated peripheral vein is 
recommended for MDMA and MDA.  In addition, the vitreous humour MDMA level 
indicates that this fluid can be an interesting alternative when a suitable blood sample is 
missing.  Considering the substantial differences in concentrations in blood samples taken 
from various sites in the body and the high levels in some tissues (e.g. in liver), we 
concluded that the influence of post-mortem redistribution should be taken into account in 
the interpretation of toxicological data when an appropriate peripheral sample cannot be 
obtained or when blood samples are not available because of  putrefaction.   
 
II Introduction 
Post-mortem instability and redistribution are known interfering processes in 
thanato-toxicological investigations (1).   However, amphetamine and its derivative 3,4-
methylenedioxymethamphetamine (MDMA, “ecstasy”) in particular are stable in blood and 
plasma in vitro (2).  The stability of methamphetamine and amphetamine in post-mortem 
rabbit tissues – stored in test tubes under four  different conditions - was studied over a 
two-year period,  and the authors concluded that skeletal muscle and bone marrow proved 
to be the most appropriate samples for accessing toxicity (3). To our knowledge, post-
mortem drug distribution and redistribution of MDMA and 3,4-methylenedioxy-
amphetamine (MDA) have barely been explored in humans, except for a few case reports 
(4-6).  More literature data are available for amphetamine and methamphetamine (7-16). 
We report an extended regional tissue distribution study in a fatal overdose case. 
 
III Case history 
One morning, a 23-year-old man was found unconscious in a bar.  He was sitting on 
a chair, resting with his head upon his forearms on the table in front of him.  The 
emergency team attempted intensive reanimation, which failed. Upon examination 28 h 
post mortem, the body weighed approximately 100 kg and was 186 cm tall.  In the pocket 
of the decedent, a small amount of white powder was found.  Some vomit was noticed on 
his T-shirt and his boxer shorts were soiled with urine.  During further external 
examination, many vibices were observed in the post-mortem lividity located on the upper 




conjunctivae and intermediary pupils was present.  A fresh puncture wound was seen on the 
right arm but inquiry revealed that it occurred during the reanimation attempt.  During 
internal inspection, signs of intensive reanimation, including a sternal fracture, were found.  
Numerous Tardieu spots were observed on the pericardium and both pleurae.  Both lungs 
weighed 1620 g, and, upon sectioning, some emphysema, severe congestion and moderate 
oedema were found.  The heart weighed 405 g and an aberrant course of the superior vena 
cava, a persistence of the left superior caval vein, was noticed.   The stomach contained a 
brownish liquid without food fragments, and the mucosa showed a few pin-point 
ulcerations.  The brain weighed 1545 g, and, apart from slight oedema and congestion of 
the white matter, nothing unusual was observed.  The remaining organs showed no obvious 
anomalies macroscopically, except for congestion. 
On histological examination, pronounced pulmonary congestion, haemorrhagic 
oedema, a slight intra-alveolar infiltration with a few polymorphonuclear cells and some 
leucocyte sludging in the pulmonary veins were found.  Groups of alveolar macrophages 
were seen, although staining with Prussian blue was negative and there were no signs of 
pulmonary hypertension.  The liver showed slight fatty infiltration, and a few 
peripancreatic lymphocyte infiltrates were found.  In the caudate nucleus and the nucleus 
lentiformis, a few venulae were surrounded by a lymphocyte infiltration.  The hippocampus 
showed no marked hypoxemic lesions.  No obvious pre-existing disease was identified 
histologically. 
Because drug abuse was suspected and amphetamines could be involved, 
appropriate samples for a distribution study were taken.  Sampling included all possible 
central and peripheral blood samples, stomach content, urine, bile and vitreous humour.  
Several small tissue fragments were taken at random throughout the organs.  The samples 
of cardiac and iliopsoas muscle, both lungs, both kidneys, liver, spleen, abdominal adipose 
tissue, all four lobes of the cerebrum, cerebellum and brainstem were preserved at – 30°C 
until analysis. 
 
IV Materials and methods  
IV.1  Reagents and materials 
All reagents and chemicals were of analytical grade and were obtained from Aldrich 
(Gillingham, U.K.) unless stated otherwise. Solvents were of HPLC grade from  Merck 
(Darmstadt, Germany). Pure MDA, MDMA and 3,4-methylenedioxyethylamphetamine 
(MDEA) standards were obtained from Sigma (St. Louis, MO). 3,4-Methylenedioxy-
methylpropylamphetamine (MDMPA) was synthesized by in-house following a procedure 
described earlier (17). Stock solutions of these active substances were prepared by 
dissolving 10 mg of the pure compound in 10 ml of methanol. Appropriate dilution with 
methanol yielded the working solutions containing all three compounds. All concentrations 
of the standards are expressed as the free base. The stock solutions were stored in the dark 
at - 20 °C and were stable for at least 1 year. Working solutions were stored under the same 





IV.2  Drug screening 
A comprehensive screening was performed on blood, urine and stomach content. 
Screening methods used were the enzyme-multiplied immunoassay technique (EMIT®), 
radioimmunoassay (RIA), and various chromatographic techniques, including high-
performance liquid chromatography-diode array detection  (HPLC-DAD) (following 
extraction under alkaline conditions), thin-layer chromatography (TLC) on Sunshine 
extracts, and gas chromatography-mass spectrometry (GC-MS), as described previously 
(18).  
 
IV.3  Apparatus 
The HPLC unit was composed of a ternary low pressure gradient pump, and an 
autosampler with a 25-µl loop (Kontron Instruments, Milano, Italy) equipped with a solvent 
degassing module (Shodex, Tokyo, Japan). A spectrofluorometric detector (RF-10Axl,  
Shimadzu, Kyoto, Japan) linked to a Kromasystem 2000 data system (Kontron Instruments) 
was used for data acquisition and storage.  
The MS analyses were carried out on a Micromass Q-TOF hybrid MS (Micromass, 
Wythenshawe, U.K.) equipped with an orthogonal electrospray source (Z-spray) and a 
Waters Alliance 2790 separation module (Waters, Milford, MA) integrated with the Q-TOF 
instrument.  
 
IV.4  Isolation of the compounds 
Serum, whole blood, vitreous humour, and urine samples (250 µl) were extracted 
with 8 ml of hexane/ethylacetate (7:3, v/v), after the addition of 50 µl of the internal 
standard solution (containing 400 ng/ml MDMPA for water, serum, whole blood and 
vitreous humour and 5 µg/ml MDMPA for urine), dilution with 1 ml of H2O and 
adjustment of the pH with 0.5 ml of 1M aqueous K2CO3  (brought to pH 9.5 with 37% 
HCl). Samples were mixed on a rotary mixing device (10 min) and centrifuged for 15 min 
(1200 x g). The organic layer was transferred to a test tube containing 50 µl methanolic 
HCl (5M acetylchloride in methanol) and evaporated using a Turbovap® evaporator 
(Zymark, Hopkinton, MA) at 35°C under nitrogen.  
Tissue samples were homogenized after a 1:4 dilution in water (1 ml of the 
homogenate corresponds to 250 mg tissue) using an Ultra-Turrax homogenizer from IKA 
(Staufen, Germany). The resulting homogenate of the tissue samples as well as bile and 
stomach content were extracted using a liquid-liquid extraction with back extraction that 
was  especially developed for the analysis of amphetamines from degraded post-mortem 
samples. After addition of the internal standard (containing 400 ng/ml MDMPA) to 1 ml 
tissue homogenate or 250 µl bile or stomach contents, 1 ml of water was added, and the pH 
was adjusted with 0.5 ml of the 1M aqueous K2CO3  solution. Subsequently, the samples 
were extracted with 8 ml of hexane/ethylacetate (7:3, v/v). To that end, samples were 
mixed on a rotary mixing device (10 min) and centrifuged for 15 min (1200 x g). The 
organic layer was transferred to a test tube containing 1 ml of 1M hydrochloric acid. After 
mixing on a rotary mixing device (10 min) and centrifuging for 15 min (1200 x g), the 




aqueous K2CO3  (also brought to pH 9.5 with 37% HCl) and again extracted with 8 ml of 
hexane/ethylacetate (7:3, v/v).  After mixing on a rotary mixing device (10 min) and 
centrifuging for 15 min (1200 x g), the organic layer was transferred to a test tube 
containing 50 µl methanolic HCl (5M acetylchloride in methanol) and evaporated at 35°C 
under nitrogen. 
The dry residues from both extraction procedures were redissolved in 125 µl of 
HPLC eluent A (for all matrices except for urine where the residue was redissolved in 250 
µl of HPLC eluent A) (see Chromatography section), and a 25-µl aliquot was injected for 
liquid chromatography coupled to fluorescence detection (LC-Fl) or LC-MS-MS. 
 
IV.5  Chromatography    
Chromatographic separation was achieved on a Hypersil BDS C18 column (100 x 
2.1 mm, 3 µm, Alltech Associates, Deerfield, IL). The mobile phase was a 0.1 M solution 
of ammonium acetate in HPLC-grade water (90%), methanol (5%) and acetonitrile (5%) 
(Eluent A) or in methanol (45%), acetonitrile (45%), and HPLC-grade water (10%). After 
an isocratic part (100 % A) of 6 min, a linear gradient from 0 to 70 % B within 14 min was 
used. After completion of the chromatographic run, the pump was programmed to regain its 
initial conditions within 0.5 min, and 8 min was allowed for reconditioning. 
 
IV.6  Fluorescence Detection 
The excitation and emission wavelengths of the fluorescence detector were 288 and 
324 nm, respectively (bandwidth was 15 nm for both slits). The results obtained with 
fluorescence detection were used for quantification.    
 
IV.7  Mass Spectrometry 
 ESI positive mass spectra (single MS and product ion scans) were acquired on a 
Q-TOF MS. The conditions, which were optimized using flow injection of standard 
solutions, were as follows: ESI capillary voltage 3100 V, cone voltage 14 V, and source 
temperature 120 °C. The ESI gas was nitrogen. For LC-MS-MS product ion analysis, the 
quadrupole was set to pass precursor ions of the selected mass (180.1 for MDA, 194.1 for 
MDMA, 208.1 for MDEA and 236.1 for MDMPA) to the hexapole collision cell (using 
argon as the collision gas for collision-induced dissociation (CID)) and product ion spectra 
were acquired with the TOF analyser. The collision energy was optimized for each 
compound (14 eV for MDA and 16 eV for MDMA, MDEA and MDMPA). All TOF 
measurements were performed at high resolution settings (5000 fwhm at mass 1500), and 
the TOF analyser was “scanned” over m/z 100 to 250 with a 3-s integration time.      
 
IV.8  Specimens 
Toxicological analyses were performed on blood collected from the subclavian 
vein, femoral vein, vena iliaca, inferior vena cava, right and left atrium, left ventricle and 
aorta ascendens. Left ventricular blood was not available.  Other specimens that have been 
analyzed include urine, vitreous humour, serum (obtained from the subclavian vein and 




right kidney, spleen, iliopsoas muscle, abdominal adipose tissue, and different parts of the 
brain, such as the temporal lobe, the parietal lobe, the frontal lobe, the occipital lobe, the 
cerebellum and the brainstem. 
 
IV.9  Calibration samples 
 Calibration curves were prepared in the corresponding blank matrix except for 
vitreous humour, which was substituted by water because of its practical unavailability and 
its high water content (± 98 %). The calibrators were prepared in serum, whole blood, 
tissue samples (for each tissue sample, kidney, liver, etc. a calibration curve in the 
corresponding blank matrix was used), bile, stomach contents and water by spiking 50 µl of 
the appropriate working solution, containing MDA, MDMA, and MDEA, in a 250-µl 
aliquot of the sample (for tissue samples, 1 ml of the homogenate was used, which 
corresponds to 250 mg tissue), resulting in 2, 10, 20, 40, 100, 400 and 1000 ng/ml 
concentrations (ng/g for tissue samples). They were all extracted according to the general 
isolation procedure. For urine the calibration samples contained MDA, MDMA, and 
MDEA  at levels of 0.1, 0.2, 0.5, 1, 2, and 5 µg/ml.  Samples exceeding the calibration 
range were appropriately diluted and reanalyzed. 
 
V Results  
V.1  Drug screening 
The routine screening of blood and urine by immunoassay techniques disclosed the 
presence of a high level of amphetamines in urine only (68.4 µg/ml), toxicologically 
irrelevant levels of cotinine (6.9 and 1.0 µg/ml urine and blood, respectively), caffeine 
(22.9 and 3.9 µg/ml urine and blood, respectively) and trace amounts of benzoylecgonine 
(only present in urine, 0.7 µg/ml). Head-space GC analysis demonstrated the absence of 
ethanol in blood and urine.  The analysis of blood, urine, and stomach contents using 
general purpose HPLC-DAD, GC-MS, and TLC methods as well as a method developed 
for the determination of cocaine and metabolites (19,20) in urine and blood, confirmed the 
results found by the preliminary screening. Simultaneously, it revealed the presence of 
MDMA in blood, urine and stomach contents. For additional confirmation, we developed a 
fully quantitative LC assay for the determination of the methylenedioxyamphetamines in all 
specimens available. 
 
V.2  Analytical performance 
Calibration curves were constructed for MDA (metabolite of MDMA, present in the 
majority of the matrices) and MDMA. The linearity ranged from 10 to 1000 ng/g for 
tissues;  from 2 to 1000 ng/ml for blood, serum, and vitreous humour; and from 0.1 to 5 
µg/ml for urine. The correlation coefficients in the different matrices ranged from 98.2 
(kidney homogenate) to 99.8 % (spleen homogenate) for MDA and from 97.6 (liver 
homogenate) to 99.9 % (serum) for MDMA. The limits of detection (LOD), which were 
determined by analyzing decreasing concentrations of the compounds added to blank 
matrices, were 0.8 ng/ml for MDA and MDMA in whole blood, serum and vitreous 




MDMA in urine. The limit of quantitation (LOQ), which  was defined as the lowest 
concentration that could be quantitated with an imprecision of < 20 %, was 2 ng/ml for 
whole blood, serum and vitreous humour, 10 ng/g for tissue samples, and 0.1 µg/ml for 
urine. Reproducibility (within-day and between-day, n = 6) was tested at low, medium and 
high concentration levels in whole blood, serum, water (substitute for vitreous humour) and 
tissue (brain tissue) and was found to be < 20% in all cases.  All samples were assayed in 
parallel using LC-MS-MS and the obtained MS  data confirmed the proper identities of the 
target compounds. 
 
V.3  Toxicological findings 
The toxicological findings are summarized in Table 6.1.  The MDMA and MDA 
tissue-to-blood ratios were calculated using the femoral blood level as reference.   The ratio 
of blood to serum MDMA levels in the subclavian vein and in the aorta are 0.83 and 0.54, 





Table  6.1  Distribution of MDMA and MDA.. 
 
sample MDMA MDA ratio: fluid or tissue ratio: fluid or tissue 
 µg/ml * µg/ml * MDMA level to MDA level to 





subclavian blood 3.5 0.090 1.13 0.97 
femoral blood 3.1 0.093 1.00 1.00 
vena iliaca blood 3.5 0.191 1.13 2.05 
inferior vena cava blood 4.8 0.199 1.55 2.14 
right atrial blood 5.5 0.185 1.77 1.99 
right ventricular blood 5.7 0.296 1.84 3.18 
left atrial blood 7.6 0.274 2.45 2.95 
blood from the aorta 4.4 0.151 1.42 1.62 
serum (subclavian blood) 4.2 0.100 1.35 1.08 
serum (blood from aorta) 8.2 0.178 2.65 1.91 
vitreous humour 3.4 0.060 1.10 0.65 
urine 170.9 4.000 NR NR 
bile 14.2 0.320 NR NR 
cardiac muscle  14.0 0.346 4.52 3.72 
right lung  12.5 0.446 4.03 4.80 
left lung 18.9 0.609 6.10 6.55 
liver 26.2 1.203 8.45 12.94 
stomach content 118.1 0.448 NR NR 
left kidney 12.1 2.700 3.90 29.03 
right kidney  13.9 3.022 4.48 32.49 
spleen 10.0 0.264 3.22 2.84 
iliopsoas muscle  4.5 0.144 1.45 1.55 
adipose tissue 0.4 < LOQ 0.13 NR 
brain :   frontal lobe 17.4 0.296 5.61 3.18 
               temporal lobe 14.9 0.252 4.81 2.71 
               parietal lobe 17.1 0.362 5.52 3.89 
               occipital lobe 12.9 0.256 4.16 2.75 
brainstem 13.2 0.220 4.26 2.37 
cerebellum 11.7 0.225 3.77 2.42 
 
NR: not relevant 










































Figure 6.1 Possible mechanism of redistribution (indicated by direction of arrows). 
Labels: RA: right atrium   D: diaphragm 
 RV: right ventricle  AO: aorta 
 LA: left atrium   VI: inferior vena cava 
 LV: left ventricle   VS: superior vena cava 
 TP: truncus pulmonalis   AR: arteria renalis  




I Discussion  
 The autopsy findings, including macroscopical features (such as increased lung 
weight) and the microscopical examination (pronounced pulmonary congestion and 
oedema), are consistent with an acute to subacute cardiopulmonary failure.  From the 
purely physiological point of view, the aberrant course of the superior vena cava 
(persistence of the left superior caval vein) was not important, as the outlet of the vena cava 
superior was also present in the right atrial cavity.  Referring to the toxicological data, we 
can conclude that the cardio-respiratory insufficiency was caused by the sympaticomimetic 
mechanism of MDMA.  Indeed, electrical instability of the heart has been described in this 
anomaly (21). 
We present a detailed distribution of MDMA and MDA concentrations in this fatal 
overdose.   Possible mechanisms of redistribution are presented in Figure 6.1.   
Our data (Table 6.1) confirm that a peripheral blood sample is strongly 
recommended and femoral blood remains the most representative. When femoral blood is 
not available, blood from the vena subclavia or vena iliaca may be appropriate;  however, 
cardiac blood samples and left atrial blood in particular, should be avoided.   The site-
dependent differences in heart blood concentrations have previously been observed for 
methamphetamine (12).   In our case, the left atrial MDMA level was the highest of all and 
can probably – or at least partially – be explained by diffusion from both lungs via the 
venae pulmonales.  It is not excluded that the high MDMA level in cardiac muscle is also 
correlated with the high MDMA concentration in the adjacent lungs, but diffusion from the 
stomach content volume could also be speculated.   The obvious difference in MDMA and 
MDA levels between both lungs could be explained by post-mortem diffusion out of the 
high reservoir of  these substances present in the stomach content volume.  Indeed, the 
stomach is only separated from the left lung by the diaphragm.   As the gastric mucosa is 
easily influenced by the autolytic process, post-mortem diffusion to the closely adjacent 
organs can be assumed.  The relatively high MDMA level in vena cava inferior blood can 
be correlated with diffusion out of the kidneys and the liver.  Indeed, the MDMA 
concentration in the liver was the highest of all organ levels.  As the liver seems to be an 
important “reservoir” of MDMA, this organ can be assumed to be capable of inducing 
considerable post-mortem redistribution at increasing post-mortem intervals.  As a result, 
blood sampling near the liver (e.g. inferior vena cava blood or blood from the right heart) 
should be avoided.     
The MDMA and MDA levels in liver and bile can point to elimination by 
biotransformation or by excretion via the bile.  However, MDA levels in the kidneys were  
higher than the corresponding MDA liver concentrations,  which may indicate that the 
impact of tubular reabsorption should not be overlooked because the MDA level in urine 
was rather low.  In our case, because the MDA blood and tissue levels (also the ratios as 
given in Table 6.1) are mainly consistent with the MDMA distribution,  though with a 
considerable difference in size, we can assume that MDA acts as a metabolite of MDMA.  
Referring to the MDA amounts, our data confirm the results of previous studies, namely 




The ratio of vitreous humour to femoral blood MDMA level of 1.1 was consistent 
with previous research in rabbits (25), indicating that equilibration was attained.  This 
assumes that vitreous humour can be a suitable alternative when an appropriate blood 
sample is lacking, but this should be confirmed with larger series.  In addition, when a 
significant degree of putrefaction has already taken place, thus making blood and vitreous 
humour sampling impossible, quantitation of MDMA in iliopsoas muscle can give relevant 
information (see values in Table 6.1). 
 The MDMA levels in the various brain regions demonstrate regional differences, 
with the highest levels being in the frontal and parietal lobes. In our data, these regional 
differences are similar for MDA.    Because  the sampling method was different, our results 
cannot be compared with recently published findings (16).   Finally, the high cerebral levels 
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I.2 Distribution study of the amphetamine derivative MDMA and its 




In this section, the distribution of MDMA and its metabolite MDA in various body 
fluids and tissues is further investigated on the basis of two additional fatalities in order to 
determine which body fluid and/or tissue sample post mortem most closely approximates 
the blood concentration at the time of death. The question is raised as to whether the 
toxicological data are consistent with those in the above-mentioned case (1).  Moreover, a 
few additional samples (such as pleural and pericardial fluids, both hemi-diaphragms and 
endocrine glands including the pituitary gland)  are studied.   
 
II Case histories 
 II.1  Case 01/122 
At about 11 a.m., an 18-year-old man was found dead.  The night before, he had 
gone out with a friend and had been drinking a lot.  He had been snoring the whole night, 
but was found lifeless, in ventral position, in the morning. 
 An initial external examination was performed in the mortuary the same day at 3:30 
p.m.  The body had been kept in the cold store since about 1:30 p.m.  His wallet was found 
with the body in the plastic body bag though without any cash.  His face and upper thorax 
were obviously cyanotic.  The lips and tip of the tongue were parchment-like desiccated.  
Rigor mortis was already obviously present on both upper and lower limbs; the hypostasis 
was distinct.  The rectal temperature measured at 3:42 p.m. was 36°C.  Subclavian blood 
and urine were sampled for toxicological screening.  As the friend of the deceased denied 
the use of drugs, and the post-mortem blood alcohol concentration was relatively low (0.56 
g/l),  and – moreover - the wallet of the young man was empty, the prosecutor ordered an 
extensive inquiry including an autopsy. 
 As the prosecutor delayed his decision whether or not to order an autopsy until 
further toxicological results were available, the autopsy was performed only 5 days post 
mortem.  External inspection disclosed a rather small young man : the body weighed 61 kg 
and was 177 cm tall.  Onset of putrefaction was noted.  Only a few slight desiccated 
abrasions in his face (possibly agonal or post mortem) and a slight excoriation on his knee 
consistent with a fall or impact, were found.  Some small scarce petechiae on the left outer 
eyelid and conjunctivae were observed.  Dental caries and a tongue bite were seen.  During 
internal examination, 160 ml bloody fluid was present in both pleural cavities.  Scattered 
Tardieu spots on both pleurae, thymus and epicardium were noted.  Pus material was 
present in the distal bronchial branches, and an overwhelming pulmonary congestion and 
oedema were found.  Generalized visceral congestion was seen, which was confirmed by 
the increased organ weights (see Table 2.1 (a)). The histological study confirmed the 
pronounced pulmonary congestion and haemorrhagic oedema and the generalized visceral 




2nd degree microvacuolar liver steatosis. Autolysis hampered the diagnosis of an acute 
tubular necrosis (ATN).  Examination of several brain regions disclosed - apart from 
pronounced congestion and oedema - a few petechial haemorrhages, obvious sludging in 
the basal ganglia and signs of protracted hypoxia in the hippocampus. 
 
   II.2  Case 01/158 
A 31-year-old man known to be addicted to alcohol, was found dead at home next 
to his bed, in an advanced state of putrefaction.   
During external examination, the body exuded a miasmatic odor.  Typical 
decomposition signs such as generalized bloating of the body associated with a discoloured  
face, venous marbling and peeling off of the skin were found.  Purge fluid was draining out 
from the mouth and nose.  The body weighed 85 kg and was 178 cm tall.  The external 
findings and police inquiry indicated a post-mortem interval of at least 7 days.  
At autopsy, putrefaction of all organs was confirmed.  About 600 ml bloody fluid 
was present in both pleural cavities.  Putrefaction vesicles on the lung surfaces were present 
and obvious pulmonary congestion could still be observed.   The organ weights are 
presented in Table 2.1 (Chapter 2).  The heart was somewhat enlarged but the coronary 
arteries showed no substantial atherosclerosis.  The putrefaction interfered with the 
microscopical examination.  However, significant myocardial scars and pronounced liver 
steatosis (by means of a fat staining) could be excluded.  Arguments for pulmonary 
congestion and oedema associated with deep vomit aspiration could be substantiated.  In 
addition, a few Prussian blue positive macrophages were observed.  There were no 
important bleeding lesions in the brain. 
 
III Toxicological data 
The previously described HPLC-method was used for the quantitation of MDMA 
and MDA (1,2).  MDMA and MDA concentrations in various body fluids and tissues are 
presented in Table 6.2.  For both cases, the cardiac blood concentrations were higher than 
the peripheral blood levels, and the pericardial fluid levels were in line with the cardiac 
blood levels.  Substantial levels were found in the majority of the organs, except for the 
abdominal adipose tissue.  The highest concentrations were observed in all lung lobes, the 
stomach content, the liver, the bile, both kidneys and the urine.  In addition, the 
concentrations in the pituitary gland were obviously higher than the brain levels.  The 
vitreous humour MDMA level in case 01/122 was in the same range as the peripheral blood 
levels. 
For case 01/122, two subclavian blood and urine samples were available: sampling 
of these occurred during the initial external examination and at the autopsy, thus with an 
interval of 5 days. Toxicological screening of the initial samples disclosed the presence of a 
blood and urinary alcohol concentration of 0.56 g/l and 1.23 g/l, respectively.  MDMA was 
detected in blood.   In addition, a potentially toxic methadone level of 1.1µg/ml in blood 
was found. 
For case 01/158 – due to the pronounced putrefaction – it was unfortunately not 




blood samples was restricted.  In addition, the brain was extremely weak and therefore 
immediately preserved on buffered formalin (10 %).  
 
Table 6.2   Distribution of MDMA and MDA. 
 
sample case 01 -122 case 01 -158 
 MDMA MDA MDMA MDA 
 (µg/ml)* (µg/ml)* (µg/ml)* (µg/ml)* 
subclavian blood : - first sample ° 0.271 0.009 - - 
                            - second sample  0.304 0.010 26.059 0.048 
femoral blood - - 13.508 0.044 
vena iliaca blood 0.510 0.017 12.422 0.029 
inferior vena cava blood 0.464 0.018 - - 
right atrial blood 0.416 0.014 57.297 0.052 
right ventricular blood 0.420 0.016 - - 
left atrial blood 0.585 0.026 - - 
left ventricular blood 0.389 0.020 - - 
pulmonary artery blood 0.589 0.021 - - 
pulmonary vein blood 0.802 0.043 - - 
aorta ascendens blood 0.460 0.021 156.887 0.093 
right pleural fluid  0.700 0.029 71.368 0.708 
left pleural fluid 0.815 0.031 137.497 0.545 
pericardial fluid 0.545 0.019 149.319 0.488 
vitreous humour 0.361 0.015 - - 
urine :  - first sample ° 3.290 0.100 - - 
            - second sample  5.090 0.210 71.560 3.480 
bile 22.075 0.764 86.954 1.782 
thymus 0.359 0.026 8.428 0.083 
thyroid gland 0.316 0.019 - - 
muscle of the right cardiac 
ventricle  
0.387 < LOQ 65.479 0.460 
muscle of the left cardiac ventricle  0.377 < LOQ 214.729 0.406 
right lung:upper lobe 3.031 0.122 79.225 5.176 
right lung:median lobe 3.399 0.179 116.866 5.303 
right lung:lower lobe 4.466 0.274 128.125 4.445 
left lung: upper lobe 2.256 0.120 85.323 5.129 
left lung:lower lobe 4.955 0.221 96.401 3.739 
right diaphragm 0.255 < LOQ - - 
left diaphragm 0.513 < LOQ - - 
liver 4.867 0.093 103.497 0.828 
stomach content 10.519 0.581 2310.709 3.940 
duodenal content - - 351.129 0.500 
right kidney 1.848 0.089 155.293 6.678 
left kidney 1.027 0.072 68.469 4.692 




Table 6.2   Distribution of MDMA and MDA (continued) 
 
sample case 01 -122 case 01 -158 
 MDMA MDA MDMA MDA 
 (µg/ml)* (µg/ml)* (µg/ml)* (µg/ml)* 
spleen 0.835 0.040 - - 
pancreas 0.369 0.018 36.909 0.179 
iliopsoas muscle  0.302 < LOQ 61.501 0.200 
abdominal adipose tissue < LOQ < LOQ - - 
pituitary gland 3.611 0.190 - - 
brain:   frontal lobe 0.685 0.026 - - 
           temporal lobe 0.407 0.015 - - 
           parietal lobe 0.811 0.026 - - 
           occipital lobe 0.858 0.034 - - 
medulla oblongata 0.492 0.017 - - 
pons 0.753 0.030 - - 
cerebellum 0.668 0.025 - - 
     
* for tissues: µg/g    
-: sample not available     
< LOQ: below limit of quantitation     
° first sampling occured during the initial external examination; second sample taken during 




The medico-legal findings in the first case (01/122) were compatible with fatal 
hyperthermia.  The rectal temperature of 36°C about 4.5 h following the discovery of the 
man – even after the body had been cooled for a few hours before the examination took 
place - suggested a high body temperature at the time of death.  The shock lungs, the 
obvious congestion and oedema associated with a few perivascular bleedings in the brain 
and signs of protracted hypoxia (e.g. in the hippocampus) were in accordance with fatal 
hyperthermia.  The pronounced putrefaction process interfered substantially with the 
investigation of the second case.  However, the obvious pleural exudations, pulmonary 
congestion and generalized visceral congestion were compatible with acute to subacute 
cardiopulmonary failure. 
These two cases were interesting for the thanato-toxicological study because of the 
relatively long post-mortem intervals of 5 and at least 7 days, respectively, which were 
more substantial than in the above mentioned distribution study in case 00/112 (1).  The 
difficulty of interpreting a MDMA blood level was confirmed in cases 01/122 and 01/158.  
Indeed, a distinct difference in concentration range of MDMA was found, viz. 0.270 µg/ml 
and 13.510 µg/ml, respectively.  The relatively low MDMA blood level in the first case 
was in accordance with a protracted agony and substantiated the diagnosis of hyperthermia.  




knowledge – only one higher MDMA level is reported in the literature, namely 18.500 
µg/ml (3).  These two extreme MDMA levels confirmed that the toxicological data should 
be interpreted in the light of the autopsy findings in order to come to a conclusion. 
The toxicological results in these two cases substantiated the recommendation that 
peripheral blood samples (preferably femoral) are the “golden standard” and that blood 
sampled centrally in the body (such as cardiac blood) should be avoided (4).  Indeed, 
referring to the high MDMA and MDA levels in the lungs and liver, cardiac blood samples 
were subject to post-mortem redistribution and can therefore be misleading in the 
interpretation as to whether the post-mortem level is potentially toxic or lethal.  Moreover, 
the MDMA concentration in the subclavian blood samples in the first case which were 
taken with a post-mortem interval of about 5 days – demonstrated that subclavian blood 
can be an appropriate sample for post-mortem toxicological analysis.  However, when 
pronounced putrefaction occurs - which was present in case 01/158 – a subclavian blood 
sample should be interpreted with caution. 
The higher MDMA and MDA concentrations in several tissues compared with their 
concentrations in blood corroborated the results in the animal experiments and the findings 
in other case studies, viz. that MDMA accumulates in or binds to various tissues (5,1,9). 
The substantial MDMA and MDA levels in the lower lung lobes were not only in 
accordance with the hypostasis - which is more pronounced in these areas - but could also 
be correlated with the closely adjacent liver and stomach.  The pericardial and pleural fluid 
levels were on the same order as the cardiac blood and lung tissue concentrations, 
respectively.   
The MDMA and MDA concentrations in liver and bile confirmed the hepatic 
biotransformation and excretion of MDMA via the bile.  The substantial kidney levels were 
directly related to the urinary levels because these tissues are inherently “contaminated” 
with urine. The relatively low MDA levels in several body fluids and tissues confirmed that 
though MDA is an active metabolite, it is not a major metabolite of MDMA in humans.   
For case 01/122, both the urinary MDMA and MDA concentrations were obviously 
higher in the second than in the first sample; this could be due to post-mortem dehydration 
with diffusion of fluid into the tissues nearby the bladder, resulting in a concentration effect 
in the urine.  
The MDMA concentration difference between the left and the right hemi-
diaphragm could be correlated with the high levels in the stomach content, which is closely 
adjacent to the left hemi-diaphragm, thus substantiating some post-mortem diffusion out of 
the stomach content.  This is in accordance with the findings in the rabbit model (6). 
The high brain MDMA and MDA concentrations were in line with expectations and 
in accordance with the brain as target organ.  In addition, the concentrations in the pituitary 
gland were even more substantial, being consistent with the neuroendocrine effects such as 
the increases in plasma cortisol and prolactin levels which have been documented in 
humans (7).  
The vitreous humour MDMA and MDA concentrations in case 01/122 
demonstrated that this specimen can be valuable, mainly when protracted agony takes place 




compartment and the vitreous body (1,8).  Unfortunately, due to the pronounced 
putrefaction in the second case, the vitreous humour was lacking. 
Finally, there is an incoherence between the MDMA concentrations in the iliopsoas 
muscle in the two cases.  In view of the first case, we could assume the iliopsoas muscle to 
be an interesting specimen when blood is lacking.  This was in line with other cases (1,9).  
However, the iliopsoas level in the second case indicated that when advanced putrefaction 
has taken place, these levels, as well, should be interpreted with caution.  The more 
substantial MDMA concentrations in the iliopsoas muscle could relate to urinary leakage in 
an advanced putrefactive status. 
In conclusion, these two cases confirm that MDMA and MDA can accumulate in 
various tissues and that post-mortem redistribution can occur out of organs such as the 
lungs and the liver into mainly cardiac blood.  To a certain extent, the influence of this 
post-mortem phenomenon can be avoided by peripheral sampling (such as using subclavian 
or femoral blood).  Vitreous humour and iliopsoas muscle can be valuable specimens for 
toxicological analysis, provided the putrefactive stage is not too pronounced.  The same 
remark is applicable to the subclavian blood.  Finally, these cases substantiate that a broad 
range of MDMA concentrations can be found in fatalities and therefore the toxicological 
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I  Abstract 
We present a case history involving one fatal case and seven survived cases of intoxication 
with 4-methylthioamphetamine (4-MTA), also called para-methylthioamphetamine (p-MTA) or 
simply methylthioamphetamine (MTA), a relatively new amphetamine analogue.   Two of the 
seven survivors required a 24-h-period of observation in hospital.  This report proves once again 
that the new amphetamine "designer drugs" are not without danger, as is thought by many young 
people.  In addition, individually different subjective reactions  are described.  Finally, the medico-
legal implications of new, as yet unregistered drugs are discussed. 
 
Key words: Drug abuse -  4-MTA -  4-Methylthioamphetamine – Amphetamines - Intoxication. 
 
II Introduction 
The substance 4-methylthioamphetamine (4-MTA), also called para-
methylthioamphetamine (p-MTA), methylthioamphetamine (MTA) or “Flatliner” (1), is a relatively 
new phenylethylamine-based compound.  It was first synthesized and investigated by Huang et al. 
(2) in the rat animal model in which MTA was proven to be non-neurotoxic at low doses, but was 
found  to induce typical serotonergic behaviour at high doses.  MTA was in fact developed as a 
potent and “purer” serotonin-releasing agent for use in experimental research (2).  This serotonin-
releasing property was compared with that of other amphetamine derivatives, and a study in rats 
indicated, for example, that MTA had a delayed reaction compared to MBDB (3) (also known as 
Methyl-J and Eden (4)).   The main site of toxicity with MDMA is believed to be within the 
serotonergic pathways in the central nervous system and explains the influence of MDMA on 
affective behaviour and thermoregulation, for example (5).   Studies in the rat indicated that 
another amphetamine derivative, methamphetamine, was able to induce apoptosis of the thymic 
and splenic lymphocytes (6).  Recently, the cardio-toxic effect of methamphetamine has been 
studied in isolated adult rat cardiomyocytes  (7).  Others have investigated the liver toxicity caused 
by single or repeated intraperitoneal doses of MDMA in the rat (8).  However, many mechanisms 
of toxicity caused by amphetamine and its derivatives still  remain to be elucidated. 
 MTA, just as MBDB (4), can be sold as an “ecstasy” pill, and the use of MTA as an illegal 
“designer” drug was first reported in the Netherlands (9).  MTA is structurally closely related to 
para-methoxyamphetamine (PMA), another ring-substituted amphetamine (see Figure 6.2).   
Some cases of fatal poisoning involving PMA have recently been reported (10,11).  To our 
knowledge, only one fatal case of MTA intoxication (1) and a very few cases of poisonings have 












Figure 6.2 Chemical structures of 4-MTA (4-methylthioamphetamine) (a) and PMA  
 (para-methoxyamphetamine) (b). 
 
 
III History and case reports 
One morning, the emergency services were called to a residence, where they found one 
person unconscious and six other people in a state of intoxication.  The six young people were 
admitted to hospital and two required a 24-h-period of observation.  Further police investigation 
revealed that another person (case 8) was also involved, but he had left the house before the 
emergency services arrived. 
 
 III.1  Case 1 (M.) 
A 27-year-old drug dealer was found in a state of cardiorespiratory arrest at about 9:00 
a.m.  The emergency team attempted intensive reanimation which failed. On post-mortem 
examination, the body weighed 55 kg and was 171 cm in length. The rectal temperature at 1:05 
p.m. was 35°C and the ambient temperature 17°C.  During the external examination, fresh 
ecchymoses on both legs and a few small fresh excoriations on both forearms and the left ankle 
were noticed.  These superficial skin lesions were consistent with slight to moderate blunt trauma 
(e.g. fall or blow). 
During internal inspection two days post mortem, obvious signs of intensive 











were observed on the pericardium, thymus and both pleurae.  Both lungs weighed 970 g and 
obvious emphysema, severe congestion and moderate oedema were found.  The heart weighed 
255 g and showed no conspicuous anomalies. The stomach contained only a small amount of 
bloody mucus and the mucosa showed a few pin-point ulcerations.  The brain weighed 1320 g 
and, apart from slight oedema and congestion of the white matter, nothing unusual was found.  The 
remaining organs showed no obvious macroscopical anomalies, except for congestion. 
On histological examination pronounced pulmonary congestion, hemorrhagic oedema, a 
slight intra-alveolar infiltration with a few polymorphonuclear cells and some leucocytic sludging in 
the septal veins were found.  Groups of alveolar macrophages were seen, although staining with 
Prussian blue was negative.  Obvious eosinophilic infiltration was found in some lymph nodules 
although it was not seen in the lungs.  The Purkinje cells in the cerebellar vermis were pyknotic and 
somewhat reduced in number.  In the nucleus lentiformis a few venulae were surrounded by a 
lymphocyte infiltration and macrophages containing hemosiderine.  The hippocampus showed no 
marked hypoxemic lesions.  No obvious pre-existing disease was identified. 
Toxicological screening revealed MDMA in the urine, MTA in the blood, urine and liver, 
and tetrahydrocannabinoic acid in the urine.  These results were confirmed by GC/MS (liver/urine) 
and HPLC/DAD (blood) analysis.  Blood, urine and liver analysis showed MTA concentrations of 
8.38 µg/ml, 100 µg/ml and 30 µg/g, respectively.  The MDMA level in the urine was 1.2 µg/ml.  
The amount of MDMA in the blood was below the limit of quantitation (< 0.1 µg/ml). The urine 
pH was 5.6.  The size of the stomach content sample was insufficient for toxicological analysis.  
No other psycho-active drugs were found.  In addition, analysis of two small plastic bags 
(containing green-brownish herbs) found in the victim's pockets, demonstrated cannabinol 
(marijuana).   
Questioning of the surviving persons revealed that M. had been walking around the whole 
night, but around 8:00 a.m. he started sweating and thrashing around on the floor.  M. started 
shaking intensely and his behaviour became increasingly more strange. This went on for quite some 
time, at least 1 h.  Somewhat later, one of them noted that M.'s heartbeat was fading and oedema 
was appearing on his mouth.  They then tried to resuscitate him, but even before the emergency 
services arrived, M. felt cold to the touch.  One of the survivors declared that M. had taken at 
least six pills: first, two pills at the same time, and then each of the other four pills at intervals of 
about 2 h.  In addition, M. had smoked five or six joints.  The girlfriend of the deceased  (case 7) 
admitted that M. was dealing in “ecstasy” pills, marijuana and speed, and he drove to the 
Netherlands for his supplies.  M. was heavily addicted to “smart pills” and easily took six of them 
in the course of a single evening followed by a shaking period that usually subsided after a few 
minutes. On the morning in question, M. started shaking but this time it did not stop after a few 
minutes.  He had told her about ingesting fifteen pills at one time in the previous year.  In the 
dealer's car, a note printed in Dutch describing some characteristics of MTA (called "MTA-1" in 











III.2  Case 2 (D.W.) 
This 18-year-old man found lying in a chair, apathetic and staring vacantly into space, was 
conveyed to hospital for observation.  Upon being discharged 24 h later, he stated to the police 
officer that he had been using drugs since the age of 14, mainly cannabis, and sometimes "a pill".  
On the night in question, all those present in the house had smoked joints and swallowed pills.  He 
could not remember exactly when, but he himself had taken two pills at the same time.  He 
described how he had taken leave of his senses thereafter, had had a "threefold" vision and 
hallucinations, and was unable to control all his acts (e.g. he could not stop his chin from 
shivering).  He felt that his heart rate had clearly increased and one moment he was sweating, 
while a few moments later he would turn icy cold.   
 
 III.3  Case 3 (B.) 
The emergency services found this 22-year-old female unsteady on her feet, although a 
certain amount of conversation was possible.  She had arrived at home at about midnight, when 
she smoked some joints together with her friends and then took one pill.  From that point on, she 
could remember very little, although she knew she had slept a lot.  She regularly smoked joints at 
the weekends, but it was the first time that she had taken such a pill.   
 
 III.4  Case 4 (W.) 
 This 15-year-old female looked extremely tired but was able to confirm that everyone had 
smoked joints and, shortly thereafter, M. had handed out "smart" pills. She was admitted to 
hospital, although observation was not required, and she was interrogated about 12 h later.  She 
herself took one pill at about 00:15 a.m., and 20 min later, she “experienced a very pleasant 
feeling”.  In order to enhance the sensation, she smoked a joint.  She was awake during the whole 
night and, like the others, she drank no alcohol. 
This subject was also able to give some information about the number of pills the different 
individuals had swallowed (see Table 6.3). W. claimed that she herself takes a pill and smokes a 
joint "now and then", but only at weekends. 
 
 III.5  Case 5 (W. W.) 
The story of this 19-year-old man, was consistent with the others. He stated that he had 
taken only one pill, followed by three joints, and had played music the whole night through.  
 
 III.6  Case 6 (D.J.) 
Although this 22-year-old man was heavily intoxicated, he agreed to make a statement. 
Since his answer frequently went beyond the question and he behaved very strangely (e.g. hitting 
his head against the table, almost falling off his chair), the police officers decided to send him to 
hospital for observation.  He was discharged 24 h later, when he was capable of being 





two pills at an interval of half an hour.  He explained that when he took one pill, nothing happened, 
but following the second, he felt good and was unable to sit still.  Somewhat later he took a third 
pill, and from then on everything was fuzzy. He recalled having difficulty in urinating but he did not 
remember being in hospital.  According to his girlfriend (case 3) it was the first time he had taken 
such a pill.  
 
 III.7  Case 7 (V.) 
This 19-year-old woman, the girlfriend of the deceased (case 1), was also interrogated the 
evening following the occurrence.  She had  been using drugs since the age of 10 and was 
addicted to marijuana and stimulating drugs (including speed and "MTA-1"). The two pills she 
swallowed made her feel sick and she vomited several times.  She fell asleep for a few short 
periods.  
 
 III.8  Case 8 (G.) 
This 20-year-old man arrived at the house at about 1:00 – 1:30 a.m. and left at about 7:30 
a.m.  He confirmed that everybody was “in a whirl” when he arrived. For the first time in his life, 
he took one pill at about 1:45 a.m. and somewhat later fell asleep.  By the time he went home, the 
effects of the pill had worn off.  When he was interrogated more than 36 h after taking the pill,  he 
was behaving totally normally, so no blood or urine sampling was ordered by the coroner. 
 
Blood and urine samples were obtained from all the other survivors (cases 2 - 7) and all 
were positive for tetrahydrocannabinoic acid.  The MTA levels found in the blood and urine 
samples and the estimated number of pills ingested are presented in Table 6.3.  The MDMA levels 
were < 0.1 µg/ml. 
 
 
Table 6.3 Summary of the data found in the surviving persons. 
Case      number a      blood  urine        urinary     MTA level (µg/ml) 
        sampling sampling     pH     in blood in urine 
     time  time        
________________________________________________________________________ 
(2) D.W.   ≥ 2      12:44 h 12:20 h        6.6       0.63  10 
(3) B.  1      16:52 h 16:57 h        8.1       1.08  4 
(4) W.  1      12:41 h 15:23 h        7.3       2.08  8 
(5) W.W. 1 or1½       12:33 h 12:23 h        6.4       1.93  4 
(6) D.J.       3, 5 or 6?      12:43 h 15:22 h        5.8       1.26  40 





a possible number of ingested pills, according to the persons’ statements 
 
The police searched the house where the event took place and the properties of all the 
persons involved.  In the building, a few pills were found.  The yellow pills, weighing 345 mg, 
contained 28 %  or 97 mg MTA.  In addition, a small amount of an unknown product, possibly 1-
(4-methylthiophenyl)propene or 1-(4-methylthiophenyl)-2-propene, was found.  This compound 
was present in the pills in less than 0.5 % of the MTA peak area in the chromatogram and could 
not be quantified due to the absence of a reference standard. 
 
IV Analytical procedures 
4-MTA reference material was supplied by the Wetenschappelijk Instituut Louis Pasteur 
in Brussels, Belgium. The reagents and chemicals were of analytical grade. The drug standards and 
the internal standards were obtained from commercial suppliers (Sigma, Radian).  
  
IV.1  Biological samples 
Routine systematic toxicological analysis was performed on the samples to investigate for 
illegal drugs, medical drugs, alcohol, volatile substances and other poisons. Immunoassay 
screenings (ADx) were performed to test for amphetamines, cannabinoids, opiate groups, 
methadone and cocaine metabolite in urine and barbiturates, salicylates, tricyclic antidepressants 
and benzodiazepines in blood. Radio-immunoassay (RIA) was used to screen for LSD in urine 
and benzodiazepines in blood. Color spot tests on urine and gastric content were used to detect 
salicylates, acetaminophen, phenothiazines and imipramines. Post-mortem blood was analyzed for 
the presence of carboxyhemoglobine and cyanide. Urine was screened for the presence of acidic, 
neutral and basic drugs by thin-layer chromatography. Gas chromatography/mass spectrometry 
(GC/MS ion trap) was used to screen urine samples for the presence of basic drugs.   Blood was 
screened by high-performance liquid chromatography with photodiode-array detection 
(HPLC/DAD). Analysis for the presence of alcohol and other volatile substances in blood and 
urine was performed by headspace gas chromatography with a flame ionization detector 
(GC/FID).  The U.V. spectrum of 4-MTA obtained by HPLC/DAD was characterized by a 
strong absorption at 253 nm. 4-MTA was confirmed by GC/MS  monitoring ions at m/z  44, 138, 
165 and 182. 
For the quantitation of 4-MTA in blood 1 ml of water was added to 1 ml of a sample or a 
spiked blood standard and then 100 µl of 3% sodium hydroxide w/v was added, along with 20 µl 
of diphenylamine as an internal standard and 6 ml of diethylether. After mixing and centrifugation 
(10 mins, 1121 x G), the organic phase was separated and transferred to a new 10 ml glass 
screw-top tube. The ether was then mixed with 0.025 M HCl, the ether was discarded and the 





extract was submitted for HPLC/DAD analysis. The correlation coefficient of the calibration curve 
was 0.9996, recovery for 4-MTA 82% (Cordonnier and Coopman, personal communication). 
  
 
IV.2  Illicit preparation  
The yellow powder was finely pulverized. The quantitation of MTA was performed with 
HPLC/DAD (Varian) monitored at 254 nm: 10 mg amounts of the powder were dissolved in 1 ml 
of methanol, then diluted with the mobile phase acetonitrile-buffer containing an external standard 
(diphenylamine 20 µg/ml) and then separated by chromatography on a Lichrocart cartridge column 
(125 x 4 mm i.d., 4 µm) filled with Superspher 10 RP-18 packing (14). Standards (10-100 µg/ml) 
containing a constant amount of the same external standard were prepared in the mobile phase. 
The concentration was calculated by comparing the peak area of the drug to the external standard 
versus the standard calibration curve (r = 0.9998).  
Identification of the contaminant was achieved by a GC/MS Saturn III Ion Trap (Varian). 
All GC/MS analyses were performed using a 0.25 mm ID x 30 m fused silica capillary column 
coated with 0.25 µm of 5% phenyl - 95% methyl-silicone. The injector was set at 250°C. The GC 
oven program consisted of 70°C, 2 min; 70-290°C at 12°C /min; 5 min. Helium was used as the 
carrier gas, with an inlet pressure of 275 kPa. Mass spectra were obtained at 70 eV.  Ethyl 
acetate was used as the solvent, instead of methanol in order to exclude the possibility of the 
formation of methylated analytical artefacts inside the injection port of the gas chromatograph.  




We report seven more or less serious and one fatal intoxication involving a relatively new 
amphetamine analogue, 4-methylthioamphetamine, also called para-methylthioamphetamine.  To 
our knowledge, there are only rare reports in the literature of such intoxications (1,12,13).   The 
analytical profile of 4-MTA was recently described (9).  As the event took place near the border 
with the Netherlands, the source of the product could probably be traced to that country.  
As MTA is a new "designer drug", there is no consensus concerning the toxic or lethal 
blood concentrations.  In our fatal case, the 4-MTA blood level established (8.38 µg/ml) was 
higher than in the previously reported case which had peri- and post-mortem MTA levels of 4.2 
µg/ml and 4.6 µg/ml, respectively (1).  Compared to other amphetamine-related compounds, the 
author assumed that MTA blood levels exceeding 4 µg/ml can potentially result in death, or at least 
constitute a serious health risk (1).  However, guidelines indicate that blood MTA levels of 0.2 – 
0.6 µg/ml result in moderate toxicity, levels higher than 0.6 µg/ml cause dangerous toxicity and 
levels exceeding 1.5 µg/ml can lead to death (12).   We believe that in our fatal case, there will be 
no argument that the detected MTA concentration in subclavian blood (8.38 µg/ml) was capable 





months prior to his death, the man claimed to have taken 15 MTA pills at once and survived 
(without medical intervention).  
Compared to MTA, blood PMA levels greater than 0.5 µg/ml are likely to be associated 
with toxic effects (11).   As for MDMA, there is also no consensus about the lethal blood level but 
in general, a blood MDMA concentration higher than 1.0 µg/ml can be potentially lethal, whereas 
levels lower than 0.6 µg/ml are capable of inducing intoxication (15).  However, there is a 
considerable range in reported fatal blood MDMA levels (16-18).  Furthermore, some toxic 
effects could also be related to contaminants (19).   
A number of studies have been carried out on the content of clandestine tablets containing 
amphetamines,  analogues and various possible impurities (e.g. 20-23).   Various analytical 
techniques have been proposed as a means of identifying the drugs incorporated in tablets or 
powder, and capillary electrophoresis has been established as a rapid method for qualitative and 
quantitative determination (24).  In the pills taken by our cases only a small amount of an unknown 
product - possibly 1-(4-methylthiophenyl)propene or 1-(4-methylthiophenyl)-2-propene - was 
found.  This product was recently also identified by Kirkbride KP et al. (25).  This may indicate 
that the  illicit 4-methylthioamphetamine might be derived from this compound, since a shipment of 
1-(4-methylthiophenyl)-2-propene was recently seized in Europe (9) .    
All the persons involved in this report took pills having the same content.  In addition, in 
some of our surviving cases, an obvious inconsistency between the MTA levels detected and the 
described clinical symptoms can be noted.   For example, case 4 had an MTA blood level of 2.08 
µg/ml and showed relatively less obvious symptoms than cases 2 and 6, with MTA blood levels of 
0.63 and 1.26 µg/ml, respectively.  In contrast to cases 2 and 6, case 4 did not require a 24-h-
period of observation in hospital. Furthermore, case 7 showed the lowest MTA blood level.  She 
took at least 2 pills, but had vomited a lot.  In addition, although she admitted being addicted to 
marijuana and stimulating drugs, including speed and "MTA-1", it seems somewhat bizarre that 
she got so sick after taking the pills.  Thus, the obvious differences in individual responses to MTA 
must be taken into consideration. This fact is substantiated by the report of de Boer et al., who 
reported a patient who  suffered from amnesia and other problems during a 2-week-period 
following the ingestion of a single pill (13).  However, the possibility cannot be excluded that 
adverse reactions may occur due to contaminants. In addition, all of them had smoked marijuana 
followed by the intake of  MTA.  We can not exclude the possibility that the MTA effect was 
enhanced by the simultaneous intake of cannabinoids. 
Pharmacological and toxicological information for MTA in the literature are scarce, but it is 
clearly not a safe product.  Moreover, although it is too speculative to draw a correlation between 
the ingested amount declared by the persons involved and their corresponding blood and urine 
concentrations, we believe that individually different rates of metabolism and/or excretion of the 
product cannot be excluded.  For amphetamine and d-methamphetamine, the urinary excretion is 





retrieved (26).  In our cases, the persons with the lowest urinary pH, cases 6 and 7 for example, 
showed the highest urinary MTA levels.  
Since MTA is a relatively new amphetamine derivative and the number of reported 
poisonings is limited, the pathological findings and the mechanism of death due to this product have 
not yet been fully evaluated.  The side-effects of MTA are probably comparable with those 
reported after MDMA intake, being mainly related to the sympathomimetic and neurotoxic effect 
of “ecstasy”, but multiple organ failure including acute hepatic decompensation and/or renal failure 
(due to rhabdomyolysis) should also be considered (27).  Some of the frequently reported 
sympathomimetic effects include tachycardia, tremors, palpitations, diaphoresis, paraesthesias, 
trismus and bruxism (28).    The symptoms described by M.’s friends were similar.  The different 
experiences of the survivors, such as agitation (see cases 1 and 6), insomnia or even a feeling of 
fatigue or being sleepy have previously also been reported after MDMA intake (29). 
The mechanism of death in this case remains uncertain. The pathology of seven deaths 
associated with MDMA and MDEA abuse has been described, and it involves centrilobular liver 
cell necrosis, catecholamine-induced myocardial damage and injuries caused by hyperthermia 
(19).  Fineschi et al. described a fatal case following MDMA and MDEA intake that presented a 
morphological picture consistent with hyperthermia and disseminated intravascular coagulation 
(DIC) (30).  In our case, the rectal temperature of 35°C measured at the scene 4 h after death, 
makes hyperthermia unlikely.  In addition, the fact that the brain weighed 1,320 g is not consistent 
with hyperpyrexia.  Moreover, none of the above-mentioned microscopical findings were 
established, and neither were there any particular arguments for multiple organ failure.   “Ecstasy” 
ingestion and sudden cardiac death has previously been reported, although the deceased in this 
particular case had a history of Wolff-Parkinson-White (WPW) syndrome (17).  In view of our 
autopsy findings a fatal cardiac arrhythmia should be considered as a possible mechanism of 
death.  However, fatal epileptic insults cannot be excluded.  The mechanism could perhaps be 
compared with epilepsy-related cardiac shock due to activation of the autonomic nervous system 
(31).  Finally, only a few microscopical signs consistent with chronic drug abuse were noted: 
eosinophilic infiltration in the lymph nodes and a somewhat decreased number of Purkinje cells in 
the brain, as well as atypical perivascular lymphocytic infiltration and siderophages in the nucleus 
lentiformis. 
As 4-methylthioamphetamine is a fairly recent “designer drug”, the medico-legal 
implications of these cases of intoxication are of considerable importance.  Indeed, at the time this 
incident occurred, MTA was not included on the list of forbidden drugs. As MTA at  present is 
still not a registered illegal drug, it is very difficult to prosecute dealers.  In our case, incidentally, 
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The case history and toxicological findings of an overdose fatality involving 4-
methylthioamphetamine (4-MTA) and 3,4-methylenedioxymethamphetamine (MDMA) 
are reported along with a description of the analytical method. Detection and quantitation 
of 4-MTA and MDMA were performed by LC-MS/MS using phentermine as internal 
standard. Application of this technique to a variety of matrices allowed an insight in the 
distribution of 4-MTA. Several blood samples such as femoral vein blood (5.23 µg/ml), 
urine (95.5 µg/ml), vitreous humour (1.31 µg/ml), bile (36.4 µg/ml), and numerous tissue 
samples such as liver (30.8 µg/g), spleen (4.10 µg/g) and frontal lobe (31.7 µg/g) were 
assayed.  These values indicated that 4-MTA could be identified as the cause of this 
fatality, whereas the concentrations of MDMA, also described, are less important because 
the concentrations found are lower. This case, for the first time, reports an extensive 
toxicological analysis of 4-MTA, by which the data presented may shed some light on the 
distribution of 4-MTA. 
 
II Introduction 
4-Methylthioamphetamine (4-MTA) or p-methylthioamphetamine (Figure 6.3), also 
known under the street name « Flatliner », is a phenylethylamine-based compound that has 
been examined as a possible, new non-neurotoxic serotonin-releasing agent. These studies 
established that 4-MTA is a potent, dose-dependent serotonin releaser that indeed appears 
to lack serotonin neurotoxicity at behaviourally relevant doses, contrary to MDMA, that 





























Except for seizures in Germany and Switzerland, where the tablets featured a five 
pointed star design, all other tablets encountered in Europe and Australia have been flat, 
half-scored and white, hence the nickname « Flatliner » was adopted (2).  However, the 
name flatliner may refer to 4-MTA, ketamine, or even phencyclidine tablets in the UK.  
The term may derive from a cult 1990s film called Flatliners, from a German motorcycle 
club or from US engineering clubs (3). However, the link with a flatliner-EKG (i.e. no 
cardiac output) is also described (3). Currently the exact route by which 4-MTA is 
produced in illicit laboratories is not known. As 4-MTA tablets have been investigated for 
the presence of 4-(4-methylthiobenzyl)pyrimidine and 4-methyl-5-(4-
methylthiophenyl)pyrimidine and as these by-products were not detected, it appears that 
illicit laboratories are not using the Leuckardt method for the preparation of 4-MTA (4). 
Identification and quantitation of 4-MTA in tablets, coming from a drug seizure in the 
U.K., were performed by GC-MS and NMR (5). 
4-MTA has up until now been encountered in three fatal overdose cases in The 
Netherlands and the UK, of which in two cases other drugs were involved. Based on these 
data, Elliott has suggested a toxicity range for 4-MTA. Blood concentrations between 0.2 
and 0.6 µg/ml are considered as moderate toxic, higher concentrations as severe toxic, and 
concentrations above 1.5 µg/ml as fatal. This range is only meant as a guide to the 
interpretation of results, particularly in post-mortem cases (6). Two analytical techniques 
have been described to determine 4-MTA in blood and urine, namely HPLC-DAD and 
GC-MS. To our knowledge, a detailed distribution study considering 4-MTA levels in 
various blood samples and tissues has not been published.  In addition, there are only rare 
reports in the literature describing post-mortem redistribution of amphetamine and 
analogues in humans.  For 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) in 
particular, only a few case reports are published (7,8). This paper reports the first LC-
MS/MS method for the determination of the tissue distribution of both 4-MTA and 
MDMA in a forensic case. 
 
III Case history 
One morning, a 27-year-old drug dealer suddenly died after a collapse and an 
intensive reanimation attempt. Police inquiry revealed that seven other youngsters were 
involved – all being, to some extent, in an intoxicated state. 
The autopsy of the normally built young man was performed 2 days after death. A 
few superficial skin lesions on the limbs indicating slight blunt trauma, and reanimation 
signs were observed. On internal examination, emphysema as well as overwhelming 
congestion and oedema of both lungs were observed. No cardiac anomalies were found. 
The brain showed only a slight congestion and oedema of the white matter. Generalized 
congestion of all organs was noticed. These macroscopical findings were confirmed by 
histological examination. Moreover, a few microscopical signs consistent with chronic 
drug abuse such as moderate eosinophilic infiltration in the lymphenodes and a slightly 
decreased number of Purkinje cells were observed. In addition, aspecific perivascular 




There were no arguments for a prolonged multiple organ failure. Neither on 
external examination at the scene, nor at autopsy, there were signs pointing to 
hyperthermia. No pre-existing pathologies were identified. Police inquiry revealed all 
youngsters had taken « smart  pills». Therefore samples for an extensive toxicological 
investigation were taken.  
 
IV Experimental 
IV.1  Reagents and materials 
All reagents and chemicals were of analytical grade. 4-MTA hydrochloride was a 
kind gift of the Scientific Institute of Public Health (Brussels, Belgium). MDMA and 
phentermine hydrochloride were available from the standards collection at the Laboratory 
for Toxicology (Ghent University, Belgium). Solvents were of HPLC grade from Romil 
Chemicals (Cambridge, UK) with the exception of water, which was from Prosan 
(Merelbeke, Belgium). 
Stock solutions containing either 4-MTA or MDMA or phentermine (internal 
standard) at a concentration of 1.0 mg/ml were prepared in methanol and stored in plastic 
bottles. Dilution with methanol of the 4-MTA and MDMA stock solutions yielded the 
working solutions at appropriate concentrations to prepare spiked calibration samples in 
the various matrices. The internal standard, phentermine, was diluted to a concentration of 
10 µg/ml in methanol. All these solutions were stored in the freezer (-20°C) and proved 
stable for at least 6 months. 
 
IV.2  Systematic Drug screening 
A comprehensive screening was performed on post-mortem blood (vena cava 
inferior blood) and urine using enzyme-multiplied immunoassay techniques (EMIT), 
radioimmunoassay (RIA), and chromatographic techniques (HPLC-DAD following 
alkaline extraction, and gas chromatography with nitrogen-phosphorus detection [GC-
NPD] and with mass spectrometry [GC-MS]) as described earlier (9).  
 
IV.3  Quantitative LC-MS/MS method 
IV.3.1  Calibration 
Calibration curves were prepared in blank matrices for blood, urine and kidney 
homogenate (used as a reference for tissue homogenates). The following calibrators were 
prepared in these three matrices: 0.1, 0.5, 1, 2.5, 5, 10, 25, 50 µg/ml for both 4-MTA and 
MDMA, with phentermine present as internal standard at 10 µg/ml. In each case a 1-ml 
aliquot of the sample or appropriate prepared tissue homogenate was spiked with both 50µl 
of the appropriate standard solution in methanol and 25µl of the internal standard solution. 
Subsequently, extraction was performed according to the general isolation procedure (see 
below). The resulting calibration curves were created by using weighted least-squares 
regression analysis (weighing factor 1/x). Concentrations of 4-MTA and MDMA were 
calculated by comparing the peak-area ratio of the specific compound and phentermine 
(internal standard) against the calibration curve. For the quantitation of vitreous humour 




samples were at least analyzed in duplicate: after a first analysis to determine roughly the 
concentration range of the sample, a second analysis was performed after appropriate 
dilution of the sample (in view of the linear dynamic range constraints of the TOF 
analyzer). 
 
IV.3.2  Isolation of the compounds 
Whole blood, vitreous humour, and urine of the victim were used as such. Tissue 
samples were homogenized in an ice bath after appropriate dilution with water (depending 
on concentration) using an Ultra-Turrax homogenizer from IKA (Staufen, Germany). All 
post-mortem samples were extracted according to a liquid-liquid extraction procedure 
developed in our laboratory (10), especially suited for the extraction of amphetamine 
analogues.  In short, after addition of the internal standard (25µl of a 10 µg/ml-standard 
solution in methanol), and after adjustment of the pH with 0.5ml of a K2CO3 buffer (1.0M, 
pH 9.5), 1 ml of the sample was extracted with 8 ml of a mixture of hexane/ethyl acetate 
(70:30, v/v). Samples were mixed on a rotary mixing device for 15 min and centrifuged at 
1100g for 10 min. The organic layer was transferred to a conical tube containing 50 µl of 
methanolic HCl (5 mol/L acetyl chloride in methanol) and evaporated using a Turbovap 
evaporator at 35°C under nitrogen. Finally, the dry residue was dissolved in 250µl of 
HPLC solvent A (see “HPLC conditions”) and 50-µl aliquots were injected for LC-MS/MS 
analysis. 
 
IV.3.3  HPLC conditions 
Chromatographic separation was achieved on an Hypersil BDS phenyl column (100 
mm x 2.1 mm i.d., 3-µm particle size) protected by a Hypersil BDS phenyl guard column 
(7.5 mm x 2.1 mm i.d., 3-µm particle size) using a Waters Alliance 2790 separation 
module integrated with the Q-TOF instrument. Both the analytical and guard column were 
from Alltech (Deerfield, IL, USA). The flow rate was set to 0.2 ml/min. After a 5 min 
isocratic elution at 100% of a mixture of water/methanol/acetonitrile (94 :3 :3, by vol.) 
containing 0.1 M ammonium acetate (solvent A), gradient elution was performed, starting 
at 100% of solvent A, then programmed linearly, within 13 min, to 35 % of a mixture of 
water/methanol/acetonitrile (6 :47 :47, by vol.) again containing 0.1 M ammonium acetate 
(solvent B). After completion of the chromatographic run, the pump was programmed to 
regain its initial conditions within 0.5 min, and a 5-min reconditioning time was allowed 
before the next injection.  
 
IV.3.4  Mass spectrometry 
The mass spectrometric analyses were conducted using a Micromass Q-TOF hybrid 
mass spectrometer (Micromass, Wythenshawe, UK) equipped with an orthogonal 
electrospray source (Z-spray) operated in the electrospray positive ion mode (ESI+). 
Nitrogen acted both as nebulizer and desolvation gas, and argon as collision gas in the 
MS/MS mode. Optimal tuning of capillary (3000V) and cone (20V) voltage, source 
(150°C) and desolvation (395°C) temperature, and collision energy was achieved by 




instrument in either of the following ways, depending on the experiment : (a) by 
continuous infusion from a syringe pump directly into the source or (b) by on-line coupling 
to the Hypersil BDS phenyl column. A suitable MS profile was used for the quadrupole 
when operated in the band-pass mode, emphasizing ion transmission for the lower mass 
region. All TOF measurements were performed at high resolution settings (5000 full width 
at half-maximum at mass 1500). The quadrupole was set up to pass precursor ions of 
selected mass to the hexapole collision cell, thus generating product ions that are further 
mass analyzed by the TOF (Figure 6.4). The so formed mass chromatograms were used for 
quantitation. To that end, selected single mass chromatograms were constructed for 4-
MTA and MDMA, whereas for phentermine a summed mass chromatogram was 
constructed (Table 6.4). Since the MS/MS spectrum is created by fragmentation simply 
and solely from the mass-selected [M+H]+ ion, an elimination of interfering ions is 
realized and clear MS/MS spectra are obtained. As the obtained selectivity was more than 
sufficient, the mass chromatograms were only reconstructed in low resolution from the 
available high resolution raw data. 
 
 
Table 6.4 MS/MS parameters. 
 4-MTA MDMA Phentermine 
Precursor mass 182.1 194.1 150.1 
Product mass 165.1 163.1 91+133.1 
Scan range (Da) 50-250 50-250 50-250 
Collision energy (eV) 11 15 13 
 
 
IV.4  Specimens 
Toxicological analyses were performed on blood collected from the subclavian vein, 
femoral vein, inferior vena cava, right and left atrium, and right and left ventricle. Other 
specimens that have been analyzed are urine, vitreous humour, serum (obtained from the 
subclavian blood), left and right lung, kidney, bile, liver, spleen, psoas muscle, cardiac 
muscle and several parts of the brain, such as the temporal lobe, the parietal lobe, the 
frontal lobe, the occipital lobe and the brainstem. All samples were stored in the freezer (-









































Figure 6.4 MS/MS spectra of phentermine (m/z 150.1 precursor mass), MDMA (m/z 194.1 




V Results and discussion 
V.1  Drug screening 
The routine screening of vena cava inferior blood and urine by immunoassay 
techniques disclosed the presence of amphetamines (only in urine, 4.5 µg/ml) and 
cannabinoids (32 ng/ml blood, 1.4 µg/ml urine) and, of toxicologically irrelevant levels of 
caffeine (1.62 µg/ml blood, 2.45 µg/ml urine) and cotinine (0.14 µg/ml blood, 4.16 µg/ml 
urine). The creatinine level in urine was 1.54 g/l. The analysis of blood and urine using 
general purpose HPLC-DAD, GC-NPD, and GC-MS methods confirmed the presence of 
4-MTA, MDMA and caffeine. Based on these findings, the dedicated, fully quantitative 
LC-MS/MS assay was used for all of the different specimens available.   
 
V.2  Analytical performance 
Calibration curves were constructed for 4-MTA and MDMA. The linearity range 
for 4-MTA varied from one matrix to another: for blood and urine it was established 
between 5-2500 ng/ml, and for kidney homogenate between 125-2500 ng/ml. For MDMA 
linearity was obtained between 5-250 ng/ml. As can be seen in Figure 6.5, for MDMA 
better correlation coefficients were obtained when excluding the three highest calibrators. 
This deviation from linearity can be attributed to the limited linear dynamic range due to 
possible depletion of the MS detector plate charge, effectively blinding the detector and 
leading to saturation of the ion counting electronics (11). The correlation coefficients in the 
different matrices ranged from 0.9987 (kidney homogenate) to 0.9992 (blood and urine) 
for 4-MTA and from 0.9967 (urine) to 0.9997 (kidney homogenate) for MDMA. The limit 
of detection (LOD), the lower limit of quantitation (LLQ), and the upper limit of 
quantitation (ULQ) for 4-MTA and MDMA were determined by analyzing respectively 
decreasing and increasing concentrations of the compounds added to the blank matrices. 
The LOD was established at the lowest concentration that produced a response of three 
times the background noise. The LLQ and ULQ were defined respectively as the lowest 
and upper concentration that could be quantified with an imprecision of <20%. These 











































Figure 6.5 Linear least-squares of standards for 4-MTA and MDMA in whole blood, urine, and 




Table 6.5 Validation parameters. 
 
4-MTA (ng/ml) Between-day reproducibility for 4-MTA (CV%) (n=5) 
 Blood Urine Tissue homogenate 
5 13,69 14,87 NA 
25 3,09 5,74 NA 
50 4,00 2,52 NA 
125 5,51 3,34 8,99 
250 6,05 2,10 9,03 
500 5,77 1,92 8,64 
1250 5,90 1,21 5,91 
2500 4,00 1,74 6,69 
 NA: not applicable   
    
MDMA (ng/ml) Between-day reproducibility for MDMA (CV%) (n=5) 
 Blood Urine Tissue homogenate 
5 10,47 3,78 9,09 
25 2,09 1,02 4,72 
50 4,47 3,52 4,17 
125 3,14 6,17 5,76 
250 6,68 6,07 3,99 
    
4-MTA  Detection and quantitation limits for 4-MTA (ng/ml) 
 Blood Urine Tissue homogenate 
LOD 2,5 2,5 50 
LLQ 5 5 125 
ULQ 2500 2500 2500 
    
MDMA Detection and quantitation limits for MDMA (ng/ml) 
 Blood Urine Tissue homogenate 
LOD 2,5 2,5 2,5 
LLQ 5 5 5 
ULQ 250 250 250 
 
 
V.3  Post-mortem findings 
4-MTA and MDMA were detected in all available autopsy specimens analyzed. 
The toxicological data of the samples taken during autopsy two days post mortem are 
presented in Table 6.6.  The 4-MTA and MDMA tissue/blood ratios are calculated using 
the mean of the subclavian and femoralis levels, resulting in 5.36 µg/ml and 12.15 ng/ml, 
respectively.  The subclavian 4-MTA and MDMA blood/serum ratios are 1.45 and 0.61, 
respectively. 4-MTA levels in blood and urine concurred with the values reported by 
Elliott (2). Based on these data and considering the autopsy findings, it can be concluded 
that a fatal cardiac arrhythmia induced by a 4-MTA intoxication should be assumed as a 
possible mechanism of death. In addition, lethal epileptic fits can not be excluded either; 






Table 6.6  Distribution of 4-MTA and MDMA. 
 
 
 4-MTA  
(µg/ml or µg/g) 
MDMA  





Blood subclavian vein 5.49 13.8 NA NA 
Serum subclavian vein 3.79 22.5 NA NA 
Blood femoralis vein  5.23 10.5 NA NA 
Blood inferior vena cava  6.39 11.8 1.19 0.97 
Right atrial blood 5.57 15.7 1.04 1.29 
Right ventricular blood 7.60 16.5 1.42 1.36  
Left atrial blood 5.16 12.9 0.96 1.06 
Left ventricular blood 8.20 18.1 1.53  1.49  
Urine 95.5 4932 NR NR 
Vitreous humour 1.31 67.6 0.24 5.56 
Left lung 16.4 59.1 3.06 4.86 
Right lung 16.7 68.6 3.12 5.65 
Kidney 2.88 32.7 0.54 2.69 
Bile 36.4 231.1 NR NR 
Liver 30.8 89.3 5.75 7.35 
Spleen 4.10 62.7 0.77 5.16 
Psoas muscle  5.79 31.6 1.08 2.60 
Cardiac muscle  6.32 48.2 1.18 3.97 
Brain: temporal lobe 34.5 82.1 6.44 6.76 
Brain: parietal lobe 35.0 96.3 6.53 7.93 
Brain: frontal lobe 31.7 76.6 5.91 6.31 
Brain: occipital lobe 36.5 89.3 6.81 7.35 
Brainstem 34.4 72.6 6.42 5.98 
 
 
1 Mean of subclavian blood and femoralis blood for 4-MTA: 5.36 µg/ml 
2 Mean of subclavian blood and femoralis blood for MDMA: 12.15 ng/ml 
NA : not applicable 
NR : not relevant 
 
 
Referring to the 4-MTA levels following remarks can be made.  The femoralis 4-
MTA blood level is the lowest peripheral, although there is only a slight difference with 
the subclavian blood concentration (a difference of 0.260 µg/ml).  The importance of 
peripheral blood specimens has previously been emphasized (13).  However, since the 4-
MTA blood levels in the cardiac ventricles in this case approach the subclavian and 
femoral concentration, these sampling sites could be considered for 4-MTA determination 
when peripheral samples are completely lacking. On the other hand, atrial blood samples 
should definitely be avoided.  The high 4-MTA blood concentration in the right atrium can 




levels in liver and bile are indeed 6 to almost 7 times higher than the peripheral blood 
concentration. The liver 4-MTA concentrations are in accordance with those reported in 
fatal PMA (para-methoxyamphetamine)-intoxications (14).  4-MTA is indeed structurally 
closely related to PMA.  In our case, the left atrial 4-MTA blood concentration is even 
more increased than the right one and can be correlated to diffusion out of the lungs.  The 
lungs indeed do show levels which are almost 3 times higher than those in the peripheral 
blood.  On the other hand, 4-MTA levels in cardiac and skeletal muscle are only slightly 
higher than the peripheral blood concentrations, which might indicate that 4-MTA does not 
tend to bind at these tissues.  The subclavian blood/serum ratio may point to a certain 
accumulation of 4-MTA in red blood cells.  The urinary 4-MTA concentration should 
probably be interpreted in light of the pH (= 5.6).  Indeed, as for amphetamine and d-
methamphetamine, the urinary excretion is pH-dependent, and it has previously been 
established that acidification increases the level found (15).  In addition, in view of the 
important 4-MTA concentration in the liver and the bile, this might indicate that 4-MTA is 
eliminated by excretion via the bile.   
4-MTA levels in the various lobes of the brain and the brainstem are similar.  Since 
the brain is the target organ, these high 4-MTA levels are in line with the expectations.  
Although it is not clear whether the man died during the distribution or the elimination 
phase, the very low vitreous humour concentration can indicate that the 4-MTA 
distribution has not yet been fully completed.  However, it is not known whether 4-MTA 
can easily pass through the blood-retinal barrier. 
The distribution of MDMA in this case is not fully comparable with the findings for 
4-MTA.  The difference between the subclavian and femoral vein concentration of MDMA 
is somewhat more pronounced.  The atrial and ventricular MDMA blood levels can be 
explained similarly to the corresponding 4-MTA concentrations.  However, the majority of 
the MDMA organ/blood ratios are higher than the corresponding 4-MTA ratios.  Muscle 
MDMA concentrations are increased compared with the blood levels determined.  The 
MDMA blood/serum ratio neither is comparable.  In addition, a blood/serum ratio lower 
than one is rather surprising.  However, hemolysis could partially account for this ratio in 
the low concentration range.  Similar to 4-MTA, the MDMA levels in the brain are high 
but in contrast with the corresponding 4-MTA levels, these show more regional variations.  
The high MDMA vitreous humour level is in contradiction with rabbit experiments where 
a good correlation between the vascular compartment and the vitreous humour was 
established: the MDMA vitreous humour to blood ratio was 1.1 in the distribution and 
elimination phase (16). 
Considering the 4-MTA and MDMA concentrations on the whole, it might be 
suggested that the MDMA has been ingested earlier than 4-MTA. 
Based on the presented data, unequivocal statements on similarity in the 
distribution of both  4-MTA and MDMA cannot be made.   
The extensiveness by which this case has been examined, could in one respect be of 
interest in forensic science, particularly when blood samples are not available, and in 
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We present a fatal case involving the combined ingestion of amphetamine (AMP), 
3,4-methylenedioxymethamphetamine (MDMA, ecstasy), 3,4-methylenedioxy-
amphetamine (MDA), and para-methoxyamphetamine (PMA, streetname: death). Various 
post-mortem specimens, e.g. several blood samples, urine, and tissue samples, were 
analysed  to study the distribution of the compounds and their metabolites in the human 
body. Quantification took place using liquid chromatography-sonic spray ionization-mass 
spectrometry (LC-SSI-MS), after pretreatment with a liquid-liquid extraction (LLE). The 
medico-legal findings were compatible with a disseminated intravascular coagulation 
(DIC) induced by hyperthermia, due to the simultaneous intake of the amphetamine 
analogues.  
 
II Introduction  
The amphetamine-based designer drugs, especially popular in the “rave” 
environment, like clubs or dance parties, have always been a great challenge for forensic 
toxicologists. In an effort to keep up with the clandestine drug laboratories we are forced to 
keep our eyes open for very fast changes in the molecular structure of the basic drug. 
Hence, we are strained to continuously search for the unknown.  
A recent evolution in this field was the introduction of para-methoxyamphetamine 
or PMA on the Belgian illicit drug market (1). However, this methoxylated 
phenylethylamine derivative (molecular formula: C10H15NO, Figure 6.6) was already sold 
on the street during the 1970s. Within a few years, the drug was associated with several 
fatalities and earned the street-name “death”, which led to its temporary disappearance 
from the drug scene (2). In the beginning of the nineties it first re-emerged in Australia, 
again leading to a number of fatal cases (3-5). Later, in 1998, it was spotted on the 
















Figure 6.6  Structural formula of para-methoxyamphetamine (PMA) and 3,4-methylenedioxy-




As its structurally related compounds MDA (3,4-methylenedioxyamphetamine), 
MDMA (3,4-methylenedioxymethamphetamine, Figure 6.6), and MDEA (3,4-
methylenedioxyethylamphetamine), PMA exhibits hallucinogenic properties. However, it 
has been postulated that it is more toxic than MDMA because of its potent effect on the 
serotonergic transmission (7). Furthermore, PMA is closely related to another new ring-
substituted amphetamine, 4-MTA (4-methylthioamphetamine) which was also identified in 
a few fatalities (9-11).  Doses of less than 50 milligrams of PMA, without co-ingestion of 
other drugs or alcohol, induce symptoms similar to MDMA, like increased heart rate, 
blood pressure, and respiratory rate, elevated body temperature, erratic eye movements, 
muscle spasms, nausea, and visual hallucinations. Higher doses are considered lethal, 
certainly when taken with other amphetamine derivatives, cannabis, cocaine, prescription 
medication or alcohol. Symptoms in severe intoxications can be cardiopulmonary related 
(e.g. cardiac arrhythmia, pulmonary oedema), but vomiting, renal failure, hyperthermia, 
convulsions, and coma prior to death can also occur (7). The drug is sold in tablets, 
capsules, or powder form, and its appearance and cost are comparable to MDMA. Analysis 
of tablets revealed that “ecstasy” tablets can contain not only PMA but also PMMA (para-
methoxymethamphetamine) (12). Because of its great similarity with the popular and well-
known MDMA it has been mistakenly ingested as “ecstasy”, with sometimes lethal 
consequences. In the last few years, an increasing number of fatal intoxications involving 
PMA have been reported (1, 3-8). However, to our knowledge, data on PMA tissue 
concentrations are scarce (13). 
We present a fatal case of the combined use of amphetamine, MDMA, MDA, and 
PMA. The complete toxicological findings of the specimens, analysed by LC-SSI-MS after 
appropriate liquid-liquid extraction, are presented and the distribution of the drugs is 
discussed. To the best of our knowledge, post-mortem drug distribution of PMA in 
combination with MDMA has barely been explored in humans. 
 
III Case history 
A 23-year-old man was found dead at home, lying in a divan. It was warm in the 
room and the ambient temperature was about 25°C.  The man was naked and his clothes 
were close nearby as if he had just undressed. The rectal temperature had reached the 
ambient temperature. The lividities were fixed, the rigor mortis had almost disappeared and 
greenish coloration of the whole abdominal wall was noticed. Slight mummification of 
lips, nose tip, fingers and toes was found. The eyeballs were depressed and dehydrated. 
These findings, correlated with the police information, revealed that the post-mortem 
interval was about three days. The man was very tiny: the body weighed 56 kg and was 
175 cm tall (body mass index: 18.3). The face showed no petechiae. Apart from a few 
slight recent excoriations on the arms, consistent with slight blunt trauma (e.g. fall or 
blow), nothing unusual was observed.   
During internal inspection, moderate putrefaction and congestion of all organs was 
found.  Both lungs weighed 1410 g and showed obvious congestion and distinct oedema. 
The left and right pleural cavity contained about 150 and 100 ml bloody fluid, respectively. 




315 g and showed - apart from a few Tardieu spots - macroscopically no anomalies.  The 
liver weighed 1160 g and slight steatosis, confirmed by microscopical inspection, was 
found.  The stomach and the bladder contained about 50 ml brown-greenish fluid and 200 
ml clear yellow urine, respectively.  The fresh brain weighed 1405 g and on dissection 
after fixation congestion and oedema were found. Microscopical study of the organs 
confirmed the generalized congestion and obvious signs of shock were found (such as 
leucocyte sludging, micro-emboli) - mainly in the sections of the heart, lungs, liver, kidney 
and brain. Eosinophilic cylinders were seen in the renal tubuli, but myoglobin 
immunostaining was negative. The medico-legal findings were consistent with 
disseminated intravascular coagulation (DIC) induced by hyperthermia.  
 
IV Experimental 
IV.1  Materials 
Para-methoxyamphetamine (PMA) was synthesized in-house according to a 
described procedure (14). 3,4-Methylenedioxymethamphetamine (MDMA or ecstasy) and 
3,4-methylenedioxyamphetamine (MDA) were purchased from Sigma-Aldrich (Bornem, 
Belgium). Amphetamine and ephedrine (internal standard) were available from the 
collection of our laboratory and also came from Sigma-Aldrich (Bornem, Belgium). All 
reagents and chemicals were of analytical grade (Merck-Eurolab Leuven, Belgium). 
Solvents were all of HPLC gradient grade, also purchased from Merck-Eurolab (Leuven, 
Belgium).  
An individual standard solution of 1 mg/ml of each compound was prepared in 
methanol and stored in the dark at -20°C until use. Under these conditions all solutions 
proved stable for more than six months. A 2-µg/ml solution of internal standard, ephedrine, 
in methanol was also prepared. We decided to use this compound because of its structural 
similarity and its sufficient separation from the amphetamine mixture.  
 
IV.2  Analysis of biochemical parameters in vitreous humour 
Glucose, lactate and potassium were determined in vitreous humour using 
enzymatic tests and specific electrodes on a routine automatic analyzer instrument. 
 
 IV.3  Drug screening 
Routine systematic toxicological analysis was performed on the samples to 
investigate for illegal drugs, medical drugs, alcohol, volatile substances and other poisons. 
Immunoassay screens (ADx) were performed to test for amphetamines, cannabinoids, 
opiates, methadone and benzoyl ecgonine on urine, and barbiturates and tricyclic 
antidepressants in blood. Radio-immunoassay (RIA) was used to screen for LSD in urine, 
and for morphine and benzodiazepines in blood. Color spot tests on urine and gastric 
content were used to detect salicylates, acetaminophen, phenothiazines and imipramines. 
Post-mortem blood was analysed for the presence of carboxyhaemoglobin and cyanide. 
Gastric content and urine were screened for the presence of basic drugs, and hydrolysed 
benzodiazepines; blood for the presence of acidic and neutral drugs by thin-layer 




derivatization, and GS-MS quadrupole with TFA/BSTFA derivatization (trifluoroacetic 
acid/N,O-bis(trimethylsilyl)trifluoroacetamide) was used to screen the urine and the gastric 
content for the presence of basic drugs. Blood was screened by high performance liquid 
chromatography with photodiode-array detection (HPLC/DAD). Analysis for the presence 
of alcohol and other volatile substances in blood and urine was performed by headspace 
gas chromatography with a flame ionization detector (GC/FID) (10). 
 
IV.4  LC-MS instrument 
Chromatography was carried out using a LaChrom separation module (Merck, 
Darmstadt, Germany) including a L-7100 Low-Pressure Gradient Pump, L-7200 
Autosampler (injection loop 100 µL), L-7360 Column Oven, and D-7000 Interface. The 
system uses the LC/3DQ-MS System Manager Software running under Windows NT TM 
version 4.0 on a Compaq Deskpro EN.  
All MS experiments were carried out on the M-8000 ion-trap based mass 
spectrometer from Merck (Darmstadt, Germany) equipped with an on-axis sonic spray 
interface (SSI) operated in positive ion mode.  
 
IV.5  Method 
IV.5.1  Sample pretreatment  
Blood and urine were not pretreated. Tissue samples were homogenized after 
appropriate dilution with water using an Ultra-Turrax homogenizer from IKA (Staufen, 
Germany). Most of the post-mortem samples were extracted according to a liquid-liquid 
extraction procedure previously developed in our laboratory (15). However, for the more 
complicated (greasy or degraded) matrices such as adipose tissue, stomach content, and 
different brain parts a liquid-liquid extraction with back-extraction was applied (16).  
 
IV.5.2  Liquid chromatography-mass spectrometry 
Chromatographic separation was achieved on a Hypersil BDS phenyl column (100 
x 2.1 mm i.d., 3-µm particle size) protected by a Hypersil BDS phenyl guard column (7.5 x 
2.1 mm i.d., 3-µm particle size), purchased from Alltech (Lokeren, Belgium). A gradient 
program with water and acetonitrile, both containing 0.001 vol% formic acid was used. 
The complete and detailed LC-SSI-MS method is described in a previous paper (17).  
 
IV.6  Specimen collection 
Toxicological analyses were performed on blood collected from the subclavian 
vein, femoral and iliac vein, inferior vena cava, right atrium, aorta ascendens, pulmonary 
artery, and right and left pulmonary vein. Left atrial and ventricular blood (right and left) 
were not available. Other specimens analysed included urine, vitreous humour, pericardial 
fluid, bile, stomach content, liver, spleen, iliopsoas muscle, abdominal adipose tissue. For 
pleural fluid, cardiac muscle, lungs and kidneys separate sampling of the left and the right 
occurred.  In addition, brainstem, cerebellum, and brain lobes were sampled. All samples 





IV.7  Calibration 
Calibration curves were prepared in blank matrices of blood, urine, brain 
homogenate and  liver. Each calibrator sample (1 ml) was spiked with 50 µl of the 2-µg/ml 
internal standard solution and with the compounds of interest, resulting in a final 
concentration of 10-1000 ng/ml (blood and urine) and 20-2000 ng/ml (tissues).  The spiked 
compound levels for each calibration graph were 0.1, 0.4, 1.0, 2.0, 4.0, and 10.0 µg/ml, 
respectively, for each matrix.  After extraction of a 1-ml aliquot of each sample according 
to the previously mentioned liquid-liquid extraction (see above), samples were analysed 
and calibration curves were created using quadratic regression analysis (in view of the 
limited linear dynamic range of the mass analyser). Quantification of the autopsy samples 
was performed by comparing the peak-area ratio of each specific compound and the 
internal standard against the calibration curve.  All samples were analysed twice. First, 1 
ml of the available post-mortem matrix (blood and urine) was spiked with the internal 
standard solution and analysed. Following these preliminary results, a second extraction 
was performed on appropriately diluted sample specimens.  
 
V Results and Discussion 
V.1  Routine biochemical parameters 
The urinary pH and creatinine concentration in this case were 7.5 and 0.3 g/l, 
respectively. The potassium level in the vitreous humour was 38.9 mmol/l.  The vitreous 
glucose and lactate concentrations were 3 and 309 mg/dl (sum value of 312 mg/dl), 
excluding  hypoglycaemia.  
 
V.2  Drug screening 
The initial drug screening (including GC-MS) revealed the presence of MDMA in 
blood and urine and amphetamine in urine. In addition, nicotine and caffeine were detected 
in blood and urine.  The results of the screening tests for the presence of other relevant 
drugs or medications were all negative. 
GC-MS analysis showed a small broad peak with a mass spectrum corresponding to 
PMA.  However, this was initially considered as non-toxicologically relevant because the 
peak area/height was relatively low and it was thought to be a methylated artefact of a p-
hydroxylated metabolite of amphetamine. 
 
V.3  Liquid chromatography-mass spectrometry 
The LC-SSI-MS method was completely validated and proved to fulfil analytical 
standard criteria (17).  
The toxicological findings for amphetamine, MDMA, MDA, and PMA in the 
different autopsy samples are summarized in Table 6.7.  The ratios of vitreous humour to 







Table 6.7  Distribution of PMA, MDMA, MDA, and AMP. 
 PMA MDMA MDA AMP 
 (µg/ml)* (µg/ml)* (µg/ml)* (µg/ml)* 
subclavian blood 2.012 1.917 0.614 0.239 
femoral blood 1.634 1.129 0.436 0.198 
vena iliaca blood 1.618 1.421 0.493 0.203 
inferior vena cava blood 2.058 1.801 0.507 0.218 
right atrial blood 2.058 1.624 0.574 0.248 
pulmonary artery blood 2.952 2.212 0.475 0.279 
left pulmonary vein blood 2.120 1.693 0.526 0.261 
right pulmonary vein blood 2.427 1.941 0.610 0.329 
aorta ascendens blood 2.031 1.726 0.558 0.252 
right pleural fluid  1.794 1.375 0.446 0.207 
left pleural fluid 3.814 3.243 0.912 0.450 
pericardial fluid 2.373 2.335 0.615 0.318 
vitreous humour 2.101 1.633 0.577 0.292 
urine 0.932 0.791 0.369 0.522 
bile 50.012 25.420 11.655 9.425 
muscle of the right cardiac ventricle  2.176 1.650 0.469 0.235 
muscle of the left cardiac ventricle  2.422 1.815 0.293 0.290 
right lung:upper lobe 4.614 2.580 0.925 0.592 
right lung:median lobe 4.460 2.535 1.023 0.693 
right lung:lower lobe 3.164 1.281 0.676 0.395 
left lung: upper lobe 3.742 2.138 0.661 0.475 
left lung:lower lobe 4.390 2.358 0.875 0.543 
liver 8.904 6.657 0.744 0.857 
stomach content 73.103 33.168 14.308 5.478 
right kidney 5.669 4.058 3.888 0.746 
left kidney 4.716 3.411 2.891 0.534 
spleen 4.390 3.050 1.454 0.666 
iliopsoas muscle  1.654 1.528 0.592 0.221 
abdominal adipose tissue 0.131 0.317 0.044 0.067 
brain:   frontal lobe 4.081 2.258 0.919 0.330 
           temporal lobe 4.188 2.289 1.035 0.358 
           parietal lobe 4.040 2.514 1.026 0.773 
           occipital lobe 3.357 1.932 0.918 0.910 
brainstem 3.200 1.951 0.761 0.346 
cerebellum 2.371 0.978 0.491 0.664 








V.4  Combined discussion of post-mortem findings and toxicological / biochemical 
 data 
Referring to the situation on the scene and the autopsy findings, the mechanism of 
death is consistent with a DIC due to hyperthermia. Even in the seventies, the hyperthermic 
effect of PMA has been investigated, and in mice, it was found that this effect was not as 
pronounced as for 3,4-methylenedioxyamphetamine (MDA)(18). Hyperthermia was a 
frequently seen symptom in patients who presented to the Emergency Department after 
ingestion of PMA (19) and was also described in a few fatalities (4). In addition, 
hypoglycaemia and hyperkalaemia have been described as typical in PMA intoxications 
(19). Analysis of the vitreous humour in our case revealed a high potassium level. This 
value could reflect an ante-mortem hyperkalaemia but - referring to the post-mortem 
interval of about 3 days (20) and the dehydration of the eyes - this potassium concentration 
should be interpreted with caution. The glucose and lactate sum value of 312 mg/dl as such 
is not consistent with hypoglycaemia. According to the study of Sippel and Möttönen, sum 
values lower than 160 mg/dl are compatible with a hypoglycaemia (21). However, in cases 
experiencing a prolonged and/or intense agony, high sum values were noticed (22) and as a 
result, the sum value in this case can be correlated to the DIC due to hyperthermia as the 
mechanism of death.     
As for MDMA, there is no consensus about the lethal blood level but in general, a 
blood MDMA concentration higher than 1.0 µg/ml can be potentially lethal (23). For 
PMA, blood levels greater than 0.5 µg/ml are likely to induce toxic effects (3). We believe 
that in our case - referring to the considerable MDMA and PMA levels in particular – both 
concentrations are definitely capable of inducing death. In the cases published by Byard et 
al.  PMA blood levels between 0.24 and 4.9 µg/ml were found (5). A PMA blood level up 
to 5.7 µg/ml has even been reported (6). 
Only after incorporation of the LC-MS technique, it became clear that the peak and 
also the concentration of PMA was toxicologically relevant.  The poor gas 
chromatographic properties of PMA resulted in a broad peak.  This was eliminated by the 
LC-MS procedure where it became clear that substantial amounts of PMA were present in 
various matrices. 
In this case, the body distribution of the four amphetamine related drugs was fairly 
comparable (Table 6.7). Our data also confirm that blood sampled from the femoral vein 
should be considered as the preferred anatomical site for blood sampling. However, when 
this sample is not available, blood from the nearby iliac vein is also appropriate. A gradient 
from the inferior vena cava and the iliac vein to the femoral vein was noticed. This 
“diffusion gradient” can be explained by the relatively high levels in the liver.  The huge 
concentrations in the bile are consistent with the excretion via the bile and are also 
indicative of a relatively long survival period after intake. However, it is not excluded that 
some post-mortem diffusion from the very high concentration in the stomach content could 
account for the latter as well. The relatively high levels in the spleen can be correlated with 
the “reservoir” of amphetamines found in the closely adjacent stomach content. The high 




blood and tissue concentrations can only partially be explained by the metabolism of 
MDMA to MDA.  
Due to the degree of putrefaction, there were only a few cardiac blood samples 
available.  However, considerable levels of all four amphetamines were found in the 
pericardial fluid. Just as for the pleural fluid, this can in part be explained by post-mortem 
diffusion out of the lungs. The higher concentrations in the left pleural fluid (as compared 
with the right) can be explained by diffusion out of the stomach, which was previously also 
postulated for co-proxamol (24). The levels in the pulmonary veins can be correlated to the 
concentrations of the adjacent lung lobes. The concentrations in the right atrial blood were 
in accordance with the levels in the cardiac muscle.  The concentrations in the iliopsoas 
muscle were fairly comparable with the peripheral blood samples and therefore this muscle 
specimen can be interesting when a blood sample is lacking (e.g. due to fulminant blood 
loss or due to putrefaction). 
The ratio of vitreous humour to femoral blood concentration of the four substances 
were fairly comparable. In an experiment in rabbits, the ratio of MDMA vitreous humour 
to blood levels at equilibration was 1.1 (25).  The fact that the ratios in this case were 
somewhat higher than one can probably be explained by a dehydration factor. Indeed, the 
vitreous humour sample which was taken from both eye balls was in this case hardly 1 ml. 
Normally, each eye of an adult contains about 3.9 ml of vitreous humour (26). The 
concentrations in the brain lobe homogenates are fairly comparable. The high brain levels 
are consistent with the described clinical symptoms (such as hyperthermia) related to the 
central effects. Considerable brain levels of PMA and MDMA were also previously 
substantiated (13, 16).  
The urinary levels were relatively low, but this may be explained by the alkaline pH 
(7.5).  Indeed, for amphetamine it has been established that acidification of the urine 
enhances excretion up to about 75 % but alkalinization can reduce recovery in urine to 
about 1 % (27). This was postulated for PMA as well (28). However, it is not known when 
and how many times prior to death, the person was urinating. In addition, for PMA it was 
shown that in humans an average of 15 % is eliminated as unchanged drug (39). 
These data also confirm that the concentrations of amphetamine derivatives  in 
adipose tissue are very low (16). 
 
VI Conclusion 
In summary, a fatal poisoning in which considerable blood levels of MDMA and 
PMA were found, is presented. We conclude that the man died of disseminated 
intravascular coagulation (DIC) - induced by hyperthermia – due to the combined ingestion 
of amphetamines. In addition, the post-mortem distribution of these amphetamine 
derivatives in the human body was discussed and further supported the use of peripheral 
blood for toxicological interpretation.  
The results also indicate that due to the poor gas chromatographic properties of 
PMA under specific conditions, this compound could be erroneously overlooked. 




chromatography and high performance liquid chromatography can reveal the presence of 
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Abuse of amphetamine derivatives such as 3,4-methylenedioxymethamphetamine 
(MDMA) and 3,4-methylenedioxyamphetamine (MDA) is an important issue in current 
forensic practice and fatalities are not infrequent.  Therefore, we investigated an 
immunohistochemical method to detect the amphetamine analogues MDMA  and MDA  in 
human tissues.  For the staining procedure, the Catalysed Signal Amplification (CSA) 
method using Peroxidase (HRP) - provided by Dako® - and specific monoclonal antibodies 
were used.  Appropriate controls for validation of the technique were included.   
The distribution of these designer drugs was studied in various brain regions 
including the four lobes, the basal ganglia, hypothalamus, hippocampus, corpus callosum, 
medulla oblongata, pons, and cerebellar vermis.  In addition, the pituitary gland was 
investigated.  A distinct positive reaction was observed in all cortical brain regions and the 
neurons of the basal ganglia, the hypothalamus, the hippocampus and the cerebellar vermis.  
In the brainstem, relatively weak staining of neurons was seen. The reaction presented as a 
mainly diffuse cytoplasmic staining of the perikaryon of the neurons, and often axons and 
dendrites were also visualised.  In addition, the immunoreactivity was present in the white 
matter. In the pituitary gland, distinct immunopositive cells were observed, with a prominent 
heterogeneity, however.  The immunohistochemical findings were supported by the 
toxicological data.   
This immunostaining technique can be used as evidence of intake or even poisoning 
with MDMA and/or MDA and can be an interesting tool in forensic practice when the usual 
samples for toxicological analysis are not available.  Furthermore, this method can be used 
to investigate the distribution of these substances in the human body.   
 
Key words: 3,4-Methylenedioxymethamphetamine (MDMA) - 3,4-Methylenedioxy-
amphetamine (MDA) – Immunohistochemistry - Human brain - Pituitary gland 
 
II Introduction 
Abuse of amphetamine and derivatives is an important problem in current forensic 
practice.  Moreover, fatal and nearly-fatal intoxications are not infrequent (1).  Post-mortem 
distribution has barely been explored for amphetamine analogues, except for some case 
reports (2-6).  Animal experiments considering this item for amphetamine or analogues are 
scarce  (7-9). 
Immunological methods are routinely used for detection of illegal drugs in clinical 
and forensic toxicology, mainly in urinary screening tests.  However, the principle of  
antigen-antibody recognition can also be applied in histological specimens 
(immunohistochemistry), allowing detection of drugs in tissue sections.  
Immunofluorescence procedures have previously been applied successfully in animal 
experiments e.g. detection of morphine in rat tissues (10), demonstration of 
tetrahydrocannabinol (11) and phenobarbital (12) in mice tissues.  Immunohistochemical 
demonstration of morphine and methadone in brain sections of overdose victims has 





Part of the behavioural, psychotomimetic and neurochemical effects of MDMA (e.g. 
increase of body temperature, mood alterations, anxiolytic-like effects) may be explained 
by affecting the serotonergic system (18,19).  Interaction of MDMA with post- as well as 
pre-synaptic 5-hydroxytryptamine (5-HT, serotonin) recognition sites is postulated (18).  In 
animal studies, high affinity of MDMA for 5-HT2 and 5-HT1A serotonin receptors (18) as 
well as 5-HT uptake sites was proven (20).   The neurotoxicity of MDMA on 5-HT neurons 
was also investigated in humans and subtle, but significant cognitive deficits were noticed 
(21).  
At present, immunohistochemical methods were used to investigate the biological 
effects of MDMA, for example, to demonstrate reductions in 5-HT axon density in rats and 
monkeys (22) or rhabdomyolysis (4,23).  Ishiyama et al. were able to demonstrate 
methamphetamine in mice tissues (24).  To our knowledge, the amphetamine derivatives 
3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine 
(MDMA, “ecstasy”) have not yet been demonstrated in human tissues.  
In this study, we applied the CSA immunostaining method - known as the most 
sensitive method at present - for the microscopical immunodetection of MDMA and MDA.  
In particular, the distribution of MDMA and MDA in slides of the human brain and the 
pituitary gland of two fatal intoxications was investigated and correlated with the 
toxicological findings.   
 
III Materials and methods  
III.1  Brief Case histories 
III.1.1  Case 1 
A 23-year-old man was found dead, sitting on a chair in a bar.  Upon examination, 
28 hours after death, the body was 186 cm tall and weighed about 100 kg.  No conspicuous 
lesions neither injection sites were noticed.  At autopsy, both lungs weighed 1620 g.  
Severe pulmonary congestion and oedema, numerous Tardieu spots on the pleurae and the 
pericardium were noticed.  The heart weighed 405 g and a persistence of the left vena cava 
superior was found.  The brain weighed 1545 g and congestion and oedema were confirmed 
by histological examination.  The macro- and microscopical findings were consistent with 
an acute to subacute cardiopulmonary failure as the mechanism of death.   
MDMA and MDA concentrations were determined in femoral blood and brain using 
a HPLC (high pressure liquid chromatography) procedure with fluorescence detection 
(25,5). For additional confirmation, a fully quantitative LC-MS (liquid chromatography-
mass spectrometry) assay for the determination of all specimens available, was used. 
Cocaine, benzoylecgonine, cocaethylene, ecgonine methylester, amphetamine, MDMA, 
MDEA (3,4-methylenedioxyethylamphetamine) and MDA were detected using 
chromatographic analysis (HPLC-DAD (HPLC with diode array detection), LC-MS, GC-
NPD (gas chromatography with nitrogen-phosphorus detection) and GC-MS of the urine 





III.2.2  Case 2 
This 23-year-old man was found dead at home.  He was naked and his clothes were 
nearby the body (as if he just undressed).  The body was in a state of beginning putrefaction 
and the cadaveric signs combined with the police inquiry revealed that the post-mortem 
interval was about 3 days.  The body weighed 56 kg and was 175 cm tall.  At autopsy, both 
lungs weighed 1410 g and showed obvious congestion and oedema. Apart from congestion 
and moderate putrefaction, the other organs showed no conspicuous anomalies. The heart 
and brain weighed 315 and 1405 g, respectively.  Microscopical examination confirmed the 
general congestion and revealed signs of shock (such as leucocyte sludging, micro-emboli), 
mainly in the sections of  the heart, lungs, liver, kidneys and brain.  Eosinophilic cylinders 
were found in the renal tubuli, but myoglobin staining was negative.  In several brain 
regions, apart from congestion and oedema, small – mainly perivascular – bleedings were 
found.  The medico-legal findings were consistent with a disseminated intravascular 
coagulation (DIC) induced by hyperthermia. 
Amphetamines and related compounds were screened by routine methods such as  
GC-MS and HPLC-DAD, while quantitative results were obtained by GC-MS and LC-MS.  
 
For both fatalities, since drug abuse was suspected, the standard protocol used at our 
department was applied and appropriate sampling for toxicological and histological 
examination was performed.  Small parts of the four brain lobes were sampled for drug 
assay and for each lobe, cortex and medulla were isolated.  Thereafter, the brain was fixed 
in 4 % buffered formaldehyde during three to four weeks.  On dissection, samples of 
various brain regions were taken, followed by embedding in paraffin.  Tissue sections were 
prepared from the frontal, temporal, parietal and occipital region, the medulla oblongata, 
pons, cerebellar vermis, corpus callosum, hippocampus, the basal ganglia (mammillary 
bodies, lentiform nucleus, caudate nucleus and thalamus) and adjacent hypothalamus.  The 
pituitary gland was treated in the same way.   
All similar samples in the control case 00/116 were taken as blanks for drug assay 
and negative control tissue for immunohistochemistry.  At random samples of other control 
cases for immunohistochemistry were also available. 
 
III.2  Antibodies and immunostaining procedure 
III.2.1  Staining procedure 
Monoclonal antibodies – which specifically recognize MDMA and MDA - were 
kindly supplied by Microgenics Corp, Fremont, CA, USA.  They were purified from mouse 
ascites and available in two clones (clone 1A9 and 5C2).   
For the staining procedure, the DAKO® Catalysed Signal Amplification (CSA) 
System, Peroxidase (HRP) was used (supplied as a kit; Code K 1500).  CSA is a very 
sensitive immunohistochemical staining procedure incorporating a signal amplification 
method based on the peroxidase catalyzed deposition of a biotinylated phenolic compound, 
followed  by a secondary reaction with streptavidin-peroxidase (28).  Sections were 
deparaffinized and rehydrated according to standard protocols.  After blocking endogenous 




the primary monoclonal mouse antibodies were applied to the tissues and an incubation of 
15 minutes followed.  For the primary antibodies dilution series ranging from 1:20 to 
1:5000 were tested.  The best results were obtained with dilutions between 1:500 and 
1:1000.  The slides were then gently rinsed with TBST buffer solution (Tris Buffered Saline 
with Tween 20) and three times placed in a fresh TBST buffer bath for 3 – 5 minutes each.  
The procedure was then continued by sequential 15-minute incubations with biotinylated 
link antibody, streptavidin-biotin complex, amplification reagent and streptavidin-
peroxidase, respectively. The staining was completed by a 3 to 5-minute incubation with 
3,3’-diaminobenzidine tetrahydrochloride (DAB) which results in a brown-coloured 
precipitate.  Hematoxylin counterstain was sometimes performed (e.g. in the pituitary gland 
in order to visualize the basophilic cells). 
For the pituitary gland, a Periodic Acid Schiff (PAS)-orange G-staining on an 
immediately adjacent slide was performed in order to discern the cell subtypes of the 
pituitary gland (acidophils, basophils and chromophobes).  
 
III.2.2 Setup of the immunohistochemical procedure 
In all staining experiments of the two amphetamine fatalities, a simultaneous 
incubation was performed with analogue sections from control cases. 
Similar samples were taken during the autopsy of a 28–year-old woman (case 
number 00/116; post-mortem interval (PMI) of 48 h) for negative control tissue.  The 
woman was murdered by a shotgun lesion through heart and lungs.  In a few staining 
procedures, at random samples of five other control cases were used.  These were a 32-
year-old female, murdered by thoracic gunshot wounds (case number 00/8; PMI of 36 h), a 
27-year-old female, murdered by multiple stab wounds (case number 00/14; PMI of 56 h), a 
26-year-old man, murdered by a gunshot through the heart (case number 00/19; PMI of 42 
h), a 17-year-old man, who died due to polytrauma after a traffic accident (case number 
01/68, PMI of 91 h), and a 30-year old female, murdered by multiple stab wounds in thorax 
and neck (case number 01/181; PMI of 58 h).   In all control cases, extensive toxicological 
investigations were negative. 
A positive control staining (recommended in the CSA-kit) with monoclonal mouse 
antibodies to human B-cell (CD231) on formalin-fixed and paraffin-embedded lymph node  
(from a patient with malignant B-cell lymphoma) and palatine tonsil tissue was performed.  
At the same time, as an additional negative control, the staining procedure with IgG1 
fraction from normal mouse (provided in the kit) and with the antibodies recognizing 
MDMA and MDA on adjacent sections of the lymph node and palatine tonsil, was applied. 
In order to test the specificity of the antibodies, we checked whether it is possible to 
saturate the antibody binding sites with its specific antigens and thus induce a negative 
immunodetection.  Therefore, either MDMA or MDA were added in various concentrations 
(dilution solution series from 10-12 g/ml to 1.5 x 10-3 g/ml) to the antibody solution.  This 
solution was placed on a rotary mixing device during 24 hours (at 4°C) prior to incubation 
of the slides.  The same procedure was performed using PMA (para-methoxyamphetamine) 
or AMP (amphetamine). For negative control incubations, the antibody was replaced by 




A few at random negative controls were performed in which phosphate buffered saline 
(PBS) or bidistillated water (used to make the MDMA or MDA solutions) were used 
instead of the primary antibody.     
To exclude that MDMA, added to the antibody solution and acting as a salt, would 
prevent antigen-antibody binding, an excess of MDMA was added to antibody solutions in 
an other immunodetection protocol.  It concerned the immunodetection of two peroxisomal 
enzymes [catalase (CAT) and alanin-glyoxylate aminotransferase (AGT)]  in liver slides of 
case and control (29). 
 
IV Results 
IV.1  Immunohistochemistry 
An overview of the immunohistochemical results is presented in Table 7.1.  Positive 
immunoreactions were obtained in the neurons of all brain regions of both fatalities, except 
for the corpus callosum due to the absence of neuronal cell bodies at that particular site.  A 
distinct positive reaction was seen in all cortical regions of the brain lobes, the neurons of 
the basal ganglia, and the cerebellar vermis.  Relatively weak staining of the neurons of the 
brainstem was found.  In addition, distinct reactivity was also observed at the level of the 
white matter fibres in the slides of the basal ganglia, the brainstem and corpus callosum in 
both cases.  A rather weak immunoreactivity of the white matter in the cerebral lobes was 
noticed; this is a discrepancy with the results from chromatographic analysis in the 
homogenates (see toxicological data below).   
 
 
Table 7.1 Immunoreaction in neurons of various brain regions in fatalities and control cases. 
 
brain region case 1 (00/112) case 2 (01/34) control cases 
 neurons neurons neurons 
frontal lobe + + - 
parietal lobe  + + - 
temporal lobe + + - 
occipital lobe + + - 
caudate nucleus + + - 
thalamus + + - 
lentiform nucleus + + - 
medulla oblongata ± ± - 
pons ± ± - 
vermis cerebelli + + - 
mammillary bodies + + - 
hypothalamus + + - 
hippocampus + + - 
corpus callosum NA NA NA 
  
+: distinct immunoreactivity  -: no immunoreactivity 




Figure 7.1 (a), 7.1 (d), 7.3 (b) and 7.4 (b) show immunoreactive neurons in the 
parietal and frontal region, the cerebellar vermis and the hippocampus, respectively.  The 
reaction presented as a mainly diffuse brownish cytoplasmic staining of the perikaryon of 
the neurons.  When the orientation of the section plane was appropriate, staining of the 
axons and dendrites was noticed.  In particular, this was obvious in the Purkinje cells 
presented in Figure 7.3 (b) where the course of the dendrites to the molecular layer could be 
followed. In addition, the granular layer cells of the cerebellar vermis were positive, but at 
higher magnification, a heterogeneity in the staining pattern of these cells was observed 
[see Figure 7.3 (b)].   The cells of the dentate gyrus in the hippocampus were also 
visualized [see Figure 7.4 (c)].  However, the heterogeneity was less pronounced there.  
When comparing all brain regions, differences in staining intensity and number of positive 
neurons were seen, but these were not quantified.   
In Figure 7.2, a macroscopic overview of the immunoreactivity in the sections of the 
cerebellar vermis in case 1 and in a control case is presented.  The focal staining pattern in 
the control differs from that in the case, as the white matter is unreactive in the control.  
Moreover, upon microscopical examination, no immunoreactive neurons were seen in the 
control. 
Positive staining reactions were found for both antibody clones; however, the 
staining aspect of both clones was somewhat different.  The two neuronal staining patterns 
are  presented in the parietal and frontal lobe (Figure 7.1 (a) and (d), respectively).  When 
antibodies of the 5C2 clone were used, the staining in the perikaryon was usually somewhat 
flocky. Incubation with 1A9 rendered a more diffuse coloring in the neuronal cytoplasm 
and the DAB precipitate was more heterogenous.    Variations in staining intensity were 
also noticed when both clones were compared.  Although both clones distinctly revealed 
visualization of the cortical neurons, we further proceeded with 1A9 because this antibody 
clone produced a crisp microscopical image. 
The validation procedure for positive control (as recommended in the kit) - using 
anti-CD231 on formalin-fixed and paraffin-embedded lymph node and palatine tonsil tissue 
- was applied and found to be positive.  The same procedure with IgG1 fraction and with the 
antibodies recognizing MDMA and MDA on lymph node and tonsil sections was negative. 
In the control cases, no neurons were revealed, except for a very faint diffuse 
cytoplasmic staining in the perikarya [see Figure 7.1 (c) and Figure 7.3 (c), parietal cortex 
and cerebellar vermis, respectively]. 
Addition of pure MDMA or MDA to the antibody solution – in the high 
concentration of the series –, totally abolished the staining reaction or reduced staining to 
the background level as seen in the control cases [see Figure 7.1 (b) and Figure 7.2, parietal 
lobe and cerebellar vermis, respectively].  In the lower MDMA concentration range, a 
gradient in the staining intensity was observed.  These results point to the specificity of the 
antibodies.  Addition of PMA or amphetamine to the antibody solution was not able to 
induce negative immunoreactivity.  In addition, incubations with mouse IgG1 fraction were 





































Figure 7.1   (a)  Immunohistochemical staining of neurons (nerve cell bodies,  axons and 
dendrites) in the parietal lobe of case 1.   
(b) Staining of the parietal lobe of case 1 after saturation of the antibody solution  
with MDMA.  As a result, negative immunodetection was induced.   
(c) Negative immunohistochemical staining of the parietal cortex in the control 
case.   
For pictures (a), (b), (c): antibody clone 1A9; magnification 190, 140 and 140x 
respectively.   
(d) Immunohistochemical staining of neurons (nerve cell bodies,  axons and 









































Figure 7.3   (a)  Positive immunostaining of the cerebellar vermis of case 2:  the nerve cell 
bodies,  axons and dendrites of the Purkinje cells are clearly visible.  The 
granular layer cells can also obviously be discerned.  In addition,  staining at 
the level of the white matter fibres is seen (overview:  magnification 95x).   
(b) Detail of the immunoreaction in the cerebellar vermis of case 2 
(magnification 270x).   
(c) Negative immunohistochemical staining of the cerebellar vermis in a control 
case (00/116;  magnification 170x).   
 (For all pictures:  staining with antibody clone 1A9)  
Figure 7.2 Macroscopic overview of 
 the slides of the cerebellar vermis: 
left: positive immunostaining in case 1;   
middle: immunostaining in case 1 after 
saturation of the antibody binding sites 
with MDMA, inducing a negative result;    
right: negative immunohistochemical 
staining of the cerebellar vermis in a 
control case (00/116). 































Figure 7.4   Staining of neurons in the hippocampus of case 2 (antibody clone 1A9).   
(a):  overview (magnification 25x);   
(b):  detail of the cortical neurons (magnification 100x);   
(c):  detail of the cells of the dentate gyrus (magnification 100x). 
 
The immunodetection of catalase and alanin/glyoxylate aminotransferase in the case 
and control liver was not affected by addition of a similar amount of MDMA used to 
saturate the MDMA-antibody.    
Figure 7.5 shows the results in the pituitary gland.  Distinct immunoreactivity was 
observed in many cells, together with a prominent heterogeneity.  As a result, different 
types of staining intensity can be discerned: highly intensely staining cells and abundant 
positive cells on the one hand.  On the other hand, some weakly stained and a few negative 
cells can be noticed.  Comparison of these results with the PAS-orange G-staining in 
adjacent sections indicates that the strongly stained cells correspond to the acidophils.  The 
weakly stained and negative cells are assumed to be the basophils and chromophobes, 




































Figure 7.5   (a)  Overview of MDMA immunoreactivity in the pituitary gland (antibody clone 
1A9;  magnification 140x).   
(b) PAS Orange-G staining of the immediately adjacent slide visualizing clearly 
the acidophilic (orange colour) and basophilic cells (violet colour),  
(magnification 140x).   
(c)  Detail of the staining reaction for MDMA in the pituitary gland (antibody clone 
1A9;  magnification 300x).   
Following types of staining reaction can be discerned (see arrows):   
(1) & (2):   obviously positive cells showing variable staining intensity 
(heterogeneity).  The highly intensively stained cells obscure the 
nucleus (see arrow 1).   
(3):  cells having weak immunoreaction.   




IV.2  Toxicological data 
In Table 7.2, the MDMA, MDA, PMA and amphetamine concentrations in femoral 
blood and homogenates of the cortex and white matter of the four brain lobes are presented.  
The analysis revealed also an important level of the drugs in the white matter. 
In the first fatality, the routine analysis of blood and urine disclosed the presence of 
a high level of amphetamines (68.4 µg/ml in urine, immunoassay result) and trace amounts 
of benzoylecgonine (0.7 mg/ml in urine, chromatographic result).  Head-space GC analysis 
demonstrated the absence of ethanol in blood and urine.  In addition, the presence of 
MDMA in blood was demonstrated by HPLC-DAD and GC-MS.  
For the second case - apart from the data presented in Table 7.2 - no alcohol, neither 
other drugs were found. 
 
 
Table 7.2 Toxicological data in femoral blood as well as cortex and medulla of the four brain 
lobes in the two fatalities. 
 
 case 1 (00/112)  case 2 (01/34)  
 MDMA MDA MDMA MDA PMA AMP 
femoral blood (µg/ml) 3.07 0.09 1.22 0.39 1.43 0.22 
brain region (µg/g)       
frontal lobe       
     - cortex 13.65 0.15 1.66 0.57 3.89 0.33 
     - white matter 13.05 0.13 1.89 0.68 3.52 0.49 
temporal lobe       
     - cortex 15.42 0.16 1.62 0.81 3.25 0.43 
     - white matter 13.53 0.21 3.00 0.81 4.40 0.44 
parietal lobe       
     - cortex 15.19 0.23 2.61 0.57 3.92 0.33 
     - white matter 12.46 0.15 3.05 0.62 2.94 0.43 
occipital lobe       
     - cortex 15.98 0.18 1.87 0.52 3.23 0.33 
     - white matter 10.87 0.19 3.30 0.57 4.74 0.32 
brainstem 13.18 0.22 1.95 0.76 3.20 0.35 
cerebellum 11.69 0.23 0.98 0.49 2.37 0.66 
       
 MDMA: 3,4-methylenedioxymethamphetamine   
 MDA: 3,4-methylenedioxyamphetamine   
 PMA: para-methoxyamphetamine    





In this study, a method for immunohistochemical detection of MDMA and MDA in 
human tissues is presented.  In addition, we examined the distribution of  MDMA and 
MDA in various brain regions and the pituitary gland.   
Positive immunostaining for MDMA and MDA was established in the neuron cell 
bodies, axons and dendrites in various regions of the brain in two fatal intoxications.  
However, the immunoreactivity was also present at the level of the white matter fibres.  The 
toxicological data confirmed that substantial concentrations of MDMA are present in the 
white matter.  This is in accordance with toxicological data obtained in methamphetamine 
users (30).  The discrepancy between the substantial concentrations in the white and the 
grey matter, as detected by GC-MS and LC-MS, and the relatively weak immunoreactivity 
of the white matter in the brain lobes, may be explained by the fact that in the latter 
approach MDMA can only be detected if it is bound to the tissue and that this complex is 
not affected by the procedure of fixation,  paraffin embedding and sectioning.  We presume 
that unbound MDMA is rinsed off during the immunohistochemical preparation procedure.  
In the tissue homogenates,  used for the GC-MS and LC-MS analysis,  both the bound 
MDMA and the soluble form remain available for detection.  For methamphetamine as 
well, positive immunoreactivity in cerebral cortex and in the white matter was 
demonstrated (24).  In our study, topographic differences in staining intensity were 
observed.  In particular, distinct immunoreactivity was found in the neurons of all cortical 
brain regions, the basal ganglia and the cerebellum.  However, the neuron cell bodies in the 
brainstem were relatively weakly stained and the white matter fibres were more pronounced 
at that site.  In addition, immunoreactivity was also found in the cells of the dentate gyrus in 
the hippocampus and the granular layer cells of the cerebellar vermis.  This was not 
observed in the immunohistochemistry of morphine and methadone (13, 14). 
The observed results in our two fatalities were well consistent with the topographic 
data obtained in rats after injection of [3H]-MDMA and [3H]-MDA (18).  We were able to 
provide further information about the regional distribution of MDMA and MDA in human 
brain tissue.  In addition, the method may be used to further investigate the biological 
effects, for example the interaction of MDMA and MDA on serotonin systems - which was 
previously  demonstrated (18, 31) – , to study the influence on memory (32) etc.  
 Immunostaining of the pituitary gland revealed a variable reaction intensity in the 
different cells (acidophils, basophils and chromophobes).  The most intensely stained cells 
are probably the acidophils as these are metabolically the most active cells.  This is in 
accordance with the MDMA induced neuroendocrine effects such as increases in plasma 
cortisol and prolactin levels which are documented in humans (33).  We will undertake 
studies to correlate the heterogeneity of the MDMA reactivity with the hormone producing 
cell types.  
Although the mechanism of death in our two fatalities was different – cardio-
pulmonary failure related to the sympaticomimetic effects of MDMA, and DIC due to 
hyperthermia, respectively – and though there were obvious differences in toxicological 
data, the immunoreactivity pattern in the brain regions of both cases was fairly comparable.  




case – leading to a more pronounced tissue autolysis – the drugs could be demonstrated 
immunohistochemically.  However, it should be well kept in mind that interfering factors 
such as putrefaction may give rise to false negative results.  On the contrary, it cannot be 
excluded that – theoretically – the putrefaction process might lead to artefactual epitopes 
which are recognized immunologically and thus could induce a false positive reaction.   
However, in the control cases (with post-mortem interval up to 2 days) no reaction was 
observed, except for a background level (see below). 
In the cases and controls no immunoreactivity was found after incubation with IgG1 
fraction from normal serum.  In the controls a very faint diffuse staining was found in a few 
neurons after incubation with the anti-MDMA antibodies.  Given the fact that saturation of 
the antibody with pure MDMA abolished staining in the cases and that in the controls no 
amphetamines could be detected by chromatographic analysis, the very weak diffuse 
reaction in some neurons of the controls must be considered as the background level.  A 
similar phenomenon of diffuse staining in control neurons was experienced by Wehner et 
al. (13, 14) in their study on immunodetection of methadone and morphine in human brain.  
As emphasized by these authors, it must be kept in mind that the CSA detection method 
yields an extreme amplification of the primary signal (antigen-antibody complex) and that 
also the slightest background becomes enhanced as a result of the sensitivity of the method. 
Since saturation of the antibody with either MDMA or MDA reduced staining to 
background level,  the specificity of the antibodies and the method was confirmed.  
According to the information obtained by the supplier, the antibodies are highly specific for 
ecstasy (MDMA) and related compounds (MDA and MDEA) while cross-reaction with 
amphetamine, methamphetamine and some medications (phentermine, 
phenylpropanolamine, pseudoephedrine) is always below 1 % (34).  
In summary, a reliable method for the specific immunohistochemical detection of 
MDMA and MDA in human brain tissues is presented.  This method can be used as 
evidence of intake or even poisoning with MDA, MDMA and/or MDEA and can be a 
reliable alternative when the usual samples (mainly blood and urine) are not available for 
toxicological analysis (for example due to fulminant blood loss in severely destructed 
bodies, such as polytrauma in train accident fatalities). 
Further studies will be undertaken in order to investigate whether this technique 
might be influenced by post-mortem processes.  In addition, MDMA immunodetection 
might be used as a basis for further study of the distribution of these amphetamine 
analogues in the human body, and thus be useful in the understanding of their biological 
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Summary and conclusions 
 
The use and abuse of amphetamine derivatives such as 3,4-methylenedioxymeth-
amphetamine (MDMA, “ecstasy”, “XTC”) has become an important public issue in 
view of the growing numbers of fatalities encountered in current forensic practice. 
Considering the broad range of blood and plasma levels in MDMA-related fatalities 
reported in the literature, the level of MDMA that can be toxic or even potentially lethal 
remains unclear.  The question as to whether or not the (ab)use of the substance has 
contributed to the cause of death remains particularly unclear because of post-mortem 
phenomena such as instability, redistribution and even neo-formation, all of which can 
interfere with post-mortem blood levels. Post-mortem degradation, on the one hand, can 
lead to falsely decreased levels, whereas post-mortem redistribution and/or neo-
formation can result in erratically high concentrations.  Possible mechanisms of post-
mortem redistribution include the diffusion of a substance into the cardiac blood out of 
the lungs and liver, or the stomach content. 
 
In this thesis research, we have studied the post-mortem redistribution of certain 
amphetamine derivatives in order to evaluate which fluid and/or tissue sampled after 
death most closely approximates the ante-mortem blood concentration.  Due to the well-
isolated position of the eye and the reliability of vitreous humour for post-mortem 
toxicology (e.g. alcohol (1)), the value of this medium for post-mortem determinations 
of amphetamine derivatives was investigated.  Our work was particularly focused on 
MDMA and its metabolite 3,4-methylenedioxyamphetamine (MDA), though we also 
examined cases involving the amphetamine analogues 4-methylthioamphetamine (4-
MTA) and para-methoxyamphetamine (PMA), which have recently been prominently 
featured in the early warning system on synthetic drugs.   
 
Part one consists of a literature survey including a review of the reported 
MDMA-related fatalities and a summary of the amphetamine-related casework 
examined at the Department of Forensic Medicine of Ghent University.  In Chapter 1, 
the relevant literature data are reviewed with emphasis on MDMA and its medico-legal 
implications. Significant inter-individual in vivo differences in susceptibility to the 
effects of MDMA were noted.  Unfortunately, at present, it is impossible to estimate the 
individual risk of using  MDMA or other amphetamines.   
The majority of the fatalities reported in the literature were men younger than the 
age of 25.  The number of “pure” MDMA intoxication were roughly equal to the 
numbers of poly-amphetamine intoxication or polydrug abuse (including MDMA 
ingestion).  With respect to the manner of death, it was obvious that MDMA-related 
fatalities were for the major part due to an unintentional overdose, though the use of 
MDMA in association with other events such as traffic accidents and suicidal acts 
should not be underestimated.  When MDMA is involved, various mechanisms of death 
have been described with hyperthermia and fatal cardiac or pulmonary complications 
being the most frequent.  In many cases, however, the manner and mechanism of death 
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remains undetermined or uncertain.  In view of the broad range of MDMA levels 
reported in the literature (viz. blood levels between 0.04 and 18.50 µg/ml in “pure” 
overdoses), it is not possible to conclude solely on the basis of the toxicological data 
whether or not a subject died of MDMA (ab)use.  Moreover, in most of the reported 
cases the blood sampling location was not specified and, as a result, it is not clear 
whether the observed post-mortem MDMA blood concentration actually represented the 
concentration at the time of death.  However, guidelines indicate that an MDMA blood 
concentration higher than 1.0 µg/ml can be potentially lethal, whereas levels below 
approximately 0.6 µg/ml are capable of inducing intoxication (2). 
The amphetamine-related fatalities examined at the Department of Forensic 
Medicine of Ghent University were reviewed and discussed in the light of the literature 
data (Chapter 2).  Because of the low number of “pure” MDMA-related deaths, we have 
included all amphetamines in this survey. The amphetamine-related fatalities represent 
only a small fraction of all the medico-legal investigations, though the number obviously 
started increasing from 1995.  We are convinced, however, that there is an 
underestimation of amphetamine-related fatalities: when somebody dies at home (e.g. 
found dead in bed, whether or not after a night out dancing), the death is often classified 
as a “natural death” and consequently no police inquiry or medico-legal investigation is 
performed.  In our cases, 11 subjects were found dead either in bed or in a chair.  
The age and sex distributions of the amphetamine-related fatalities examined at 
the Department were fully in accordance with the data from the literature.  A wide range 
of MDMA concentrations was found in cases of “pure” intoxication (blood levels 
between 0.27 µg/ml and 13.51 µg/ml), which was in line with those reported in the 
literature.  “Pure” amphetamine intoxications, polydrug overdoses and the combination 
of amphetamine (ab)use and polytrauma were the most prominent causes of death.  As 
for the manner of death in these fatalities, unintentional overdoses were most frequent, 
though traffic accidents and suicides associated with amphetamine use also accounted 
for significant percentages.  As for the mechanism of death, acute to subacute 
cardiopulmonary failure was most frequent, followed by hyperthermia.   
 
On the basis of both surveys in Part One (Chapters 1 and 2), post-mortem 
distribution and redistribution were studied in order to evaluate which post-mortem fluid 
or tissue sample best approximates the actual concentration at the time of death.  At first, 
the results obtained in experiments using rabbits were presented (Part Two).  Thereafter, 
the experimental data were compared with some cases found in current forensic practice 
(Department of Forensic Medicine, Ghent University) (Part Three). 
 
In the first study presented in Part Two (Chapter 3), the value of post-mortem 
vitreous humour levels was investigated for the purpose of avoiding possible thanato-
chemical difficulties such as post-mortem redistribution.  First, the pharmacokinetics of 
MDMA in the rabbit after intravenous (iv) administration were considered.  A high 
volume of distribution (5 l/kg), a high systemic clearance (4.1 l/kg per h) and a relatively 
short half-life (1 h) was found following iv administration of MDMA.  A distinct 
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relationship between the MDMA concentrations in the vascular compartment and the 
vitreous humour was substantiated.  Equilibration between the vascular compartment 
and the vitreous humour was attained about one hour after intravenous administration.  
The ratio of the MDMA concentration in vitreous humour to the MDMA blood level 
was about 1.1 at 120 and 240 minutes after infusion, which indicates a slight 
accumulation of MDMA in the vitreous compartment.  Moreover, a preliminary thanato-
toxicological investigation - in which a post-mortem interval up to 72 h was considered - 
demonstrated that MDMA concentrations in cardiac blood increased post mortem 
whereas vitreous humour MDMA levels were more stable and thus presumably more 
representative of the ante-mortem blood concentration.  
In Chapters 4 and 5, the post-mortem stability and redistribution of MDMA in 
rabbits were further analysed. In Chapter 4, the distribution and redistribution of 
MDMA and its metabolite MDA were studied in various fluids and tissues after 
intravenous administration.  In a first group  (control group, sampling done immediately 
after killing) considerable MDMA concentrations were found in the brain and both 
lungs.  Our data also pointed to substantial elimination of MDMA by hepatic 
biotransformation and excretion via the bile in addition to renal excretion.  In a second 
group (post-mortem interval either 24 or 72 h prior to sampling), an increase of MDMA 
and MDA levels in the liver and the eye globe walls was noted.  In the lungs, on the 
other hand, levels tended to decline as a function of increasing post-mortem interval.  
MDMA concentrations in cardiac and iliopsoas muscle were fairly comparable, 
remaining stable up to 72 h after death.  As post-mortem increases in cardiac blood 
levels can be due to vascular diffusion out of blood-rich organs such as the liver and 
lungs (3), the large vessels around the heart were ligated (immediately after killing) in 
another group (group 3), and the animals were further handled as in group 2.  However, 
significant differences in blood and tissue MDMA concentrations between the animals 
of groups 2 and 3 could not be demonstrated.   Therefore, in the rabbit, post-mortem 
redistribution of MDMA at the cellular level (viz. by pure diffusion gradient from higher 
to lower concentrations) is probably more important than its redistribution via vascular 
pathways. In addition, MDA levels were relatively low in all samples, indicating that 
this molecule is not a major metabolite in the rabbit, at least within the first two hours 
after administration.  Furthermore, the value of vitreous humour as a reliable post-
mortem specimen was confirmed. The distribution and redistribution of MDMA and 
MDA in rabbit tissues were in line with the data obtained after administration of 
amphetamine in the rat (4,5). 
Since drug levels can be affected by gastric diffusion when the stomach contains 
a substantial amount of the drug or by diffusion from the trachea when agonal aspiration 
or post-mortem regurgitation of vomit occurs, these phenomena were simulated in 
another rabbit model (Chapter 5).  After post-mortem tracheal infusion, MDMA can 
easily diffuse not only into the lungs but also in large quantities into the cardiac blood 
and – to a lesser extent – into the cardiac muscle. MDMA was also found in the closely 
adjacent diaphragm and in the upper abdominal organs, including the liver and the 
stomach.  Following post-mortem infusion into the stomach, considerable MDMA levels 
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were found in cardiac blood and muscle, both lungs, diaphragm and liver tissue when the 
solution was concentrated nearby the lower oesophageal sphincter.   However, when the 
MDMA solution was present deeper in the stomach, MDMA levels were high in the 
spleen and liver and relatively low in cardiac blood and muscle.  These results indicate 
that the diffusion of MDMA out of the stomach content or due to aspirated vomit and 
particularly gastro-oesophageal reflux, can lead to considerable post-mortem 
redistribution. In both experiments, MDA levels were low or below the limit of 
quantitation in most tissues, but were substantial in cardiac blood and muscle, lung and 
diaphragm, thus indicating that MDMA can be converted into MDA even after death. 
 
In Part Three, the post-mortem distribution of MDMA (and its metabolite MDA) 
and some other amphetamine derivatives was studied in the human body in order to 
evaluate which fluid and/or tissue sampled after death best approximates the ante-
mortem concentration at the time of death.  These findings were correlated with the 
experimental data on post-mortem redistribution in rabbits.  In the human fatalities, the 
post-mortem phenomena were investigated using two different - but complementary – 
approaches, namely the thanato-toxicological and the immunohistochemical.   
In the study discussed in Chapter 6, concentrations in various fluids (blood 
sampled at different locations, vitreous humour, urine and bile) and tissues such as 
cardiac muscle, lungs, liver, kidneys, spleen, ilio-psoas muscle, and brain were 
determined in overdose victims.  Apart from MDMA and MDA, some other 
amphetamine derivatives, namely 4-methylthioamphetamine (4-MTA) and para-
methoxyamphetamine (PMA), were examined as well.  For the relatively new derivative, 
4-MTA, the data of persons who survived after ingestion are also presented, and clinico-
pathological findings are discussed.  In the surviving subjects, an obvious inconsistency 
between the 4-MTA levels detected and the described clinical symptoms was noted, 
substantiating that differences in individual responses to 4-MTA must be taken into 
consideration.   In the amphetamine-related fatalities, very high concentrations were 
found in cardiac blood and tissues located centrally in the body (lungs and liver in 
particular).  This confirms that post-mortem redistribution due to diffusion from higher 
to lower concentration can easily take place, mainly at longer post-mortem intervals and 
when putrefaction occurs.  These findings corroborated the animal experimental data in 
which post-mortem redistribution of MDMA into cardiac blood was substantiated (6,7).  
Our data confirmed that for post-mortem quantitation of amphetamine and derivatives, 
peripheral blood sampling remains compulsory.  When such samples are not available 
(due to severe loss of blood, such as in polytrauma), iliopsoas-muscle and vitreous 
humour could be valuable alternatives.  However, when advanced putrefaction has taken 
place, vitreous humour is often no longer available due to dehydration, and iliopsoas 
muscle levels should be interpreted with caution (see case 01/158: the iliopsoas muscle 
value was obviously higher than the femoral blood level).  In contrast to the rabbits 
experiments, there are arguments for a direct transvascular redistribution, for example, 
from the lungs to the cardiac chambers.  Moreover, due to the post-mortem processes, 
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the toxicological and autopsy findings should be considered as a whole in drawing the 
medico-legal conclusions.  
In Chapter 7, an immunohistochemical method for the detection of MDMA and 
MDA in human post-mortem brain tissues and the pituitary gland is presented and 
correlated with the toxicological findings.  The detection method comprises an elaborate 
amplification of the original signal (antigen-antibody recognition; Catalyzed Signal 
Amplification; CSA (8)).  The method has already been applied for the detection of 
morphine and methadone in human fatalities (9,10). A distinct positive reaction was 
observed in all cortical brain regions and the neurons of the basal ganglia, the 
hypothalamus, the hippocampus, the cerebellar vermis, and the pituitary gland.  In the 
brainstem, relatively weak staining of neurons was seen. These findings were in line 
with the toxicological data.  This immunohistochemical method can be used as evidence 
of intake of or even poisoning with MDA, MDMA and/or MDEA, and it can serve as an 
alternative method when the usual samples (mainly blood and urine) are not available 
for toxicological analysis (for example in polytrauma).  However, with the currently 
available antibodies, it is not possible to distinguish the closely related amphetamine 
derivatives (MDA, MDMA and MDEA) from one another. In addition, 
immunodetection could possibly be used as a basis for further study of the distribution of 
these amphetamine analogues in the human body, and may contribute to the 
understanding of their neuro-biological effects.  However, the limitation of the 
immunohistochemical approach is that in the brain sections, only the fraction bound to 
the tissue can be demonstrated.  This constitutes a fundamental difference between this 
approach and the toxicological quantitation in tissue homogenates, in which both the 
bound and the unbound fractions can be assessed.  
 
 In conclusion, the experimental data in rabbits, which were corroborated by the 
results in some human cases, have enabled us to demonstrate that post-mortem 
redistribution of the amphetamine derivatives – MDMA and MDA, in particular, but 
also 4-MTA and PMA – should be taken into account in the toxicological assessment of 
the cause of death, especially with longer post-mortem intervals.  Peripheral blood 
sampling remains the golden standard.  However, when this is not possible due, for 
example, to extreme loss of blood in polytrauma or putrefaction, iliopsoas muscle and 
vitreous humour can be useful in arriving at a valid conclusion.  Immunohistochemical 
detection in brain tissues can serve as an additional tool in the forensic inquiry as well.  
Finally, as there is still considerable debate as to what MDMA level can be toxic or even 
potentially lethal, it is strongly advisable to interpret the anatomo-pathological findings 
and the toxicological results together in arriving at a conclusion.  This guideline is 
important in view of the different possible mechanisms of death which implicate quite 
different survival times following amphetamine intake (e.g. cardiopulmonary 
complications, hyperthermia). 
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Résumé et conclusions 
 
 La consommation et l’abus d’amphétamine et analogues comme la 3,4-méthylène-
dioxyméthamphétamine (MDMA, « Ecstasy », « XTC ») constituent un important 
problème social et des cas fatals sont assez fréquents en pratique médico-légale courante.  
En se référant aux importantes différences entre les concentrations sanguines ou 
plasmatiques détectées dans les cas fatals décrits dans la littérature, il est difficile de se 
faire une idée précise de la concentration toxique ou même potentiellement fatale de la 
MDMA.  Reste à savoir si l’usage ou l’abus d’un produit a contribué à la mort vu les 
phénomènes post mortem comme l’instabilité d’un produit, la redistribution et même la 
néoformation qui peuvent tous interférer avec la concentration sanguine post mortem.  En 
cas de dégradation post mortem, des taux faussement diminués sont retrouvés, tandis que la 
redistribution et/ou néoformation post mortem peuvent donner lieu à des taux 
exceptionnellement élevés.  La diffusion d’une substance dans le sang cardiaque à partir 
des poumons ou du foie, ou du contenu gastrique, est un mécanisme possible de 
redistribution post mortem. 
 
 Dans cette thèse de doctorat, la redistribution post mortem de quelques dérivés 
d’amphétamines a été étudiée afin de savoir quel liquide et/ou tissu corporel cadavérique 
est le plus approprié pour évaluer la concentration sanguine ante mortem. En se référant à 
la position bien isolée de l’œil et à la valeur de l’humeur vitrée pour la toxicologie post 
mortem (p.ex. pour la détermination d’alcool (1)), la fiabilité de ce médium pour la 
détection d’amphétamines post mortem a été examinée.  Dans cet ouvrage, la MDMA et 
son métabolite 3,4-méthylènedioxyamphétamine (MDA) ont été particulièrement étudiés, 
mais également les dérivés d’amphétamine, la 4-méthylthioamphétamine (4-MTA) et la 
para-méthoxyamphétamine (PMA) – qui ont reçu récemment pas mal d’attention. 
 
 La première partie comprend un aperçu de la littérature y compris un résumé des 
cas mortels publiés liés à la MDMA et un bilan des fatalités relatives à l’usage 
d’amphétamines examinées au Département de Médecine Légale de l’Université de Gand.  
Chapitre 1 décrit les données de la littérature pertinentes concernant la MDMA et ses 
implications médico-légales.  In vivo, on aperçoit une importante vulnérabilité inter-
individuelle aux effets de la MDMA.  En ce moment, il est impossible d’estimer le risque 
individuel et, par conséquent, de prévoir les effets de la consommation de la MDMA ou 
d’autres amphétamines. 
 La majorité des cas mortels qui ont été décrit dans la littérature concerne des 
hommes de moins de 25 ans.  Le nombre d’intoxications « pures et simples » relatives à la 
MDMA  égale à peu près le nombre d’ingestion de la MDMA faisant partie d’une 
intoxication complexe liée à d’autres amphétamines, drogues ou médicaments.  En ce qui 
concerne les circonstances médico-légales du décès, il est bien clair que la plupart des 
décès étaient dus à une dose excessive involontaire, mais l’usage de la MDMA associé à 
d’autres évènements comme p.ex. les accidents de la route et le comportement suicidaire ne 
Résumé et conclusions 
________________________________________________________________________________ 
 2
peut pas être sous-estimé.  Lorsque la MDMA est impliquée dans la mort, différents 
mécanismes de décès sont décrits: l’hyperthermie et les complications cardiales ou 
pulmonaires sont les plus fréquentes.  Toutefois, dans beaucoup de cas, les circonstances 
ou le mécanisme de la mort sont indéterminés ou indécis.  Se référant à l’intervalle large 
des concentrations létales de la MDMA retrouvé dans la littérature (plus particulièrement, 
des concentrations de 0.04 à 18.5 µg/ml considérant des intoxications « pures »), il n’est 
pas évident de répondre correctement à la question si – uniquement à base d’un résultat 
toxicologique – une personne est morte à cause de la consommation ou d’abus de la 
MDMA.  En outre, dans la majorité des cas, l’endroit où le sang a été prélevé n’est pas 
spécifié et – par conséquent – il n’est pas clair si le taux de la MDMA déterminé dans le 
sang post mortem représente effectivement la concentration réelle au moment du décès.  
Néanmoins, une règle empirique indique qu’une concentration de la MDMA excédant 1 
µg/ml serait potentiellement mortelle, tandis que des taux équivalents ou inférieurs à 0.6 
µg/ml pourraient être toxiques (2). 
Dans le deuxième Chapitre – à la lumière de ces données de la littérature – tous les 
cas mortels liés aux amphétamines rencontrés au Département de Médecine Légale de 
l’Université de Gand sont révisés.  Dû au nombre relativement petit des intoxications 
mortelles « pures » à la MDMA, tous les décès liés à l’usage des amphétamines sont 
rapportés.  Le nombre de fatalités dans lesquelles les amphétamines sont concernées n’est 
qu’une fraction minime de toutes les expertises médico-légales, mais ce nombre augmente 
sensiblement depuis 1995.  Néanmoins, nous sommes convaincus qu’il doit y avoir une 
sous-estimation du nombre de décès liés à la consommation des amphétamines: lorsque 
quelqu’un est retrouvé mort à la maison (p.ex. dans son lit, à la suite d’ une sortie), le décès 
est souvent classé comme « naturel » et par conséquent, il n’y a pas d’investigation 
policière ni d’examen médico-légal.  Des cas étudiés, 11 victimes ont été retrouvées 
décédées au lit ou dans un fauteuil. 
La distribution de l’âge et du sexe retrouvée chez la majorité des victimes liées aux 
amphétamines sont plutôt en concordance avec les données de la littérature.  Un grand 
éventail de concentrations de la MDMA chez les intoxications « pures » a été constaté 
(concentrations entre 0.27 et 13.51 µg/ml) et ceci est également conforme aux cas décrits 
dans la littérature.  Des intoxications « pures » aux amphétamines, des intoxications 
combinées et la consommation d’amphétamines combinée à des polytraumatismes étaient 
les causes de la mort les plus fréquentes.  En ce qui concerne les circonstances du décès 
constatées dans notre échantillon d’étude, il apparaît que les intoxications non-
intentionnelles étaient les plus fréquentes.  L’usage des amphétamines en rapport avec les 
accidents de trafic et le suicide constituent aussi un groupe important.  Quant au mécanisme 
du décès, on note en premier lieu une insuffisance cardio-pulmonaire aiguë ou subaiguë 
suivie par l’hyperthermie.  
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A base des  aperçus rapportés dans la première partie (Chapitre 1 et 2), la 
distribution et redistribution post mortem ont été étudiées afin d’examiner quel liquide ou 
tissu prélevé après la mort représente au mieux la concentration réelle au moment du décès.  
D’abord, les résultats obtenus à l’aide d’un modèle expérimental animal (utilisant des 
lapins) sont présentés (deuxième partie).  Ensuite, on a examiné si les données 
expérimentales pourraient être confirmées par l’étude des cas en pratique médico-légale 
courante (Département de Médecine Légale de l’Université de Gand) (troisième partie). 
 
Dans la première étude de la deuxième partie, la valeur de l’humeur vitrée prélevée 
après la mort a été étudiée afin d’éviter les problèmes thanato-chimiques comme la 
redistribution post mortem.  D’abord, la pharmacocinétique de la MDMA chez le lapin 
après injection intraveineuse (iv) a été examinée.  Un volume de distribution assez grand (5 
l/kg), une clairance totale importante (4.1 l/kg par heure) et une demi-vie relativement 
courte (1 heure) étaient remarqués chez le lapin après injection iv de la MDMA.  On a pu 
démontrer une corrélation nette entre la concentration de la MDMA dans le compartiment 
vasculaire et dans l’humeur vitrée.  Un équilibre entre le compartiment vasculaire et 
l’humeur vitrée est atteint environ une heure après injection iv.  Le rapport de la 
concentration de la MDMA dans le vitré à la concentration sanguine de la MDMA, 120 
minutes ou 240 minutes après administration iv, s’approchait de 1.1; ce qui porte à croire 
qu’il y a une accumulation légère de la MDMA dans l’humeur vitrée.  En plus, notre étude 
thanato-toxicologique préliminaire – en considérant un délai post mortem jusqu’à 72 heures 
– a prouvé que les concentrations de la MDMA dans le sang cardiaque augmentaient  après 
la mort, tandis que les concentrations de la MDMA dans l’humeur vitrée étaient plus 
stables et donc mieux représentatives de la concentration sanguine ante mortem. 
Dans le quatrième et cinquième Chapitre, la stabilité et la redistribution de la 
MDMA après la mort ont été analysées plus profondément chez le lapin.  Dans le 
quatrième Chapitre, la distribution et la redistribution de la MDMA et son métabolite 
MDA ont été étudiées dans  divers liquides et tissus du corps après administration iv.  Dans 
un premier groupe (groupe de contrôle, prélèvement immédiatement après la mort), de 
considérables concentrations de la MDMA étaient démontrées dans le cerveau et les 
poumons.  Les données toxicologiques indiquent donc une élimination importante de la 
MDMA par biotransformation hépatique et excrétion biliaire associée à élimination rénale.  
Dans un deuxième groupe d’animaux (conservé pendant soit 24, soit 72 heures avant de 
prendre des prélèvements), une élévation des concentrations de la MDMA et de la MDA 
dans le foie et dans la paroi oculaire a été remarquée.  D’autre part, les concentrations 
pulmonaires avaient tendance à diminuer en fonction d’un délai post mortem avancé.  Les 
concentrations de la MDMA dans le muscle cardiaque et l’iliopsoas étaient bien 
comparables et restaient stables jusqu’à 72 heures après le décès.  Puisque les élévations 
des concentrations post mortem dans le sang cardiaque pourraient être le résultat d’une 
diffusion vasculaire à partir des organes fort vascularisés comme le foie et les poumons (3), 
les grands vaisseaux affluant au cœur ont été ligaturés (immédiatement après la mort); ces 
animaux ont été traités comme ceux du deuxième groupe.  On n’a pas pu démontrer des 
différences significatives entre les groupes 2 et 3.  C’est pourquoi, chez le lapin, la 
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redistribution post mortem de la MDMA au niveau cellulaire est probablement plus 
importante que la redistribution de cette substance par voie vasculaire.  Par ailleurs, les 
concentrations de la MDA étaient relativement basses dans tous les échantillons, ce qui 
signifie que cette molécule n’est pas un métabolite important pour le lapin, tout au moins 
dans les 2 heures après administration.  En plus, la valeur de l’humeur vitrée comme 
spécimen stable après la mort, a été confirmée.  La distribution et la redistribution de la 
MDMA et de la MDA dans les tissus des lapins étaient en concordance avec les données 
établies après l’administration de l’amphétamine chez le rat  (4,5). 
Puisque les concentrations de divers produits tels que les drogues peuvent être 
influencées par la diffusion à partir de l’estomac – quand il s’y trouve encore une quantité 
importante au moment du décès – ou par la diffusion à partir de la trachée lors d’ une 
aspiration agonale ou d’une régurgitation post mortem du contenu gastrique, ces 
phénomènes ont été simulés à l’aide d’un autre modèle  expérimental animal de laboratoire 
(Chapitre 5).  L’infusion post mortem de la MDMA dans la trachée du lapin a donné lieu à 
une diffusion aisée de la MDMA non seulement dans les poumons, mais aussi dans le sang 
cardiaque d’une façon considérable et à un degré moindre dans le muscle cardiaque.  La 
MDMA a été également retrouvée dans le diaphragme adjacent et les organes abdominaux 
supérieurs comme le foie et l’estomac.  Après infusion post mortem de la MDMA dans 
l’estomac, des concentrations de la MDMA importantes étaient découvertes dans le sang 
cardiaque, le muscle cardiaque, les poumons, le diaphragme et le foie – ceci quand la 
solution de la MDMA était concentrée au niveau du sphincter cardial.  Si la solution de la 
MDMA était concentrée dans le corps de l’estomac des concentrations considérables 
étaient retrouvées dans la rate et le foie, et des concentrations relativement basses dans le 
sang cardiaque et le muscle cardiaque.  Ces résultats indiquent que la diffusion de la 
MDMA à partir du contenu de l’estomac ou de l’aspiration de vomissure, et plus 
particulièrement du reflux gastro-oesophagale, peut contribuer à une redistribution post 
mortem importante.  Dans ces deux expériences, les concentrations dans la majorité des 
tissus de la MDA étaient relativement modestes ou inférieures à la limite de quantification, 
sauf dans le sang cardiaque, le muscle cardiaque, les poumons et le diaphragme ce qui 
montre que après la mort, la MDMA peut encore être transformée en MDA. 
 
Dans la troisième partie, la distribution post mortem de la MDMA (et son 
métabolite la MDA) ainsi de quelques autres dérivés de l’amphétamine a été étudiée dans 
le corps humain afin d’examiner quel liquide et/ou tissu prélevé après la mort est le plus 
approprié pour évaluer la concentration ante mortem au moment de la mort.  Ces 
constatations ont été corrélées aux données expérimentales de la redistribution post mortem 
chez le lapin.  En cas de fatalités humaines, les phénomènes post mortem ont été examinés 
au moyen de deux approches différentes – mais toutefois complémentaires, c’est-à-dire, du 
point de vue thanato-toxicologique et immunohistochimique.  
Dans le sixième Chapitre, les concentrations de la MDMA et MDA dans des divers 
liquides corporels (le sang prélevé à divers endroits, l’humeur vitrée, l’urine et la bile) et 
dans les tissus comme le muscle cardiaque, les poumons, le foie, les reins, la rate, le muscle 
iliopsoas, le cerveau étaient déterminées dans les victimes d’une dose excessive.  Quelques 
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autres dérivés d’amphétamine ont aussi été étudiés, à savoir la 4-méthylthioamphétamine 
(4-MTA) et la para-méthoxyamphétamine (PMA). En ce qui concerne le dérivé 
relativement récent, la 4-MTA, les données toxicologiques des personnes ayant survécu 
une ingestion ont été présentées et les constatations clinico-pathologiques également 
discutées.  Chez ces survivants, on a observé une inconsistance évidente entre les 
concentrations de la 4-MTA et les symptômes cliniques observés, de sorte qu’après une 
consommation de la 4-MTA, des réactions individuelles très différentes doivent être 
considérées.  Dans toutes les fatalités liées aux amphétamines, des concentrations très 
élevées ont été constatées dans le sang cardiaque et les tissus se trouvant au centre du corps 
humain (les poumons et le foie en particulier).  Ceci confirme que la redistribution post 
mortem se fait à la suite d’une diffusion d’organes à concentration élevée de MDMA, plus 
particulièrement en cas de délais post mortem considérables et de putréfaction.  Ces 
constatations sont en concordance avec les expérimentations chez les animaux de 
laboratoire où une redistribution post mortem de la MDMA dans le sang cardiaque a été 
démontrée (6,7).  Nos données confirment qu’un échantillon sanguin périphérique pour les 
analyses toxicologiques post mortem de l’amphétamine et ses dérivés est recommandé.  
Lorsque ceci est impossible (dû à une perte de sang considérable, p.ex. dans les 
polytraumatismes), le muscle iliopsoas et l’humeur vitrée peuvent être des substances de 
substitution valables.  Toutefois, lorsque la putréfaction est avancée, il n’y a plus d’humeur 
vitrée suite à la déshydratation, et les concentrations du muscle iliopsoas doivent être 
interprétées avec précaution (voir cas 01/158: la concentration du muscle iliopsoas était 
nettement plus élevée que celle du sang provenant de la veine fémorale).  Par opposition 
aux résultats expérimentaux chez le lapin, il existe des arguments pour supposer une 
redistribution trans-vasculaire directe p.ex. des veines pulmonaires vers les cavités 
cardiaques.  En plus – se référant aux procès post mortem – les données toxicologiques et 
les résultats de l’autopsie doivent être conçues comme un tout afin d’aboutir à une 
conclusion médico-légale fiable.  
Dans le septième Chapitre, une approche immunohistochimique post mortem pour 
la détection de la MDMA et la  MDA dans le tissu cérébral humain et dans l’hypophyse est 
présentée et corrélée aux résultats toxicologiques.  La méthode de détection est basée sur 
une amplification détaillée de la réaction antigène-anticorps initiale (Catalyzed Signal 
Amplification; CSA (8)).  Cette méthode a déjà été appliquée dans la détection de la 
morphine et la méthadone chez des victimes intoxiquées (9,10).  Une réaction nettement 
positive a été observée dans toutes les régions cérébrales ainsi dans les neurones des 
noyaux gris centraux, l’hypothalamus, l’hippocampe, le vermis cérébelleux et l’hypophyse.   
Dans le tronc cérebral, une coloration relativement faible des neurones a été observée.  Ces 
constatations étaient en concordance avec les données toxicologiques.  La méthode 
immunohistochimique présentée peut être utilisée comme preuve d’ingestion ou même 
d’intoxication à la MDA, MDMA et/ou MDEA et peut être considérée comme une 
méthode alternative lorsque les échantillons classiques pour l’analyse toxicologique 
(principalement le sang et l’urine) ne sont pas disponibles (p.ex. comme conséquence de 
polytraumatisme).  Néanmoins, il n’est pas possible de distinguer les dérivés 
d’amphétamines similaires (MDA, MDMA et MDEA) au moyen des anticorps disponibles 
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actuellement.  En outre, l’immunodétection peut être employée comme base d’étude 
ultérieure de la distribution de ces analogues d’amphétamine dans le corps humain et être 
une méthode valable pour comprendre leurs effets neurobiologiques.  Néanmoins, 
l’approche immunohistochimique est limitée par le fait que uniquement la fraction liée aux 
tissus peut être démontrée dans les coupes histologiques.  Ceci est une différe 
fondamentalement des analyses toxicologiques des tissus homogénéisés par lesquelles aussi 
bien la fraction liée que la fraction non-liée peut être détectée. 
 
En conclusion, on peut affirmer que suite aux données expérimentales animales  
confirmées par des cas humains, la distribution post mortem des dérivés d’amphétamine – 
plus particulièrement la  MDMA et la MDA, mais également de la  4-MTA et la PMA – a 
été démontrée et qu’il faut en tenir compte lors de la constatation du décès, et 
principalement lors des délais post mortem plus longs.  Un prélèvement sanguin 
périphérique doit être la norme.  Lorsque le prélèvement sanguin  est impossible suite à une 
hémorrhagie sérieuse en cas de polytraumatisme ou de putréfaction, le muscle iliopsoas et 
l’humeur vitrée doivent être considérés comme spécimens valables pour aboutir à une 
conclusion fiable.   La détection immunohistochimique usant du tissu cérébral peut 
également être une aide complémentaire dans l’examen médico-légal.  En définitive, 
comme il n’existe à présent pas de consensus véritable pour évaluer une concentration 
toxique ou létale de MDMA, il est recommandé d’interpréter les constatations anatomo-
pathologiques et toxicologiques simultanément afin d’arriver à une conclusion fiable.  
Cette directive est primordiale, se référant aux différents mécanismes possibles du décès 
(p.ex. des complications cardio-pulmonaires, l’hyperthermie) qui peuvent résulter en des 
temps de survie très divers après l’ingestion d’amphétamines. 
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Samenvatting en conclusies 
 
 Gebruik en misbruik van amfetamine – en analogen zoals 3,4-methyleendioxy-
methamfetamine (MDMA, “Ecstasy”, “XTC”) is een belangrijk maatschappelijk probleem 
en fatale gevallen zijn vrij frequent in de courante medico-legale praktijk.  Verwijzend naar 
de grote verschillen in bloed- en plasmaconcentraties die werden gedetecteerd bij de in de 
literatuur beschreven fatale MDMA-gerelateerde doden, is het nog niet duidelijk welke 
MDMA concentratie toxisch of zelfs potentieel dodelijk kan zijn.  De vraag of het 
gebruik/misbruik van een product heeft bijgedragen tot de dood blijkt moeilijk te 
beantwoorden omwille van postmortale fenomenen, zoals instabiliteit van een stof, 
redistributie en zelfs neoformatie die alle een post-mortem bloedconcentratie kunnen 
beïnvloeden.  Als postmortale afbraak plaatsvindt, worden vals verlaagde concentraties 
gevonden, terwijl postmortale redistributie en/of neoformatie aanleiding kunnen geven tot 
buitengewoon hoge concentraties.  Diffusie naar het cardiaal bloed van een substantie 
vanuit de longen of de lever enerzijds en vanuit de maaginhoud anderzijds zijn mogelijke 
mechanismen van postmortale redistributie. 
 
 In dit proefschrift werd de postmortale redistributie van enkele amfetamine-
derivaten bestudeerd teneinde te evalueren welke lichaamsvloeistof en/of welk weefsel na 
de dood het best de ante-mortem bloedconcentratie benaderen.  Verwijzend naar de goed 
geïsoleerde positie van het oog en de reeds bewezen waarde van het vitreumvocht (of 
glasvocht) voor postmortale toxicologie (bv. voor alcohol-bepalingen (1)), werd de 
betrouwbaarheid van dit medium voor post-mortem toxicologie onderzocht. In dit werk 
werden, in het bijzonder, MDMA en zijn metaboliet 3,4-methyleendioxyamfetamine 
(MDA) bestudeerd, maar ook de amfetaminederivaten 4-methylthioamfetamine (4-MTA) 
en para-methoxyamfetamine (PMA) – die recent heel wat aandacht kregen – werden 
onderzocht. 
 
 Deel 1 bevat een beschouwing van de literatuur inclusief een overzicht van de 
gepubliceerde MDMA-gerelateerde overlijdens en een samenvatting van de amfetamine-
gerelateerde doden die werden onderzocht binnen de Vakgroep Gerechtelijke Geneeskunde 
van de Universiteit Gent.  In Hoofdstuk 1 werden de relevante literatuurgegevens, 
geconcentreerd op MDMA en zijn medico-legale implicaties, samengevat.  In vivo wordt 
een belangrijke inter-individuele gevoeligheid voor de effecten van MDMA opgemerkt.  
Voor het ogenblik is het onmogelijk om een individueel risico en aldus de gevolgen in te 
schatten bij gebruik van MDMA of andere amfetamines.   
De meerderheid van de dodelijke slachtoffers die in de literatuur beschreven werden 
zijn mannen jonger dan 25 jaar.  Het aantal “pure” MDMA intoxicaties en MDMA inname 
als onderdeel van poly-amfetamine intoxicaties of poly-drug misbruik was ongeveer 
evenredig verdeeld.  Wat betreft de wijze van sterven was het duidelijk dat de MDMA-
gerelateerde slachtoffers voor het overgrote deel een gevolg waren van onvrijwillige 
overdosis, maar het gebruik van MDMA geassocieerd aan andere gebeurtenissen, zoals 
Samenvatting en conclusies 
________________________________________________________________________________ 
 2
verkeersongevallen en zelfmoordgedrag, mag niet onderschat worden.  Wanneer MDMA 
betrokken is bij een overlijden worden verschillende mechanismen van sterven beschreven: 
hyperthermie en fatale cardiale of pulmonale complicaties waren het meest frequent.  In 
vele gevallen echter is de wijze en het mechanisme van overlijden onbepaald of onzeker.  
Verwijzend naar het brede interval van MDMA concentraties beschreven in de literatuur 
(meer in het bijzonder bloedconcentraties tussen 0.04 en 18.5 µg/ml in “pure” intoxicaties) 
is het dus niet evident om zich - zuiver op basis van een toxicologisch resultaat - uit te 
spreken over de vraag of een persoon al dan niet overleden is ten gevolge van MDMA 
gebruik of misbruik.  Bovendien werd in het merendeel van de gepubliceerde casussen de 
bloedafnameplaats niet gespecifiëerd en aldus was het niet duidelijk of de vastgestelde 
postmortale MDMA bloedconcentratie effectief de concentratie op het moment van het 
overlijden weerspiegelde.  Nochtans, een vuistregel geeft aan dat een MDMA 
bloedconcentratie hoger dan 1 µg/ml potentieel dodelijk kan zijn, terwijl waarden gelijk aan 
of lager dan 0.6 µg/ml mogelijk een intoxicatie kunnen induceren (2). 
In Hoofstuk 2 werden - in het licht van deze literatuurgegevens - alle amfetamine-
gerelateerde doden, onderzocht binnen de Vakgroep Gerechtelijke Geneeskunde van de 
Universiteit Gent, opnieuw kritisch bekeken.  Omwille van het relatief kleine aantal “pure” 
MDMA-gerelateerde overlijdens werden alle amfetamine-gecorreleerde slachtoffers in dit 
overzicht opgenomen.  Het aantal overlijdens waarin amfetamines betrokken zijn, is slechts 
een fractie van het totaal aantal medico-legale opdrachten, maar het aantal is duidelijk aan 
het toenemen sedert 1995.  Nochtans zijn we er sterk van overtuigd dat er een 
onderschatting van het aantal amfetamine-gerelateerde doden is: wanneer iemand thuis 
levenloos wordt aangetroffen (bv. dood in bed gevonden, al dan niet na een party), wordt 
dit dikwijls als een “natuurlijk overlijden” geklasseerd en bijgevolg wordt er geen 
politioneel onderzoek noch een medico-legale schouwing verricht.  In onze studiegroep 
werden 11 slachtoffers dood aangetroffen in bed of zetel.   
De bevindingen qua verdeling van leeftijd en geslacht bij de amfetamine- 
gecorreleerde slachtoffers die werden onderzocht binnen de Vakgroep waren merendeels in 
overeenstemming met de literatuurgegevens.  Een brede waaier van MDMA concentraties 
bij “pure” intoxicaties  werd vastgesteld (bloedconcentraties tussen 0.27 en 13.51 µg/ml): 
ze lagen in dezelfde lijn als deze beschreven in de literatuur.  “Pure” amfetamine 
intoxicaties, poly-drug overdosissen en amfetamine-gebruik gecombineerd met polytrauma 
werden als meest voorkomende doodsoorzaken opgemerkt.  Wat de wijze van sterven in 
onze studiegroep betrof, bleken niet-intentionele intoxicaties het meest frequent, maar 
amfetaminegebruik in relatie tot verkeersongevallen en zelfmoord vormde eveneens een 
belangrijke groep.  Wanneer het mechanisme van overlijden beschouwd werd, bleek acuut 
tot subacuut cardiopulmonaal falen het meest voorkomend, gevolgd door hyperthermie. 
 
Op basis van de overzichten beschreven in Deel 1 (Hoofdstuk 1 en 2), werden de 
postmortale distributie en redistributie bestudeerd teneinde na te gaan welke 
lichaamsvloeistof of welk weefsel na de dood gepreleveerd, het meest de werkelijke 
bloedconcentratie op het moment van het overlijden benaderen.  Vooreerst worden de 
resultaten bekomen in een proefdiermodel (gebruik makend van konijnen) voorgesteld 
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(Deel 2).  Vervolgens werd nagegaan of deze experimentele gegevens bevestigd worden bij 
enkele casussen van de courante forensische praktijk (Vakgroep Gerechtelijke 
Geneeskunde, Universiteit Gent) (Deel 3).  
 
In een eerste studie van Deel 2 (Hoofdstuk 3) werd het belang van een post-mortem 
vitreum- of glasvochtconcentratie bestudeerd om de mogelijke thanato-chemische 
problemen zoals post-mortem redistributie te omzeilen.  Vooreerst werd de farmacokinetiek 
van MDMA in het konijn na intraveneuze (iv) toediening onderzocht.  Een vrij hoog 
distributievolume (5 l/kg), een belangrijke systemische klaring (4.1 l/kg per uur) en een 
relatief kort half-leven (1 uur) werden opgemerkt na iv toediening van MDMA bij het 
konijn.  Een duidelijk verband tussen de MDMA concentraties in het vasculaire 
compartiment en het vitreumvocht werd aangetoond.  Een evenwicht tussen het vasculaire 
compartiment en het glasvocht werd bereikt ongeveer een uur na iv toediening.  De 
verhouding van de MDMA concentratie in het glasvocht op de MDMA bloedconcentratie 
120 en 240 minuten na intraveneuze toediening benaderde 1.1, wat wijst op een lichte 
opstapeling van MDMA in het vitreumvocht.  Bovendien toonde een preliminair thanato-
toxicologisch onderzoek – waarbij een post-mortem interval tot 72 uur werd bekeken - aan 
dat MDMA concentraties na de dood in het  cardiaal bloed toenamen, terwijl MDMA 
concentraties in het vitreumvocht meer stabiel waren en dus meer representatief waren voor 
de ante-mortem bloed concentratie. 
In Hoofdstuk 4 en 5 werden de postmortale stabiliteit en redistributie van MDMA in 
het konijn verder geanalyseerd.  In Hoofdstuk 4 werden de distributie en redistributie van 
MDMA en zijn metaboliet MDA onderzocht in verscheidene lichaamsvochten en weefsels 
na iv toediening.  In een eerste groep (controle groep, staalname onmiddellijk na het doden) 
werden aanzienlijke MDMA concentraties gevonden in de hersenen en beide longen.  De 
toxicologische gegevens wezen eveneens op een belangrijke eliminatie van MDMA via 
hepatische biotransformatie en biliaire excretie geassocieerd aan renale excretie.  In een 
tweede groep dieren (bewaard gedurende hetzij 24, hetzij 72 uur vooraleer over te gaan tot 
staalname), werd een toename van MDMA en MDA concentraties in de lever en de 
oogbindvliezen opgemerkt.  Anderzijds toonden de longconcentraties een neiging om te 
dalen in functie van het toenemend postmortaal interval.  MDMA concentraties in de hart- 
en iliopsoasspier waren vrij goed vergelijkbaar en bleven stabiel tot 72 uur na het 
overlijden.  Vermits postmortale stijgingen in cardiaal bloedconcentraties een gevolg 
kunnen zijn van vasculaire diffusie vanuit bloedrijke organen zoals de lever en de longen 
(3), werden in een andere groep (groep 3) de grote vaten rond het hart afgebonden 
(onmiddellijk na het doden); deze dieren werden overigens op dezelfde manier behandeld 
als groep 2.  Significante verschillen tussen groep 2 en 3 konden niet aangetoond worden.  
Vandaar dat, in het konijn, postmortale redistributie van MDMA op cellulair niveau (met 
name door een zuivere diffusiegradiënt van hoge naar lage concentratie) waarschijnlijk 
belangrijker is dan redistributie van deze stof via vasculaire weg.  Daarenboven waren  de 
MDA concentraties relatief laag in alle stalen, wat erop wijst dat deze molecule geen 
belangrijke metaboliet is in het konijn, tenminste binnen de 2 uur na toediening.  Bovendien 
werd de waarde van het vitreumvocht als stabiel post-mortem specimen bevestigd.  De 
Samenvatting en conclusies 
________________________________________________________________________________ 
 4
distributie en redistributie van MDMA en MDA in de weefsels van konijnen lagen in de lijn 
van de data die bekomen werden na toediening van amphetamine bij de rat (4,5). 
 Vermits concentraties van diverse producten zoals drugs kunnen beïnvloed worden 
door diffusie vanuit de maag - wanneer aldaar nog een belangrijke hoeveelheid van het 
product aanwezig is - of door diffusie vanuit de trachea bij agonale aspiratie of postmortale 
regurgitatie van braaksel, werden deze fenomenen in een ander proefdiermodel gesimuleerd 
(Hoofdstuk 5).  Bij postmortale infusie van MDMA in de trachea van het konijn, bleek dat 
MDMA niet alleen gemakkelijk diffundeerde in de longen, maar ook in belangrijke mate in 
het cardiaal bloed en in mindere mate in de hartspier.  MDMA werd eveneens 
teruggevonden in het dichtbij gelegen diafragma en de bovenste abdominale organen zoals 
de lever en de maag.  Na post-mortem infusie van MDMA in de maag, werden belangrijke 
MDMA- concentraties teruggevonden in het cardiaal bloed, de hartspier, beide longen, het 
diafragma, en de lever voor zover dat de MDMA-oplossing vlakbij de onderste 
slokdarmsphincter geconcentreerd was.  Anderzijds - wanneer de MDMA-oplossing dieper 
in de maag aanwezig was - werden hoge MDMA concentraties aangetroffen in de milt en 
de lever en relatief lage concentraties in het cardiaal bloed en de hartspier.  Deze resultaten 
wijzen erop dat de diffusie van MDMA vanuit de maaginhoud of door braakselaspiratie, en 
meer in het bijzonder gastro-oesophageale reflux, aanleiding kan geven tot belangrijke 
postmortale redistributie.  In beide experimenten waren de MDA concentraties relatief laag 
of beneden de kwantificeerbare limiet in de meeste weefsels, maar toch belangrijk in het 
cardiaal bloed, de hartspier, de longen en het diafragma wat erop wijst dat MDMA ook na 
het overlijden kan omgezet worden naar MDA. 
 
In Deel 3 werd de postmortale distributie van MDMA (en zijn metaboliet MDA) 
evenals van enkele andere amfetaminederivaten bestudeerd in het menselijk lichaam 
teneinde na te gaan welke vloeistof en/of welk weefsel gepreleveerd na de dood het best de 
ante-mortem concentratie op het moment van het overlijden benaderen.  Deze bevindingen 
werden gecorreleerd aan de experimentele post-mortem redistributie-data bij het konijn.  
Bij de humane slachtoffers werden de  postmortale fenomenen onderzocht gebruik makend 
van twee verschillende – doch complementaire – benaderingen, namelijk respectievelijk 
vanuit thanato-toxicologisch en vanuit immunohistochemisch oogpunt. 
In Hoofdstuk 6 werden concentraties in verschillende lichaamsvochten (bloed 
gepreleveerd op verschillende plaatsen, vitreumvocht, urine en gal) en in weefsels zoals 
hartspier, longen, lever, nieren, milt, iliopsoasspier, hersenen bepaald in slachtoffers van 
een overdosis.  Naast MDMA en MDA werden enkele andere amfetaminederivaten, 
namelijk 4-methylthioamphetamine (4-MTA) en para-methoxyamphetamine (PMA) 
eveneens bestudeerd.  Voor het relatief nieuwe derivaat, 4-MTA, werden eveneens 
gegevens van personen die overleefden na inname ervan, voorgesteld en aldus werden de 
klinisch-pathologische bevindingen besproken.  Bij de overlevende personen werd een 
duidelijke inconsistentie tussen de 4-MTA concentraties en de geobserveerde klinische 
symptomen vastgesteld, waardoor individuele verschillen in reactie na 4-MTA inname 
beschouwd moeten worden.  In alle fatale amfetamine-gerelateerde casussen werden zeer 
hoge concentraties gevonden in cardiaal bloed en weefsels die zich centraal in het menselijk 
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lichaam bevinden (longen en lever in het bijzonder).  Dit bevestigt dat postmortale 
redistributie als gevolg van diffusie van een hoge naar een lage concentratie gemakkelijk 
plaatsvindt, voornamelijk bij grotere postmortale intervallen en wanneer putrefactie 
voorkomt.  Deze vaststellingen zijn in overeenstemming met de dierexperimentele 
gegevens bij dewelke post-mortem redistributie van MDMA in cardiaal bloed werd 
aangetoond (6,7).   Onze data bevestigden dat een perifeer genomen bloedstaal voor post-
mortem toxicologische bepaling van amfetamine en analogen aangewezen is.  Wanneer dit 
echter onmogelijk is (als gevolg van ernstig bloedverlies bv. in polytrauma) kunnen 
iliopsoasspier en vitreumvocht waardevolle alternatieven zijn.  Echter, wanneer een 
gevorderde putrefactie heeft plaatsgevonden, is er meestal geen vitreumvocht meer 
aanwezig ten gevolge van dehydratatie, en concentraties in iliopsoasspier moeten 
voorzichtig geïnterpreteerd worden (zie casus 01/158: de iliopsoasspierconcentratie was 
duidelijk hoger dan de concentratie in het vena femoralis bloed).  In tegenstelling tot de 
resultaten in de experimenten bij het konijn, zijn er bij de mens argumenten om aan te 
nemen dat een directe transvasculaire redistributie optreedt bv. vanuit de longen naar het 
hartbloed.  Daarenboven - verwijzend naar de post-mortem processen – moeten de 
toxicologische en de autoptische gegevens als een geheel beschouwd worden om tot een 
betrouwbare medico-legale conclusie te kunnen komen. 
In Hoofdstuk 7 werd een immunohistochemische methode voor de detectie van 
MDMA en MDA in post-mortem humaan hersenweefsel en de hypofyse voorgesteld en 
gecorreleerd met de toxicologische bevindingen.  De detectiemethode is gebaseerd op een 
uitgebreide amplificatie van het oorspronkelijke signaal (antigen-antilichaam herkenning; 
Catalyzed Signal Amplification; CSA (8)).  Deze methode werd reeds toegepast voor de 
detectie van morfine en methadone in slachtoffers van dergelijke intoxicatie (9,10). Een 
duidelijk positieve reactie werd geobserveerd in alle hersengebieden en de neuronen van de 
basale ganglia, de hypothalamus, de hippocampus, de vermis cerebelli en de hypofyse. In 
de hersenstam werd een relatief zwakke aankleuring van de neuronen opgemerkt.  Deze 
bevindingen waren in overeenstemming met de toxicologische data.  De voorgestelde 
immunohistochemische methode kan gebruikt worden als een bewijs van inname of zelfs 
intoxicatie met MDA, MDMA en/of MDEA en kan een alternatief zijn wanneer de 
klassieke stalen voor toxicologisch onderzoek (voornamelijk bloed en urine) niet 
voorhanden zijn (bv. als gevolg van polytrauma).  Nochtans is het met de huidig 
beschikbare antilichamen niet mogelijk om de sterk op elkaar gelijkende amfetamine-
derivaten (MDA, MDMA en MDEA) van elkaar te onderscheiden.  Daarenboven kan 
immunodetectie gebruikt worden als basis voor verdere studie van de distributie van deze 
amfetamine-analogen in het menselijk lichaam en kan de methode waardevol zijn in het 
begrijpen van hun neuro-biologische effecten.  Echter, de immunohistochemische 
benadering is gelimiteerd door het feit dat enkel de fractie gebonden aan weefsels kan 
aangetoond worden in de histologische coupes.  Dit is een fundamenteel verschil met de 
toxicologische bepalingen in weefsel-homogenaten waarbij zowel de gebonden als de niet-
gebonden fractie gedetecteerd wordt. 
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Samenvattend kunnen we stellen dat, aan de hand van de dierexperimentele data 
ondersteund door enkele humane gevallen, postmortale redistributie van 
amfetaminederivaten – MDMA en MDA in het bijzonder, maar ook van 4-MTA en PMA – 
aangetoond werd en dat  hiermee moet rekening gehouden worden bij het vaststellen van 
het overlijden, voornamelijk bij langere postmortale intervallen.  Perifere afname van een 
bloedstaal blijft de “gouden standaard”.  Echter, wanneer dit onmogelijk is als gevolg van 
ernstig bloedverlies in polytrauma of door putrefactie, kunnen iliopsoasspier en 
vitreumvocht waardevolle specimens zijn om tot een betrouwbare conclusie te komen.  
Immunohistochemische detectie in hersenweefsel kan eveneens een aanvullend hulpmiddel 
zijn in het forensisch onderzoek.  Tot slot, vermits er nog steeds geen consensus bestaat 
over welke MDMA concentratie toxisch of potentieel letaal kan zijn, is het aangewezen om 
de anatomo-pathologische en toxicologische bevindingen als één geheel te interpreteren om 
tot een conclusie te komen.  Deze richtlijn is belangrijk verwijzend naar de verschillende 
mogelijke mechanismen van overlijden (bv. cardiopulmonale verwikkelingen, 
hyperthermie) die tot sterk verschillende overlevingstijden na inname van amfetamines 
aanleiding geven. 
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Figure 4.2      Mean MDMA (a) or MDA (b) concentrations in blood, vitreous humour, bile, and 
     tissues in rabbits after an iv injection of 1 mg/kg MDMA.  
     Sampling occurred 120 min after infusion or immediately after killing (group 1, n = 3).  
     (Values expressed as mean ± SD).
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Figure 4.3   (a) Individual MDMA concentrations in blood, vitreous humour and eye globe walls after iv injection of 1 mg/kg in rabbits (R) of groups 1, 2 and 3.
(b) Individual creatinine concentrations (mg/dl) and individual ratios of MDMA to creatinine concentrations in vitreous humour in rabbits (R) of 




Figure 4.4 (a) Mean post-mortem MDMA concentrations in rabbit tissues after iv injection 
of 1 mg/kg MDMA.  (Values expressed as mean ± SD)
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Figure 4.4 (b) Mean post-mortem MDA concentrations in rabbit tissues after iv injection
of 1 mg/kg MDMA.  (Values expressed as mean  ± SD)
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Figure 5.2 Individual MDMA and MDA concentrations in rabbits (n = 6) after post-mortem infusion 
of 1 mg/kg MDMA in the trachea (PIT), 24, 48 and 72 h after administration.
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Figure 5.3 Thoracic and abdominal post-mortem diffusion after tracheal instillation of 1 mg/kg  
MDMA in rabbits (n = 2), in which spreading of the solution occurred predominantly in 
the left bronchus,  24 and 48 h after administration.
Labels: RA: right atrium AO: aorta
RV: right ventricle VI: inferior vena cava
LA: left atrium VS: superior vena cava
LV: left ventricle AR: arteria renalis
TP: truncus pulmonalis VR: vena renalis
























Figure  5.4 Individual MDMA and MDA concentrations in rabbits (n = 6) after post-mortem infusion of 
1 mg/kg MDMA in the stomach (PIS), 24, 48 and 72 h after administration.
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(PMI = 72 h)
Figure 5.5 Thoracic and abdominal post-mortem diffusion after gastric instillation of 1 mg/kg  MDMA 
in rabbits (n = 2), showing the difference between the intra-gastric (a), 
and supra-diaphragmatic pattern (b) 72 h after instillation.
Labels: RA: right atrium AO: aorta
RV: right ventricle VI: inferior vena cava
LA: left atrium VS: superior vena cava
LV: left ventricle AR: arteria renalis
TP: truncus pulmonalis VR: vena renalis






























Figure 6.1 Possible mechanism of redistribution (indicated by direction of arrows)
Labels: RA: right atrium D: diaphragm
RV: right ventricle AO: aorta
LA: left atrium VI: inferior vena cava
LV: left ventricle VS: superior vena cava
TP: truncus pulmonalis AR: arteria renalis







































































































Figure 6.5 Linear least-squares of standards for 4-MTA and MDMA in whole blood, urine,






































Figure 7.1   (a)  Immunohistochemical staining of neurons (nerve cell bodies,  axons and dendrites) 
in the parietal lobe of case 1.   
(b)  Staining of the parietal lobe of case 1 after saturation of the antibody solution with 
MDMA.  As a result, negative immunodetection was induced.   
(c) Negative immunohistochemical staining of the parietal cortex in the control case.  
For pictures (a), (b), (c): antibody clone 1A9; magnification 190, 140 and 140x 
respectively.   
(d)  Immunohistochemical staining of neurons (nerve cell bodies,  axons and dendrites) 
























Figure 7.2.   Macroscopic overview of the slides of the cerebellar vermis:    
left : positive immunostaining in case 1;   
middle: immunostaining in case 1 after saturation of the antibody binding sites with 
MDMA, inducing a negative result;    
right : negative immunohistochemical staining of the cerebellar vermis in a control case 
(00/116).  


















































Figure 7.3   (a)  Positive immunostaining of the cerebellar vermis of case 2:  the nerve cell bodies,  
axons and dendrites of the Purkinje cells are clearly visible.  The granular layer cells 
can also obviously be discerned.  In addition,  staining at the level of the white matter 
fibres is seen (overview:  magnification 95x).   
(b) Detail of the immunoreaction in the cerebellar vermis of case 2 (magnification 
270x).   
(c) Negative immunohistochemical staining of the cerebellar vermis in a control case 
(00/116;  magnification 170x).   




































Figure 7.4   Staining of neurons in the hippocampus of case 2 (antibody clone 1A9).   
(a):  overview (magnification 25x);   
(b):  detail of the cortical neurons (magnification 100x);   










































Figure 7.5   (a)  Overview of MDMA immunoreactivity in the pituitary gland (antibody clone 1A9;  
magnification 140x).   
(b)  PAS Orange-G staining of the immediately adjacent slide visualizing clearly the 
acidophilic (orange colour) and basophilic cells (violet colour),  (magnification 140x).  
(c)  Detail of the staining reaction for MDMA in the pituitary gland (antibody clone 
1A9;  magnification 300x).   
Following types of staining reaction can be discerned (see arrows):   
(1) & (2):  obviously positive cells showing variable staining intensity (heterogeneity).  
The highly intensively stained cells obscure the nucleus (see arrow 1).  (3) cells having 
weak immunoreaction.  (4) negative cells. 
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